Glaucoma, Vision & Longevity: Supplements & Science

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/could-glaucoma-surgery-become-a-10-minute-office-procedure-first-human-results-from-obi-coreTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Could Glaucoma Surgery Become a 10-Minute Office Procedure? First Human Results From OBi Core Short answer: OBi Core is one of the more interesting new glaucoma procedures because it attempts to combine the pressure-lowering power of filtration surgery with the convenience of an office-based slit-lamp procedure. But the current evidence is still extremely early. The publicly reported human experience consists of a small first-in-human series of approximately 10 eyes with detailed results, followed by a company update describing 11 treated eyes. Follow-up is short, patient-level data are not publicly available, and approximately 30% of eyes required reintervention in the initial detailed report. () The technology is therefore promising, but not yet proven to replace trabeculectomy. Its most important scientific question is not whether it can lower pressure initially. The early data suggest that it can. The difficult question is whether the subconjunctival bleb can remain functional for years without recreating the fibrosis, needling, medication, and monitoring burden of conventional filtering surgery. The Bottom Line OBi Core is not a conventional angle-based minimally invasive glaucoma surgery. It creates a direct pathway from the anterior chamber to a subconjunctival or sub-Tenon filtration space. The device appears to use a 27-gauge, 6-millimeter punch needle to create an oblique scleral microchannel approximately 150 ± 50 micrometers in diameter. () It does create a subconjunctival filtration bleb, meaning it shares the central biological weakness of trabeculectomy, XEN Gel Stent, and PreserFlo MicroShunt: wound healing and fibrosis can eventually reduce flow. The detailed first-in-human report involved 10 eyes followed for up to approximately 6 weeks. Mean intraocular pressure fell from 30.1 to 10.2 millimeters of mercury, a calculated absolute reduction of 19.9 millimeters of mercury, or approximately 66%. Mean glaucoma medications fell from 2.2 to 0.8, an absolute reduction of 1.4 medications, or approximately 64%. Seventy percent of eyes reportedly achieved complete success under the study definition, and approximately 78% were medication-free, although the denominators and patient-level data were not fully disclosed. Thirty percent required reintervention, including repeat OBi Core procedures or other filtration procedures. The reasons for those interventions have not been publicly separated into fibrosis, obstruction, inadequate flow, or surgical learning-curve effects. () A September 2026 company update described 11 treated eyes, including mild, moderate, and advanced glaucoma, with early pressures in the single digits to low teens and no reported device- or procedure-related adverse events. No detailed aggregate results from the eleventh eye were provided. () The “10-minute” description is not yet supported by a published procedural-time dataset. The channel-creation step may take seconds, but the full visit—including preparation, anesthesia, mitomycin C, intraocular pressure management, and postoperative testing—has not been formally reported. What Is OBi Core? Manufacturer and development status OBi Core is being developed by Hexiris Ophthalmics, a Canadian company based in Dieppe, New Brunswick. Hexiris describes OBi Core as a device for minimally invasive bleb surgery, usable either at the slit lamp or in an operating room. () The clinical-trial registry uses the more generic name Hexiris Microinvasive Scleral Trephine, or MIST. The registered first-in-human study is a Canadian, multicenter, open-label, single-arm study intended to enroll 25 adults with primary open-angle glaucoma. The first five cases are planned in an operating room, after which the safety monitor may allow the remaining procedures to move to an aseptic slit-lamp setting. () Hexiris states that OBi Core has a Health Canada medical device license and is FDA registered. FDA registration does not by itself mean that a device has received United States clearance or approval for routine commercial use. The company has indicated that commercial introduction in selected markets may begin in early 2027, subject to regulatory requirements. () Device design The publicly described OBi Core system consists of: A handpiece A 27-gauge punch needle A needle approximately 6 millimeters long An actuator that advances the cutting element A scleral punch that removes a small core of tissue A resulting oblique microchannel approximately 150 ± 50 micrometers in diameter The device is not described as leaving a permanent implant in place. Instead, it creates a tissue channel. A related Hexiris patent describes the concept as a drainage pathway created by removing a small tissue core, with no artificial tube left inside that channel. () That is an important distinction: XEN and PreserFlo leave a permanent implant. OBi Core appears to create a micro-sclerostomy without leaving a permanent tube. A separate Hexiris product called OBi Shunt is being developed as an implantable device, but it is a different product and should not be confused with OBi Core. () What Drainage Pathway Does It Create? The publicly described pathway is: > Anterior chamber → scleral microtunnel → posterior subconjunctival or sub-Tenon space → absorption through surrounding tissues and episcleral vessels The approach is ab externo, meaning the surgeon approaches the eye from the outside. The device is placed through the conjunctiva and sclera, with the punch directed into the anterior chamber. The described target location is generally the superior or superotemporal sclera, approximately 1.0 to 1.5 millimeters behind the limbus. () The procedure is therefore a form of penetrating filtration surgery, although it is much smaller than a traditional trabeculectomy. Is a bleb formed? Yes. OBi Core is a bleb-forming procedure. Aqueous humor is intended to collect in a posterior subconjunctival or sub-Tenon space, creating a filtration reservoir. This reservoir is commonly called a bleb. The fluid is then absorbed through surrounding tissue and blood vessels. () This means OBi Core does not completely escape the biological problems of conventional glaucoma filtration surgery. It may reduce tissue trauma, but it still depends on: A functioning drainage channel A healthy subconjunctival space Controlled wound healing A bleb that remains open rather than becoming scarred or encapsulated How Is the Procedure Performed? The exact first-in-human operative protocol has not been published in a peer-reviewed clinical paper. However, the publicly described technique includes the following elements. Publicly described procedural sequence The eye is anesthetized with topical anesthesia. The procedure is performed at the slit lamp in an aseptic office environment. A small subconjunctival or sub-Tenon pocket is created or accessed. A bolus of cohesive ophthalmic viscoelastic is placed in the anterior chamber to reduce excessive early flow. The OBi Core device is positioned on the superior or superotemporal sclera. The actuator advances the punch needle through the conjunctiva and sclera into the anterior chamber. A small scleral tissue core is removed, creating the microchannel. Mitomycin C is injected into the subconjunctival pocket. Pilocarpine may be used to pull the iris away from the internal opening. The surgeon performs a Seidel test to look for leakage. Postoperative antibiotics and steroids are prescribed. The bleb and intraocular pressure are monitored closely. The described technique includes mitomycin C at 0.4 milligrams per milliliter, equivalent to approximately 0.04%. The registered MIST trial specifies a subconjunctival mitomycin C concentration of 0.02% to 0.04%. () Is it performed entirely at a slit lamp? The intended office-based version appears to be performed at the slit lamp, without major capital equipment. However: The first five cases in the registered study are planned in an operating room. The procedure can also be performed in an operating room. The surgeon must still enter the anterior chamber. The eye must be prepared with sterile or aseptic technique. The practice must be capable of recognizing and managing hypotony, bleeding, iris obstruction, wound leakage, and other intraocular problems. Thus, “office-based” does not mean “noninvasive” or “risk-free.” How long does it take? The available clinical sources call the procedure rapid, and the underlying patent describes the tissue-channel creation step as occurring in the order of seconds. However, no reliable published study currently reports the total procedure time from patient preparation to discharge. () The most accurate conclusion is: > OBi Core may be a short office procedure, but the public evidence does not yet establish that the complete treatment reliably takes 10 minutes. The full time would include topical anesthesia, sterile preparation, conjunctival manipulation, anterior chamber viscoelastic, mitomycin C injection, pressure testing, and postoperative instructions. Reconstructing the First Human Results Detailed first-in-human report The most detailed publicly available report came from a presentation at the 2026 American Society of Cataract and RefractiveSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/can-high-dose-vitamin-b3-protect-the-optic-nerve-a-new-glaucoma-trial-will-test-3-grams-a-dayTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Can High-Dose Vitamin B3 Protect the Optic Nerve? A New Glaucoma Trial Will Test 3 Grams a Day Research updated September 13, 2026 Introduction Glaucoma treatment has traditionally focused on one target: lowering intraocular pressure. That strategy clearly helps, but it does not eliminate risk. Some patients continue to lose retinal ganglion cells and visual-field sensitivity even when their eye pressure appears well controlled. The NADIR trial—NCT07808333—is designed to test a different strategy. It will add high-dose oral nicotinamide, the non-flushing form of vitamin B3, to standard glaucoma treatment and measure whether the inner retinal layers thin more slowly. The central biological idea is straightforward: > Retinal ganglion cells may become metabolically fragile before they die. If nicotinamide raises cellular nicotinamide adenine dinucleotide availability, it might help stressed but living cells withstand glaucoma-related injury. That hypothesis is supported by striking animal research, early human electrophysiology studies, and a plausible link between aging, mitochondrial dysfunction, impaired axonal transport, and retinal ganglion-cell degeneration. But the human evidence remains preliminary—and 3 grams daily is a pharmacological dose, not an ordinary nutritional supplement dose. My overall assessment is that nicotinamide is one of the most credible current candidates for pressure-independent glaucoma neuroprotection, but it is not yet proven to slow glaucoma progression in humans. --- The NADIR Trial: What Is Actually Being Tested? As of September 13, 2026, NADIR is listed as not yet recruiting. It is a single-center University of Chicago study expected to begin enrollment in June 2027. The registry describes it as a Phase 2 study, while the protocol title calls it a Phase 2a trial. () Trial summary For the full table, please open this article on visualfieldtest.com. The trial is important because it is not asking whether nicotinamide lowers eye pressure. It is asking whether it protects retinal tissue despite ongoing standard pressure-lowering treatment. Who can participate? NADIR is designed for adults with mild to moderate primary open-angle glaucoma, not advanced disease. Key inclusion requirements include: Age 40 to 80 years Primary open-angle glaucoma in at least one eye Study-eye visual-field mean deviation between −2.0 and −12.0 decibels At least one reliable Humphrey 24-2 visual-field test Fixation losses of 33% or less False-positive responses of 15% or less Best-corrected visual acuity of 20/40 or better Structural damage on optical coherence tomography and/or a reproducible glaucomatous visual-field defect Macular ganglion cell-inner plexiform layer and retinal nerve fiber layer thickness above the device’s measurement floor Stable pressure-lowering therapy for at least four months Screening intraocular pressure of 21 millimeters of mercury or less The visual-field range is strategically chosen. Patients with mean deviation between −2 and −12 decibels still have enough surviving retinal tissue for a protective treatment to be measurable, but they have established disease rather than merely being glaucoma suspects. () Who is excluded? The important exclusions include: Advanced glaucoma with mean deviation worse than −12 decibels Best-corrected visual acuity worse than 20/40 Significant retinal disease, including advanced age-related macular degeneration or more than mild diabetic retinopathy Non-glaucomatous optic neuropathy Recent eye surgery Liver dysfunction, including alanine aminotransferase or aspartate aminotransferase greater than twice the upper limit of normal Total bilirubin greater than 1.5 times the upper limit of normal Estimated glomerular filtration rate below 30 milliliters per minute per 1.73 square meters Poorly controlled diabetes, defined as hemoglobin A1c greater than 9% Current use of nicotinamide, high-dose vitamin B3, nicotinamide adenine dinucleotide supplements, gingko biloba, coenzyme Q10, or certain drugs that could complicate safety interpretation Pregnancy or breastfeeding Active ocular inflammation Media opacity that prevents reliable imaging Patients with untreated normal-tension glaucoma are also excluded. NADIR is therefore testing an adjunctive treatment in patients whose glaucoma is being treated conventionally, not a therapy for every glaucoma subtype. () Nicotinamide dosing: Why 1.5 grams, then 3 grams? Participants assigned to the treatment arm will take: Weeks 1–6: 500 milligrams three times daily, totaling 1.5 grams daily Week 7 through month 12: 1,500 milligrams twice daily, totaling 3 grams daily The tablets are taken with meals. Advancement to the full dose requires an early safety review confirming acceptable gastrointestinal tolerance and no significant hepatic adverse event. () What is the basis for the escalation? The publicly available record does not describe a formal human exposure-response pharmacokinetic model. The dose appears to come from three sources: The earlier Australian human glaucoma study, which used 1.5 grams daily for six weeks followed by 3 grams daily for six weeks. Mouse glaucoma studies, in which relatively high nicotinamide exposure produced the strongest protection. A mechanistic assumption that substantial nicotinamide availability may be needed to overcome age-related or disease-related limitations in the nicotinamide adenine dinucleotide salvage pathway. The 3-gram dose was not selected because it is a standard nutritional requirement. The recommended daily amount of vitamin B3 is roughly 14–16 milligrams in adults, making 3 grams approximately 150 to 200 times the usual nutritional intake. Animal investigators have described 3 grams daily as the lowest human-equivalent dose likely to reproduce the effective exposure seen in their mouse model. A later rat study used doses equivalent to approximately 2.1 grams and 6.3 grams daily in a 70-kilogram adult, with the higher dose needed for some intervention settings. This is body-surface-area extrapolation, not proof that humans require the same exposure. () NADIR’s endpoints Primary endpoint The primary outcome is the annualized rate of macular ganglion cell-inner plexiform layer thinning. Measurements will occur at: Baseline Month 3 Month 6 Month 12 The statistical analysis will use a linear mixed-effects model with: A participant-level random intercept Repeated measurements over time A treatment-arm-by-time interaction The key question is whether the nicotinamide group has a less negative slope than the standard-care group. Secondary structural and functional endpoints The secondary outcomes include: Annualized rate of peripapillary retinal nerve fiber layer thinning Visual-field mean deviation slope Grade 2 or higher hepatic and gastrointestinal adverse events Nicotinamide adherence Study retention Additional exploratory measures include: Macular superficial capillary plexus perfusion density by optical coherence tomography angiography Peripapillary radial capillary plexus perfusion density The registry specifies that optical coherence tomography and visual-field readers will be masked to treatment assignment through de-identified participant identifiers, even though participants and investigators will know which treatment is being given. () Statistical strengths and weaknesses Strengths Randomized 1:1 allocation Active standard-care control Stratification by mild versus moderate disease Stratification by race and ethnicity Masked structural and visual-field reading Repeated optical coherence tomography measurements A structural primary endpoint that may be more sensitive than visual-field change over only one year Weaknesses The trial is open-label There is no placebo Only 96 participants are planned It is being conducted at one center Twelve months is short for proving long-term visual-field preservation The public registry does not provide a detailed power calculation or a prespecified minimum clinically important difference A positive NADIR result would therefore be important, but it would probably be considered proof of biological activity, not definitive proof that nicotinamide should immediately become routine treatment. --- Why Might NAD Matter in Glaucoma? Nicotinamide adenine dinucleotide is an energy and repair molecule Nicotinamide adenine dinucleotide is needed for: Mitochondrial energy production Transfer of electrons during cellular respiration Maintenance of redox balance DNA repair Regulation of protein acetylation through sirtuin enzymes Calcium handling Axonal transport Cellular responses to oxidative stress Retinal ganglion cells are unusually vulnerable to energy failure. They have long axons, high electrical activity, substantial transport demands, and a portion of their axons that remain unmyelinated inside the retina. Their energy supply must remain reliable even when pressure-related mechanical stress affects the optic nerve head. Mitochondrial dysfunction may occur before obvious cell loss In the DBA/2J mouse model of glaucoma, abnormal mitochondrial gene expression, mitochondrial cristae disruption, oxidative phosphorylation changes, synapse loss, and pattern electroretinogram abnormalitSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/four-new-glaucoma-developments-from-the-last-two-weeks-which-one-could-matter-most-for-patientsTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Four New Glaucoma Developments From the Last Two Weeks — Which One Could Matter Most for Patients? Between August 21 and September 4, 2026, four glaucoma developments attracted attention: G01 / rhNGF-V2 neuroprotective eye drops Acid sphingomyelinase and ceramide metabolism as retinal ganglion-cell targets Optical coherence tomography angiography for earlier progression detection NCX 470, now called K-911, approaching United States regulatory review They are not equally important. One is already available as a diagnostic technology. One is close to possible approval but appears to be an incremental pressure-lowering improvement. The other two could eventually change the biology of glaucoma, but both remain uncertain and relatively early. This assessment uses information available through September 4, 2026, with the current regulatory status checked through September 11, 2026. > Important: The probabilities below are informed estimates, not clinical-trial results or regulatory predictions. “Changing care” means becoming sufficiently useful that it changes routine glaucoma management within approximately the next 5–10 years. At-a-Glance Comparison For the full table, please open this article on visualfieldtest.com. The Short Answer Most likely to help patients in the next 5–10 years NCX 470 / K-911 is the most likely to produce a measurable patient benefit because it has already completed large Phase 3 trials and has entered regulatory review. Most likely to improve glaucoma monitoring Optical coherence tomography angiography is the most immediately useful development. It may identify progression roughly two years before visual-field progression in some patients, although it is not perfect and does not directly treat glaucoma. () Highest upside G01 / rhNGF-V2 has the greatest potential upside because it aims to protect retinal ganglion cells independently of intraocular pressure. However, its current evidence is much weaker than the evidence supporting NCX 470. Most interesting biological discovery The acid sphingomyelinase–ceramide pathway may reveal a new way to protect retinal ganglion cells, but it is still a target rather than a treatment. --- G01 / rhNGF-V2 Neuroprotective Eye Drops What was reported? G01 is an investigational eye drop being developed in China for optic nerve injury associated with open-angle glaucoma. A Phase 2 study was updated on August 24, 2026, after being first posted on August 20, just outside the requested date range. The randomized, double-masked study plans to enroll approximately 90 patients with progressing primary open-angle glaucoma. It compares G01 concentrations of 100 micrograms per milliliter and 200 micrograms per milliliter with placebo. The study’s primary outcome is change in visual-field mean deviation after approximately 24 weeks of treatment, with additional structural, electrophysiological, pharmacokinetic, and immunogenicity measurements. Completion is estimated for late 2027. () A separate Phase 1 study in healthy volunteers is testing single and repeated doses of 100, 200, and 400 micrograms per milliliter. No public clinical efficacy results were available by September 4, 2026. () What is rhNGF-V2 supposed to do? Nerve growth factor is a neurotrophic protein involved in neuronal survival and repair. The goal is not to lower eye pressure but to make retinal ganglion cells more resistant to injury. Public company information identifies G01’s active ingredient as recombinant human nerve growth factor variant 2. A related patent describes a modified nerve growth factor known as K34D, which appears to be the likely molecular identity of rhNGF-V2, although the exact identity and characteristics of the clinical product have not been independently confirmed in a peer-reviewed clinical publication. This is therefore a strong inference, not a fully established fact. () The proposed advantage of the modified molecule is greater signaling through the protective tropomyosin receptor kinase A pathway with less potentially harmful signaling through the p75 neurotrophin receptor. The patent reports substantially reduced binding to the p75 receptor for K34D and even more receptor selectivity for a related double-mutant molecule. () Strength of the evidence Known facts G01 is in a registered Phase 2 glaucoma trial. No G01 efficacy results have been publicly reported. A separate healthy-volunteer safety and pharmacokinetic study is also registered. A patent reports protective effects for K34D in rat ocular-hypertension models. Earlier human research with conventional recombinant human nerve growth factor established short-term safety but did not demonstrate statistically significant neuroenhancement. Animal evidence In a patent-described rat model of chronic ocular hypertension, treatment began after pressure elevation had already occurred. K34D eye drops did not lower intraocular pressure, but they were associated with: Less retinal ganglion-cell loss Less optic-nerve axon damage Better pattern electroretinogram responses In one experiment, retinal ganglion-cell loss was approximately 59% in vehicle-treated animals versus 31% with K34D, a roughly 50% relative reduction in cell loss. However, the groups were small, the work was reported in a patent rather than an independent peer-reviewed paper, and the findings have not yet been replicated publicly by unrelated laboratories. () Human evidence for the nerve growth factor class A Phase 1b randomized trial gave conventional recombinant human nerve growth factor to 40 patients and vehicle to 20 patients for eight weeks. It found: No treatment-related serious adverse events No meaningful intraocular-pressure effect No statistically significant short-term improvement in visual fields or optical coherence tomography Ocular pain in approximately half of the nerve-growth-factor group Irritation, photophobia, and other surface symptoms in some patients The researchers noted that the trial was too short and too small to test true neuroprotection. Still, the absence of a clear short-term functional signal is important. It means that the modified G01 molecule must prove that it is meaningfully better than conventional nerve growth factor, not merely safer or more selective. () Biological plausibility The biological rationale is strong enough to justify clinical testing: Retinal ganglion cells depend on neurotrophic support. Glaucoma involves axonal injury, impaired transport, metabolic stress, and eventual cell death. Neurotrophic signaling could theoretically preserve stressed but living retinal ganglion cells. The patent data suggest a possible advantage from modifying receptor selectivity. The main biological problem is delivery. A topical eye drop must reach the retina and optic nerve in an adequate concentration. The cornea, anterior chamber, lens, vitreous, and retinal barriers make posterior-segment delivery difficult. A large dose may be needed, which could worsen surface pain or irritation. Potential magnitude of benefit Maximum plausible benefit If the animal findings translate unusually well to humans, G01 could: Slow retinal ganglion-cell death by a substantial amount Delay visual-field progression Provide benefit even when intraocular pressure is already at target Possibly improve function in retinal ganglion cells that are impaired but not yet dead Most realistic benefit The more realistic initial outcome would be a modest slowing of progression, perhaps in a subgroup of patients with active disease despite acceptable intraocular pressure. A benefit of approximately 10–25% slower functional deterioration would be clinically useful but would not constitute a cure. The possibility of a 30–50% reduction in progression is biologically conceivable but currently speculative. Risks The major known concern is tolerability. Conventional nerve growth factor produced substantial ocular pain and irritation in the Phase 1b trial. A modified molecule may have a better profile, but this has not yet been demonstrated in patients. Other concerns include: Ocular surface inflammation Photophobia and discomfort Immunogenicity against a repeated protein treatment Insufficient retinal exposure Possible unintended effects on sensory nerves or inflammatory signaling The need for multiple daily doses Likely patient population The most likely initial target would be patients with: Progressing open-angle glaucoma Intraocular pressure already reasonably controlled Mild-to-moderate disease with surviving retinal ganglion cells Documented structural or visual-field progression Patients with advanced glaucoma could benefit from preservation of remaining vision, but a treatment cannot rescue retinal ganglion cells that have already died. Does it work independently of intraocular pressure? Probably yes. The patent experiments reported no intraocular-pressure lowering, yet showed retinal ganglion-cell and axon protection. The current Phase 2 trial also appears designed for patients with relatively controlled pressure, strengthening the idea that G01 is intended as an adjunctive, pressure-independent treatment. () Could it preserve or restore vision? Preserve vision: Potentially yes. Restore lost function:Support the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/a-new-glaucoma-drug-is-approaching-fda-approval-can-it-lower-eye-pressure-better-than-today-s-best-dropsTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:A New Glaucoma Drug Is Approaching FDA Approval — Can It Lower Eye Pressure Better Than Today’s Best Drops? Evidence reviewed through September 10, 2026 Bottom line NCX 470—now called K-911, with the proposed generic name bimatoprost grenod—has been accepted for Food and Drug Administration review. The New Drug Application was submitted by Kowa on June 30, 2026, accepted for review on August 27, 2026, and assigned a Prescription Drug User Fee Act decision date of April 30, 2027. It is not yet approved. Kowa FDA acceptance announcement () The clinical evidence shows that NCX 470: Lowers intraocular pressure by approximately 8 to 10 millimeters of mercury in patients starting with pressures around 26 to 28 millimeters of mercury. Produces roughly 0.5 to 0.8 millimeters of mercury more reduction than latanoprost in the strongest published phase 3 dataset. Performs better than latanoprost at several individual time points, but the average advantage is modest rather than dramatic. Has more conjunctival hyperemia, or eye redness, than latanoprost. Has not been directly compared with bimatoprost, latanoprostene bunod, Rocklatan, or Cosopt in a pivotal head-to-head trial. Has not been adequately studied in patients starting with pressures in the mid-teens or in patients who need targets near 10 to 12 millimeters of mercury. My overall judgment: NCX 470 appears to be a meaningful incremental improvement over latanoprost, but not a breakthrough that is likely to replace combination therapy, selective laser trabeculoplasty, or glaucoma surgery. --- Current regulatory status For the full table, please open this article on visualfieldtest.com. FDA acceptance means the application was considered complete enough for formal review. It does not mean that approval is guaranteed. Kowa product pipeline Kowa FDA announcement () The application is supported principally by the MONT BLANC and DENALI phase 3 trials. A small phase 3b study called WHISTLER examined the drug’s effect on aqueous humor outflow but was exploratory and was not required for the New Drug Application. Nicox pre-New Drug Application update () --- What is NCX 470? NCX 470 is a nitric-oxide-donating version of bimatoprost. After the molecule is exposed to esterases in the eye, it releases: Bimatoprost-related prostaglandin activity, which primarily increases uveoscleral outflow. Nitric oxide, which is intended to relax the trabecular meshwork and improve drainage through the conventional trabecular meshwork–Schlemm canal pathway. In simplified terms: Bimatoprost helps fluid leave through the uveoscleral route. Nitric oxide attempts to improve the eye’s conventional drainage system. This is conceptually similar to latanoprostene bunod, marketed as Vyzulta, which combines a prostaglandin effect with nitric oxide donation. The difference is that Vyzulta releases a latanoprost-derived prostaglandin, whereas NCX 470 releases bimatoprost-related activity. NCX 470 mechanism and preclinical research MONT BLANC publication () --- The pivotal clinical trials MONT BLANC phase 3 trial The MONT BLANC study was a randomized, double-masked, multicenter phase 3 trial conducted at 56 United States sites and one site in China. A total of 691 patients were randomized. MONT BLANC publication ClinicalTrials.gov record () Treatment groups NCX 470 0.065%, once daily NCX 470 0.1%, once daily Latanoprost 0.005%, once daily The 0.065% arm included 30 initial patients and was stopped after the planned interim analysis. The final efficacy comparison involved: NCX 470 0.1%: 328 patients Latanoprost 0.005%: 333 patients The drops were administered to both eyes, generally in the evening. Baseline intraocular pressure The final treatment groups had very similar baseline values: For the full table, please open this article on visualfieldtest.com. These patients had relatively high baseline pressures. They were required to have untreated or washed-out pressure of at least approximately 26 millimeters of mercury at 8:00 a.m., 24 at 10:00 a.m., and 22 at 4:00 p.m. ClinicalTrials.gov results MONT BLANC responder analysis () Primary endpoint The primary endpoint was the reduction from time-matched baseline pressure at: 8:00 a.m. and 4:00 p.m. Week 2 Week 6 Month 3 The primary statistical goal was noninferiority to latanoprost. A secondary analysis examined whether NCX 470 was statistically superior. MONT BLANC: actual numerical results The table below uses the reported mean reductions from baseline. Percent reductions are calculated from the published baseline values. For the full table, please open this article on visualfieldtest.com. The reductions were statistically significant compared with baseline at every evaluated time point. NCX 470 was numerically better than latanoprost at all six time points and statistically better at four of them. ClinicalTrials.gov numerical results () Mean diurnal pressure results The secondary mean diurnal pressure analysis showed: For the full table, please open this article on visualfieldtest.com. This suggests that the average incremental benefit over latanoprost was approximately 0.5 to 0.8 millimeters of mercury, with an average across these visits of about 0.64 millimeters of mercury. That is a real difference. However, it is not the type of difference that usually transforms a patient from needing several medications to needing none. --- DENALI phase 3 trial DENALI was the second pivotal phase 3 trial. It randomized 696 patients at 90 sites in the United States and China: NCX 470 0.1%: 348 patients Latanoprost 0.005%: 348 patients Treatment was once daily in both eyes. All patients were followed through approximately six months, while a subset contributed safety data through 12 months. DENALI trial summary ClinicalTrials.gov DENALI record () Baseline pressure For the full table, please open this article on visualfieldtest.com. Reported efficacy Across the six prespecified efficacy time points: NCX 470 reduced pressure by 7.9 to 10.0 millimeters of mercury. Latanoprost reduced pressure by 7.1 to 9.8 millimeters of mercury. NCX 470 was numerically better at five of six time points. The difference favored NCX 470 by as much as 0.8 millimeters of mercury. Statistical superiority was demonstrated at three of six time points, but the overall superiority endpoint was not achieved. Thus, DENALI confirmed the general pattern seen in MONT BLANC: NCX 470 is at least as effective as latanoprost and sometimes modestly better, but the average advantage is not large. DENALI topline results () --- Comparison with other glaucoma medications Cross-trial comparisons must be interpreted cautiously. The studies used different entry pressures, populations, follow-up periods, statistical methods, and treatment schedules. A drug that appears stronger in one trial may have been tested in patients with higher starting pressure. Quantitative comparison For the full table, please open this article on visualfieldtest.com. Sources include the first-line glaucoma medication network meta-analysis, Vyzulta clinical review, ROCKET netarsudil trials, ROCKET-4, MERCURY Rocklatan pooled analysis, and fixed-combination medication meta-analysis. () NCX 470 versus latanoprost This is the best-established comparison. NCX 470 appears to provide: Approximately 0.5 to 0.8 millimeters of mercury more mean diurnal reduction in MONT BLANC. Approximately 0 to 0.8 millimeters of mercury more reduction in DENALI. A somewhat stronger morning effect, but the difference at 8:00 a.m. was inconsistent and small, ranging from 0.22 to 0.58 millimeters of mercury in MONT BLANC. The advantage is therefore statistically credible but clinically modest. NCX 470 versus bimatoprost This question is central because NCX 470 releases bimatoprost-related activity. NCX 470 has not been directly compared with marketed bimatoprost in a large pivotal human trial. A network meta-analysis of first-line drugs estimated that bimatoprost reduced pressure by approximately 5.61 millimeters of mercury, compared with 4.85 millimeters of mercury for latanoprost, a difference of approximately 0.76 millimeters of mercury. Network meta-analysis () That is important because the average NCX 470 advantage over latanoprost—roughly 0.5 to 0.8 millimeters of mercury—is similar in size to the historical advantage often reported for bimatoprost over latanoprost. Therefore, the pivotal trials do not prove that nitric oxide adds a large benefit beyond bimatoprost itself. Some of the observed difference may come from the bimatoprost component rather than the nitric oxide component. NCX 470 versus Vyzulta Vyzulta, or latanoprostene bunod, is the closest mechanistic competitor because it also combines a prostaglandin effect with nitric oxide donation. In the APOLLO and LUNAR trials: Mean baseline diurnal pressure was approximately 26.7 millimeters of mercury for latanoprostene bunod and 26.5 millimeters of mercury for timolol. Three-month mean pressure was approximately 17.8 millimeters of mercury with latanoprostene bunod and 19.1 millimeters of mercury with timolol. The implied reduction was approximately 8.9 millimeters of mercury with latanoprostene bunod, compared with approximatSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/a-new-scan-may-detect-glaucoma-progression-years-before-it-shows-up-on-a-visual-field-testTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:A New Scan May Detect Glaucoma Progression Years Before It Shows Up on a Visual Field Test Introduction A study published online on September 3, 2026, reported that optical coherence tomography angiography, or OCTA, detected event-based glaucoma progression an average of 2.3 years before visual-field progression. Conventional structural optical coherence tomography, or OCT, detected progression about 1.5 years before visual-field progression. JAMA Ophthalmology study () That sounds like a major breakthrough. It could imply that clinicians might identify worsening glaucoma long before patients lose measurable vision. However, the result needs careful interpretation. The study did not prove that OCTA detects the biological beginning of glaucoma damage two years earlier. It showed that an OCTA measurement crossed a predefined statistical threshold before a visual-field algorithm crossed its own threshold. Those are not necessarily the same thing. The most defensible conclusion is: > OCTA may provide an earlier vascular signal of progression in some eyes, but the evidence does not yet show that it reliably outperforms the best structural OCT strategy or that every OCTA alert represents irreversible retinal ganglion-cell loss. The New Study: What It Actually Found Study design and participants The study used patients from the Diagnostic Innovations in Glaucoma Study, a longitudinal research cohort. It included: 116 patients 180 eyes 111 eyes with perimetric glaucoma, meaning repeatable visual-field damage was already present 69 preperimetric eyes, meaning glaucomatous optic-nerve or structural damage was present without repeatable visual-field loss Mean age: 67.6 years Mean follow-up: 5.1 ± 1.4 years Minimum eligibility: at least 2 years of follow-up and at least four visits with each testing method The public abstract does not provide a detailed breakdown into mild, moderate, and advanced glaucoma. Therefore, it is not possible to know from the published abstract whether the two-year lead time was concentrated in early disease, moderate disease, advanced disease, or spread evenly across stages. JAMA Ophthalmology study () What was measured? The study compared: OCTA vessel-density change Circumpapillary retinal nerve fiber layer thickness change, measured by structural OCT Visual-field progression The abstract states that OCT and OCTA progression were defined as a change exceeding test-retest variability at two consecutive visits. Visual-field progression was assessed using the instrument’s Guided Progression Analysis. Important details are not available in the public abstract: The exact OCTA device The scan size Whether the main metric was peripapillary vessel density, optic-nerve-head vessel density, macular vessel density, or a combined measure The exact retinal slab The numerical test-retest thresholds Whether visual-field progression meant “possible” or “likely” Guided Progression Analysis progression Whether the structural OCT algorithm used only event analysis or also a slope-based trend analysis These missing details matter because OCTA vessel-density values are highly dependent on the device, scan size, software version, segmentation method, signal strength, and region measured. A related 2024 study from the same research group used an Optovue Avanti AngioVue system, with a 4.5-by-4.5-millimeter optic-nerve-head scan and a peripapillary annulus. But that study should not automatically be assumed to have used the identical protocol. Related event-based OCT/OCTA study () Progression detection During follow-up: For the full table, please open this article on visualfieldtest.com. Among the 107 eyes classified as progressing by at least one method: OCTA was the earliest detector in 40 eyes, or 37.4% Circumpapillary retinal nerve fiber layer OCT was earliest in 32 eyes, or 29.9% Visual-field testing was earliest in 26 eyes, or 24.3% These figures do not mean that OCTA was correct in 37.4% of all patients. They mean that among eyes in which at least one test detected progression, OCTA was the first test to cross that study’s threshold in about one-third of cases. Specificity and false-positive rates Among 45 eyes considered stable, reported specificity was: OCTA: 68.9% Circumpapillary retinal nerve fiber layer OCT: 75.6% That corresponds to approximate false-positive rates of: OCTA: 31.1%, or about 14 of the 45 stable eyes Circumpapillary retinal nerve fiber layer OCT: 24.4%, or about 11 of the 45 stable eyes This is an important limitation. The OCTA signal appeared earlier, but it was also less specific than the structural OCT measurement. The study did not report a conventional sensitivity against an independent gold standard because there is no perfect gold standard for slow glaucoma progression. Visual fields cannot serve as a completely independent reference when the question is whether OCTA detects change before visual fields. The number 58 of 107 progressing eyes, or approximately 54%, is a detection proportion, not a true sensitivity. Exact lead time The reported mean lead times were: OCTA before visual-field progression: 2.3 years 95% confidence interval: 1.3 to 3.2 years Circumpapillary retinal nerve fiber layer OCT before visual-field progression: 1.5 years 95% confidence interval: 0.6 to 2.4 years OCTA versus structural OCT: 0.2 years 95% confidence interval: −0.6 to 0.9 years That last comparison is crucial. The study did not show a clear two-year advantage over structural OCT. The difference between OCTA and retinal nerve fiber layer OCT was only 0.2 years, and the confidence interval included no difference and even favored structural OCT slightly. Therefore: > The strongest finding was that OCTA crossed its progression threshold earlier than visual fields. The evidence that OCTA is meaningfully earlier than structural OCT is weak. Why the Two-Year Advantage Should Not Be Accepted at Face Value It is a comparison of thresholds, not necessarily disease onset Visual-field progression is difficult to detect because visual-field testing is noisy. A test may need several abnormal results before the Guided Progression Analysis labels progression. OCTA may therefore appear to lead visual fields for two reasons: OCTA detected genuine earlier biological change. The visual field required more time and more repeated tests to overcome measurement noise. The study cannot fully distinguish these possibilities. The definition of progression was not identical across tests OCTA and OCT were considered positive when a measurement exceeded test-retest variability on two consecutive visits. Visual fields used Guided Progression Analysis. These algorithms ask different questions: OCTA asks whether a quantitative imaging measurement fell beyond an expected repeatability boundary. Structural OCT asks whether tissue thickness changed beyond its own boundary. Visual-field analysis asks whether sensitivity at selected points worsened beyond expected variability. A test with a lower threshold or greater biological responsiveness will tend to be classified as “earlier,” even if it is not more accurate. The study was retrospective and based on a referral cohort The Diagnostic Innovations in Glaucoma Study is valuable, but it is not a random sample of the general glaucoma population. Referral-center cohorts often contain: More atypical cases More established glaucoma More patients with suspicious or borderline findings More frequent imaging than ordinary clinical practice The results may not apply equally to patients with mild glaucoma, ocular hypertension, high myopia, cataract, diabetes, or poor-quality scans. The stable group was small The specificity estimate was based on only 45 stable eyes. A small change in the number of apparent false positives could substantially change the reported specificity. “Earlier” did not necessarily mean “actionable” An OCTA measurement might decline two years before the field crosses a statistical threshold, but the clinician still needs to know: Is the decline repeatable? Is it topographically consistent with the retinal nerve fiber layer or ganglion-cell layer? Is it still present after signal-strength correction? Could it reflect blood pressure, intraocular pressure, medication, or cataract changes? Does it predict future visual disability? The study did not establish that an OCTA alert should automatically lead to treatment escalation. Could the Early OCTA Signal Be an Artifact? Yes. Several explanations are biologically plausible. Visual-field noise Standard automated perimetry varies because of: Attention Fatigue Learning effects False-positive responses False-negative responses Fixation instability Dry eye and blinking Anxiety Advanced damage at the tested location The variability is often greater at already damaged locations. Guided Progression Analysis is designed to reduce false alarms, but false positives still occur. In one analysis of stable visual fields, the five-year cumulative false-positive rate was approximately 34% for “possible progression” and 7% for “likely progression.” Global mean-deviation and visual-field-index trend criteria had lower five-year false-positive rates of approximately 4% to 5%. Visual-field progression analSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/scientists-found-a-new-abnormality-inside-human-glaucoma-nerve-cells-could-it-lead-to-a-new-treatmentTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Scientists Found a New Abnormality Inside Human Glaucoma Nerve Cells — Could It Lead to a New Treatment? Short answer: Possibly—but the evidence is still early. A newly published human donor-retina study found that glaucoma was associated with less sphingomyelin inside retinal ganglion cells, more acid sphingomyelinase protein, and greater activity of the lysosomal form of that enzyme. The study also found more retinal ganglion cells containing ceramide aggregates, although total ceramide was not significantly higher overall. That pattern is biologically interesting because acid sphingomyelinase can break down sphingomyelin into ceramide. Excessive or mislocalized ceramide can disturb lysosomes, cell membranes, autophagy, mitochondria, inflammatory signaling, and programmed cell death. However, the human study is observational and postmortem. It does not prove that acid sphingomyelinase starts glaucoma or that inhibiting it will preserve vision. The strongest evidence for causality still comes from animal and cell studies, not from patients. > My overall interpretation: Acid sphingomyelinase is a credible contributor to retinal ganglion-cell injury in at least a subset of glaucoma, but it is unlikely to be the only cause or a universal treatment target. --- What the New Human Study Actually Found The newest study, published online on August 31, 2026, examined donated human retinas from people with and without a glaucoma diagnosis. It used a sphingomyelin-binding probe called enhanced green fluorescent protein-conjugated non-toxic lysenin and identified retinal ganglion cells using the retinal ganglion-cell marker RNA-binding protein with multiple splicing. The researchers also measured acid sphingomyelinase, neutral sphingomyelinase, sphingomyelin synthase 1, sphingomyelin synthase 2, enzyme activity, and ceramide distribution. Human glaucoma donor-retina study () What can be determined from the currently accessible report? For the full table, please open this article on visualfieldtest.com. The article is currently labeled an early accepted version that may undergo further editing before the final version of record. Therefore, exact numeric values should be taken from the full downloadable article and supplementary data once they are accessible in a stable form, rather than reconstructed from figures or secondary summaries. Scientific Reports article page () The most important negative finding The study did not show a simple, uniform increase in total ceramide throughout the retina. That matters. A straightforward model would predict: > More acid sphingomyelinase → less sphingomyelin → more total ceramide. Instead, the study found: > Less sphingomyelin in retinal ganglion cells → more acid sphingomyelinase → more ceramide-containing aggregates, but no statistically significant increase in total retinal ganglion-cell ceramide. This suggests that the important abnormality may be local ceramide clustering, rather than a large increase in the average ceramide concentration across the whole retina. That is biologically plausible because ceramide can act as a membrane-organizing signal. A small amount concentrated in the wrong lysosomal or plasma-membrane domain may be more damaging than a larger amount dispersed throughout the cell. --- Why the Study Is Interesting but Not Yet Proof of Cause The human findings support a coherent mechanism, but several alternative explanations remain possible. Acid sphingomyelinase may increase because retinal ganglion cells are already dying Damaged neurons often activate lysosomal enzymes, inflammatory pathways, and membrane-recycling systems. Therefore, increased acid sphingomyelinase could be: an early cause of retinal ganglion-cell injury; a response to mechanical, vascular, or metabolic injury; or a late consequence of degeneration. The human study cannot determine the timing because postmortem tissue provides only one snapshot. Lower sphingomyelin may partly reflect cell loss Glaucomatous retinas contain fewer retinal ganglion cells. A whole-retina dot blot can therefore show lower sphingomyelin simply because the tissue contains fewer sphingomyelin-rich neurons. The cell-level analysis is stronger because it compares sphingomyelin labeling in identified retinal ganglion cells. Even then, survivor bias remains possible: the analysis may compare surviving glaucoma retinal ganglion cells with healthy cells while missing the most severely damaged cells that have already disappeared. The lysenin probe does not measure every sphingomyelin species equally Enhanced green fluorescent protein-conjugated lysenin preferentially binds certain, especially longer-chain, sphingomyelin species. It is therefore best interpreted as a measure of accessible membrane-associated sphingomyelin, not necessarily a complete measurement of every sphingomyelin molecule in the cell. Visualizing sphingomyelin in the retina () Postmortem tissue is vulnerable to artificial biochemical changes Important limitations include: postmortem delay, which can alter lysosomal pH and enzyme activity; hypoxia or agonal illness before death; systemic infection, diabetes, vascular disease, or inflammation; cause of death; age and sex differences; glaucoma medications; antidepressant or antihistamine exposure; retinal region sampled; fixation and tissue-processing differences; incomplete removal of vitreous or other surrounding tissue; loss of fragile or already-degenerated cells; uncertainty about the exact glaucoma subtype and severity. These factors are particularly important because acid sphingomyelinase is a stress-responsive enzyme. --- Reconstructing the Proposed Pathway The proposed pathway is: > Acid sphingomyelinase activation → sphingomyelin breakdown → ceramide generation and clustering → lysosomal and membrane dysfunction → mitochondrial stress → apoptosis → retinal ganglion-cell and axon loss Each step has a different level of evidence. Step 1: Acid sphingomyelinase activation Acid sphingomyelinase is encoded by the SMPD1 gene. Its main form is located inside lysosomes, where it works best in an acidic environment. A separate form can be processed and secreted outside the cell. The lysosomal form is often described as the zinc-independent pool, whereas secreted acid sphingomyelinase is more dependent on zinc at neutral extracellular pH. The new human study found increased retinal ganglion-cell acid sphingomyelinase expression and increased zinc-independent activity, while the secretory pool did not significantly change. That pattern points toward an intracellular lysosomal abnormality rather than a generalized rise in circulating or extracellular enzyme. Step 2: Sphingomyelin breakdown Acid sphingomyelinase converts sphingomyelin into: ceramide; phosphorylcholine. Sphingomyelin is not merely structural fat. It contributes to: plasma-membrane stability; membrane thickness and order; lipid-raft organization; receptor signaling; lysosomal membrane properties; vesicle trafficking. The 2022 retinal and optic-nerve-head study found that sphingomyelin species were concentrated in the retinal ganglion-cell layer, optic nerve, and choroidal regions. In experimental ocular hypertension, retinal acid sphingomyelinase activity increased from approximately 54.98 mU/mg protein at baseline to 121.6 mU/mg protein, about a 2.2-fold increase. In the optic nerve head, activity increased from approximately 95.6 to 267.0 mU/mg protein, about a 2.8-fold increase. Sphingomyelinases in retinas and optic nerve heads () Step 3: Ceramide accumulation and clustering Ceramide is a signaling lipid, not simply a waste product. Depending on its chain length, location, and concentration, ceramide can: promote membrane-domain formation; cluster death receptors; alter calcium handling; impair vesicle trafficking; affect lysosomal stability; stimulate inflammatory signaling; disrupt mitochondrial membranes; activate caspases and apoptosis. The new human glaucoma study suggests that ceramide aggregation in selected retinal ganglion cells may be more important than total retinal ceramide. This would explain why whole-tissue lipidomics may fail to detect a large increase: the damaging signal may be concentrated in a small number of vulnerable cells. Step 4: Lysosomal and autophagy dysfunction Lysosomes must maintain a precise lipid composition. Too much sphingomyelin can impair lysosomal function, but too little acid sphingomyelinase can also be harmful. This is demonstrated by acid sphingomyelinase-deficient mice. Complete deletion caused: progressive photoreceptor degeneration; reduced electroretinogram responses; retinal pigment epithelium dysfunction; lipofuscin accumulation; abnormal sphingomyelin and sphingosine accumulation; increased autophagosome-associated protein. Lack of acid sphingomyelinase induces age-related retinal degeneration () This is a critical warning: complete acid sphingomyelinase blockade is not a safe therapeutic goal. The likely goal would be partial, localized, and disease-stage-specific reduction. Step 5: Mitochondrial stress Retinal ganglion cells are highly energy-dependent neurons with long axons. Mitochondrial dysfunction is an established earlySupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/a-glaucoma-eye-drop-designed-to-protect-the-optic-nerve-is-already-in-phase-ii-trialsTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:A Glaucoma Eye Drop Designed to Protect the Optic Nerve Is Already in Phase II Trials Status reviewed: September 4, 2026 Introduction Glaucoma treatment has one major limitation: lowering intraocular pressure protects the eye indirectly, but it does not directly repair or support retinal ganglion cells. Some patients continue to lose retinal nerve fibers and visual field despite apparently acceptable pressure control. G01 eye drops are designed to address that gap. The active ingredient is described as recombinant human nerve growth factor variant 2, or rhNGF-V2. The drug is being tested in a randomized Phase II trial in people with progressing primary open-angle glaucoma whose intraocular pressure is already controlled. The central question is whether a protein placed on the eye’s surface can reach the retina and optic nerve in a sufficient amount to: keep stressed retinal ganglion cells alive; restore function to damaged but living cells; stabilize retinal nerve fiber and ganglion-cell layers; or, more ambitiously, regenerate damaged optic-nerve connections. The short answer is: > G01 is biologically plausible as a neuroprotective and possibly neuroenhancing treatment. Genuine optic-nerve regeneration is much less established. The largest unresolved problem is whether enough of the drug reaches the posterior eye after topical dosing. The evidence is promising but uneven. Much of the strongest evidence comes from animal models and a small human case series. A previous randomized trial of conventional recombinant human nerve growth factor was safe but did not show statistically significant short-term improvement. G01 may be more potent because it is a modified molecule, but that remains unproven in humans. --- The Current Phase II G01 Trial The study is registered as NCT07777861, titled: > “A Randomized, Double-Masked, Placebo-Controlled Phase II Clinical Trial Evaluating the Efficacy and Safety of G01 Eye Drops in the Treatment of Optic Nerve Injury Associated With Open-Angle Glaucoma.” It is being sponsored by Qingdao WanMing BioCell Pharmaceutics Co., Ltd. in China. The trial began enrolling on March 18, 2026. The registry lists an estimated 90 participants, with primary completion expected on October 1, 2027, and overall study completion on December 1, 2027. No results had been posted as of September 4, 2026. G01 trial record () Trial design For the full table, please open this article on visualfieldtest.com. The public registry lists two active concentrations and a placebo. Its summary formatting is not entirely consistent about the number of “groups,” but the intervention listing clearly describes two active dose arms plus a matched placebo arm. The precise allocation ratio is not stated in the accessible public record. G01 trial record () Who can enter the study? The trial is designed for people with active, measurable glaucoma progression, not simply people with an abnormal optic nerve. Key inclusion criteria include: Primary open-angle glaucoma in one or both eyes. Progression in the study eye demonstrated by Guided Progression Analysis of visual-field tests. Visual-field mean deviation between −3 and −16 decibels. Best-corrected visual acuity of at least 0.3 in decimal notation. Intraocular pressure between 10 and 21 millimeters of mercury, with pressure considered stable by the investigator. Ability to attend visits, follow the protocol, and provide informed consent. Agreement to use effective contraception when applicable. The mean-deviation range is important. A value closer to zero represents better visual-field function. A value of −16 decibels represents substantially more damage than −3 decibels. However, the trial excludes many patients with end-stage glaucoma, especially those with mean deviation worse than −16 decibels or only a small central island of remaining vision. G01 trial record () Major exclusion criteria The public protocol excludes patients with: Angle-closure, secondary, or inflammatory forms of glaucoma. Ocular hypertension without established glaucoma. Active or recently active herpes keratitis. Significant infection, uveitis, keratitis, endophthalmitis, or other ocular inflammation. Retinal disease, pathological myopia, diabetic retinopathy, retinal vascular occlusion, retinal detachment, retinitis pigmentosa, or another optic neuropathy that could affect the measurements. Severe macular or optic-nerve disease unrelated to glaucoma. Monocular status. Recent corneal surgery, intraocular surgery, ocular trauma, laser trabeculoplasty, or glaucoma-filtering surgery. Conditions that make intraocular-pressure measurement unreliable. Known allergy to the study drug or placebo. Recent or ongoing treatment with other potentially neuroprotective agents, including brimonidine, citicoline, nicotinamide, coenzyme Q, ginkgo biloba extract, mecobalamin, other nerve growth factor products, and certain biological preparations. Systemic corticosteroids or other immunosuppressive medications. Poorly controlled diabetes, severe cardiovascular disease, severe liver or kidney disease, or significant blood disorders. Active malignancy or ongoing chemotherapy. Pregnancy or breastfeeding. Heavy cigarette or alcohol use, recent drug dependence, or participation in another clinical trial. These exclusions make scientific sense because they reduce competing causes of visual-field change. However, they also mean the study will not tell us whether G01 works in combination with nicotinamide, brimonidine, citicoline, or other neuroprotective therapies. G01 trial record () --- What the Trial Will Measure Primary endpoint: visual-field mean deviation The primary endpoint is the change from baseline in visual-field mean deviation at Day 168, corresponding to approximately 24 weeks of treatment. Mean deviation is a summary score from automated visual-field testing. A worsening score generally indicates loss of visual sensitivity. An improvement would suggest that the patient detects dimmer test lights than at baseline. However, mean deviation is not a perfect measurement of retinal ganglion-cell health. It is influenced by: patient attention; fatigue; learning effects; cataract or ocular-surface disease; refractive correction; test reliability; day-to-day biological variability. A single positive mean-deviation result would therefore be insufficient to prove neural recovery. Secondary visual-field assessments Visual-field mean deviation is also measured at: Day 28; Day 84; Day 252; Day 336. The later measurements are particularly valuable because the treatment period ends at approximately Day 168. If a benefit remains at Days 252 and 336, that would support a persistent biological effect rather than a short-lived testing artifact. The trial does not appear to use a conventional long-term visual-field slope as its primary endpoint. That is a limitation. A 24-week period is short for proving that glaucoma progression has slowed, particularly when visual-field tests are noisy. Retinal nerve fiber layer thickness The trial measures retinal nerve fiber layer thickness by optical coherence tomography at Days 28, 84, 168, 252, and 336. The retinal nerve fiber layer contains the axons of retinal ganglion cells as they converge toward the optic nerve. A successful neuroprotective drug might cause: slower thinning; stabilization of thickness; or, less likely, measurable thickening if some axons or supporting structures recover. A major caution is that dead retinal ganglion-cell axons cannot normally be restored simply by keeping the remaining cells healthy. Therefore, the most realistic structural result would be less thinning, not a large increase in retinal nerve fiber layer thickness. Macular ganglion-cell inner plexiform layer The trial also measures the macular ganglion-cell inner plexiform layer. This layer is often useful because it captures the cell bodies and dendritic structures of retinal ganglion cells in the central retina. It may be more sensitive than peripapillary retinal nerve fiber layer measurements in some stages of glaucoma. Again, an apparent increase could have several explanations: genuine recovery of stressed cells; changes in dendritic structure; altered tissue hydration; segmentation error; measurement noise. A convincing result would require reproducible, dose-related preservation across multiple scans and preferably agreement with visual-field and visual-evoked-potential findings. Pattern visual-evoked potential The trial measures the P100 wave amplitude and latency of the pattern visual-evoked potential. This test records electrical responses from the visual system after a patterned image is shown. In general: higher P100 amplitude can indicate stronger visual pathway responses; shorter P100 latency can indicate faster conduction. The test is potentially valuable because it examines function along the visual pathway rather than only the retina. However, it is affected by visual acuity, attention, refractive error, electrode placement, and technical factors. A genuine recovery signal would ideally involve: improved or preserved mean deviation; increased or stabilized P100 amplitude; reduced or stabilized P100 latency; no meaningful intraocular-pressure difSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/helping-eye-cells-take-out-their-trash-may-protect-the-optic-nerve-from-glaucomaTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Helping Eye Cells Take Out Their Trash May Protect the Optic Nerve From Glaucoma Evidence review current to September 2, 2026 Introduction Lowering eye pressure remains the most proven way to slow glaucoma. Yet some people continue to lose retinal nerve tissue and vision even when their eye pressure is considered controlled. This is especially relevant in normal-tension glaucoma, but it can also occur in ordinary open-angle glaucoma after pressure-lowering treatment. One possible explanation is that pressure is only the initial stress. The lasting damage may also depend on whether retinal ganglion cells can maintain their mitochondria, transport cellular cargo along their axons, control oxidative stress, and remove damaged cell parts. A study published in 2026 provides some of the clearest evidence so far for this idea. The investigators used Torin 2, a powerful laboratory inhibitor of the mechanistic target of rapamycin pathway, to increase autophagy and mitophagy—the processes cells use to recycle damaged proteins and mitochondria. In mouse glaucoma models, Torin 2 reduced the buildup of abnormal mitochondria and preserved retinal ganglion cells, optic nerve axons, and electrical retinal responses. It also increased survival of retinal ganglion cells in human retinal tissue maintained in the laboratory. () The findings are important, but they do not establish Torin 2 as a treatment. The compound was given by injection into the mouse eye at a research concentration, it has broad kinase effects, visual behavior was not tested, and the study did not directly measure mitochondrial respiration or energy production. The most useful interpretation is narrower: > Glaucoma may involve a failure of mitochondrial quality control, and selectively restoring mitochondrial clearance could become a form of pressure-independent neuroprotection. What the Recent Torin 2 Study Actually Showed The experimental design The study used several complementary approaches: A glucocorticoid-induced ocular hypertension mouse model, in which eye pressure was elevated for 10 weeks. A mutant myocilin mouse model, representing a form of inherited open-angle glaucoma. Mt-Keima reporter mice, which allow researchers to measure mitophagy flux—the delivery of mitochondria to acidic lysosomes for degradation. Retinal ganglion-cell-specific deletion of autophagy-related gene 5, testing what happens when autophagy is removed directly from retinal ganglion cells. Human retinal explants, cultured outside the body under conditions that normally cause progressive retinal ganglion-cell death. () The investigators found that chronic eye-pressure elevation caused abnormal mitochondrial accumulation, oxidative DNA damage, and reduced mitophagy flux. Importantly, the mitophagy defect appeared before substantial retinal ganglion-cell loss, suggesting that impaired clearance may be an early event rather than merely a consequence of dying neurons. () Reported effects of Torin 2 For the full table, please open this article on visualfieldtest.com. The pattern electroretinogram result can be expressed in two ways: Compared with injured vehicle-treated eyes, the mean response was approximately 83% higher: \[ (31.82 - 17.36) / 17.36 \approx 83\% \] Relative to the entire deficit between injured eyes and non-hypertensive controls, Torin 2 closed approximately 92% of the electrophysiological gap: \[ (31.82 - 17.36) / (33.04 - 17.36) \approx 92\% \] These calculations should not be interpreted as “92% vision restoration.” Pattern electroretinogram amplitude is a laboratory measure of inner-retinal function, not the same as visual acuity or visual-field preservation. What happened when autophagy was removed? The genetic experiments strengthened the argument that autophagy is not merely an incidental response. When autophagy-related gene 5 was selectively removed from retinal ganglion cells: Pattern electroretinogram amplitude fell from 21.78 to 8.61 microvolts, a reduction of approximately 60%. Retinal ganglion-cell number fell by approximately 39%. The number of healthy optic nerve axons fell by approximately 59%. Swollen and abnormal mitochondria accumulated in retinal ganglion-cell axons. Oxidative DNA damage increased. () A separate 2026 study using autophagy-related gene 7 and autophagy-related gene 5 deletion found progressive retinal ganglion-cell and optic nerve degeneration without inducing high eye pressure. The retinal ganglion-cell bodies accumulated swollen mitochondria, distended endoplasmic reticulum, abnormal synaptic vesicles, and enlarged Golgi structures. () This supports the idea that normal, ongoing autophagy is necessary for retinal ganglion-cell housekeeping, even in the absence of glaucoma-related pressure elevation. What did Torin 2 do to “mitochondrial function”? The answer requires precision. Torin 2: increased measured mitophagy flux; reduced the accumulation of structurally abnormal mitochondria; improved the apparent pool of healthy mitochondria; reduced oxidative DNA damage; improved axonal transport and electrical retinal function. However, the study did not report direct measurements of: adenosine triphosphate production; oxygen consumption; respiratory-chain complex activity; mitochondrial membrane potential; calcium handling; mitochondrial adenosine triphosphate reserve. Therefore, it is safest to say that Torin 2 improved mitochondrial quality control and mitochondrial structural health, while direct restoration of mitochondrial bioenergetics remains to be demonstrated. Important limitations The study has several important limitations: Torin 2 was administered by intravitreal injection, not as a clinically practical eye drop or tablet. The reported concentration—1 millimolar in mice—cannot be translated directly into a human dose. The human experiment involved retinal tissue outside the body, exposed to 100 micromolar Torin 2 under artificial stress conditions. The treatment was tested over a relatively short period. The mutant myocilin model had a fall in eye pressure after Torin 2, making it difficult to separate direct neuroprotection from pressure reduction. The glucocorticoid model did not show an eye-pressure reduction, making that model more persuasive for pressure-independent retinal protection. No living-human safety data exist for Torin 2 as an eye treatment. No behavioral test of vision was performed. () Why Retinal Ganglion Cells Are So Dependent on Mitochondria Retinal ganglion cells are unusually vulnerable to energy failure for several anatomical and physiological reasons. They have long, energy-demanding axons Retinal ganglion-cell axons travel from the retina through the optic nerve and eventually to visual centers in the brain. Much of the axon within the retina and optic nerve head is unmyelinated. Unlike a myelinated nerve, an unmyelinated axon must continuously restore ion gradients along a large length of membrane after each electrical impulse. That requires constant activity from sodium-potassium pumps and other energy-consuming transport systems. Retinal ganglion cells also maintain large dendritic trees, synapses, and active transport pathways. Their energy demand is therefore high even at rest. () Mitochondria must be positioned throughout the neuron Mitochondria are not useful only in the cell body. They must be moved to: dendritic synapses; the axon initial segment; the optic nerve head; regions of high calcium influx; distant axonal terminals in the brain. The optic nerve head is particularly vulnerable because retinal ganglion-cell axons bend sharply and undergo major structural changes as they pass from the retina into the optic nerve. Their high mitochondrial density in this region reflects the need to support electrical activity and axonal transport. () Retinal ganglion cells cannot dilute damaged organelles by dividing Retinal ganglion cells are long-lived, postmitotic neurons. A dividing cell can distribute damaged proteins and organelles between daughter cells. A retinal ganglion cell cannot. It must repair, recycle, or remove its own damaged components for decades. This makes defective autophagy particularly dangerous. If damaged mitochondria are not removed, they can: produce excessive reactive oxygen species; release oxidized mitochondrial DNA; impair adenosine triphosphate production; disrupt calcium balance; activate apoptotic pathways; obstruct axonal transport; damage synapses and dendrites. The 2026 autophagy-deficiency study directly observed this type of intracellular accumulation in retinal ganglion cells. () Why Damage Can Continue Even When Eye Pressure Is Controlled Eye pressure remains important, but it is not the only determinant of retinal ganglion-cell survival. Pressure-related stress can initiate a chain of secondary problems: Compression or distortion at the optic nerve head. Impaired axonal transport. Reduced delivery of target-derived survival factors. Mitochondrial transport failure. Energy shortage and oxidative stress. Synapse and dendrite loss. Neuroinflammation and glial dysfunction. Irreversible retinal ganglion-cell death. Once this process becomes self-sustaining, lowering pressure may remove the original trigger without immediSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/could-one-extra-injection-make-glaucoma-surgery-last-longer-new-evidence-points-to-better-trabeculectomy-successTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Could One Extra Injection Make Glaucoma Surgery Last Longer? New Evidence Points to Better Trabeculectomy Success Evidence reviewed through August 30, 2026 Introduction Trabeculectomy remains one of the most powerful operations for lowering eye pressure in advanced or progressing glaucoma. It can reduce eye pressure to levels that are difficult to achieve with eye drops, laser treatment, or many newer minimally invasive procedures. Its main weakness is scarring. After surgery, the body may treat the new drainage pathway as an injury that needs to be repaired. Fibroblasts move into the area, collagen is deposited, and the filtering bleb can become thick, flat, or sealed. When that happens, the operation may gradually lose its effect. A new long-term report suggests that a single intravitreal injection of bevacizumab given during trabeculectomy, in addition to mitomycin C, may substantially improve the chance that the operation remains medication-free three years later. The reported difference is striking: 92.3% medication-free success with bevacizumab plus mitomycin C 71.2% medication-free success with mitomycin C alone Absolute difference: approximately 21 percentage points Approximate number needed to treat: 5 patients The result is important, but it is not yet enough to conclude that every patient undergoing trabeculectomy should receive the injection. The trial was relatively small, took place at one center, involved a largely European-ancestry population, and has not yet been independently reproduced with the same technique. The Short Answer The new evidence is promising and biologically plausible, and it is stronger than most earlier studies of anti–vascular endothelial growth factor treatment during trabeculectomy. However, the evidence currently supports the following conclusion: > Intravitreal bevacizumab may be a useful adjunct to mitomycin C in selected trabeculectomy patients, but it is not yet established routine care. The apparent benefit seems to come mainly from better control of the early postoperative wound-healing response, rather than from permanently lowering eye pressure by itself. The injection produced larger, less inflamed blebs early after surgery, and this early advantage was associated with fewer medications and fewer failures later. The next step should be larger, independent, multicenter trials with more diverse patients and at least five years of follow-up. What the New Randomized Trial Actually Found Study design and patient population The study was the three-year follow-up of the Bevacizumab in Trabeculectomy Study, conducted at a single tertiary ophthalmic center in South Australia. It included adults with progressing glaucoma for which the treating surgeon believed trabeculectomy was necessary. Participants could undergo: Primary trabeculectomy Redo trabeculectomy Trabeculectomy combined with cataract surgery A total of 131 patients were randomized: 65 patients received bevacizumab 66 patients received placebo The bevacizumab group received 1.25 milligrams in 0.05 milliliters by intravitreal injection at the end of trabeculectomy. The control group received an intravitreal injection of balanced salt solution. Both groups also received trabeculectomy with mitomycin C. The surgical protocol used: Mitomycin C concentration of 0.04% Two minutes of exposure for lower-risk eyes Three minutes for higher-risk eyes A standardized fornix-based surgical technique A standardized scleral flap and suturing approach The original trial was double-masked, randomized, and placebo-controlled. Both the patient and surgical team were masked to whether bevacizumab or placebo had been injected. The randomization was stratified by surgeon and by primary versus redo trabeculectomy in the original trial. Intravitreal Bevacizumab Improves Trabeculectomy Survival at 3 Years () There were some important population details: The average age was approximately 76 years. About 91% of eyes underwent primary rather than redo trabeculectomy. Nearly all participants were of European ancestry: 129 of 131 participants in the original report. Combined cataract surgery was more common in the bevacizumab group: approximately 34% compared with 18% in the control group. Active retinal vascular disease, active iris neovascularization, and several unusual forms of glaucoma were excluded. The cataract-surgery imbalance is important. Combined cataract surgery can sometimes reduce trabeculectomy success, although the investigators found that it did not independently explain the results. How did the researchers define success? The study used a personalized target eye pressure, based on the patient’s preoperative eye pressure and visual-field damage. This is more individualized than simply defining success as an eye pressure below 21 millimeters of mercury. Complete success Complete success meant that: Eye pressure remained at or below the patient’s target No topical pressure-lowering medication was needed This is the basis for the widely reported 92% versus 71% medication-free success result. Qualified success Qualified success meant that: Eye pressure remained at or below the target Additional eye drops were allowed if needed Failure Failure occurred if: Eye pressure was above the target on at least two occasions despite maximum medical treatment Further glaucoma filtration surgery was required Irreversible blindness resulted from glaucoma or a surgical complication A return to the operating room to treat early hypotony-related maculopathy was not automatically classified as surgical failure because it is a recognized complication of filtration surgery. Intravitreal Bevacizumab Improves Trabeculectomy Survival at 3 Years () Three-year results At 36 months, the reported survival estimates were: For the full table, please open this article on visualfieldtest.com. The statistical results were: Complete success: P = .001 Hazard ratio for complete-success failure: 0.17, 95% confidence interval 0.06 to 0.52, P = .002 Qualified success: P = .03 Hazard ratio for qualified-success failure: 0.07, 95% confidence interval 0.01 to 0.80, P = .03 A hazard ratio of 0.17 suggests that the bevacizumab group experienced approximately 83% fewer failures over the follow-up period, although hazard ratios should not be interpreted as exactly the same as an 83% reduction in individual patient risk. Absolute risk reduction and number needed to treat Using the reported three-year success percentages: Complete success Failure with bevacizumab: approximately 7.7% Failure with mitomycin C alone: approximately 28.8% Absolute reduction in failure: approximately 21.1 percentage points Approximate number needed to treat: 5 In practical terms, if the result applies to similar patients, treating about five patients with the additional intravitreal injection could result in one additional patient remaining medication-free at three years. Qualified success Failure with bevacizumab: approximately 1.5% Failure with mitomycin C alone: approximately 10.6% Absolute reduction in failure: approximately 9.1 percentage points Approximate number needed to treat: 11 These numbers are approximate because the study used survival analysis with some loss to follow-up, rather than a simple comparison in which every patient was observed continuously for exactly three years. Did bevacizumab permanently lower eye pressure? Not clearly. The bevacizumab group had lower eye pressure at approximately one month, but later average eye pressures were similar. This does not mean the treatment had no effect. The control group required more rescue treatment, including: Additional eye drops Bleb needling with 5-fluorouracil Further glaucoma surgery Once these rescue treatments were given, the average eye pressures in the two groups became more similar. Therefore, the more meaningful result may be that bevacizumab helped the original operation work without additional treatment. Did it reduce repeat glaucoma surgery? The 12-month report found that approximately: 2% of patients in the bevacizumab group required further glaucoma surgery 10% of control patients required further glaucoma surgery That is an approximate absolute reduction of 8 percentage points, corresponding to a rough number needed to treat of 13 to avoid one additional glaucoma operation during the first year. However, the three-year publication primarily reported survival outcomes rather than a detailed, independently powered comparison of repeat operations. It would be inappropriate to assume that the same eight-percentage-point reduction continues unchanged to five years. Intravitreal Bevacizumab Improves Trabeculectomy Survival at 12 Months () What Happened to the Bleb? The study included detailed photographic assessments using the Moorfields Bleb Grading System. At one month, blebs in the bevacizumab group were: Larger in central area Larger in total area Taller Less inflamed around the blood vessels The reduction in vessel inflammation was statistically very strong, with P values below .0001 in several comparisons. By later visits, many of these differences had become smaller or disappeared. Bleb height remained greater in the bevacizuSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/can-damaged-optic-nerve-cells-be-made-young-again-the-first-human-glaucoma-reprogramming-trial-has-begunTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Can Damaged Optic Nerve Cells Be Made Young Again? The First Human Glaucoma Reprogramming Trial Has Begun As of August 28, 2026, the first human trial of partial epigenetic reprogramming is underway. Life Biosciences’ experimental therapy, ER-100, is being tested in adults with open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy. The first participant was dosed on June 9, 2026, after the United States Food and Drug Administration cleared the investigational new drug application in January. () The treatment is not a stem-cell transplant. It does not replace the optic nerve with new tissue. Instead, it attempts to make surviving retinal ganglion cells behave more like younger cells by temporarily activating three powerful gene-regulating proteins: OCT4, SOX2, and KLF4, collectively called OSK. The central question is extraordinary but precise: > Can an old or injured retinal ganglion cell recover enough of its youthful function to preserve, or perhaps partially restore, vision? The answer is not yet known. Animal studies provide a credible biological rationale, including improvements in retinal ganglion-cell activity, optic-nerve axon measurements, DNA methylation patterns, and visual behavior. But the human trial is small, primarily designed to test safety, and has not yet produced publicly reported efficacy results. --- The Short Answer Fact In mice, OSK expression has: Restored aspects of youthful DNA methylation and gene-expression patterns. Increased retinal ganglion-cell survival after optic-nerve injury. Promoted optic-nerve axon regeneration after an experimental crush injury. Improved pattern electroretinogram signals. Improved visually guided behavior in a mouse glaucoma model. Produced prolonged visual improvement after glaucoma-like damage. Shown no obvious retinal tumors or gross retinal structural abnormalities in long-term mouse studies. () In nonhuman primates, company-reported studies of a non-arteritic anterior ischemic optic neuropathy-like injury found improved retinal ganglion-cell electrical activity and increased axon-density measurements after treatment. These findings have been presented by Life Biosciences and described in a patent, but the most detailed nonhuman-primate data have not yet appeared as a fully independent peer-reviewed clinical efficacy publication. () Inference ER-100 is biologically more likely to help surviving but dysfunctional retinal ganglion cells than to replace cells that have already died. It may also help some damaged axons resume function or grow over limited distances. However, there is currently no direct evidence that ER-100 can rebuild a completely lost human optic nerve, restore all missing retinal ganglion cells, or correctly reconnect new axons with the visual centers of the brain. Prediction The most realistic early success would be: Evidence that the therapy reaches retinal ganglion cells. No unacceptable inflammation, pressure elevation, retinal damage, or uncontrolled cellular reprogramming. A reproducible improvement in retinal electrical activity or visual-field performance in a subset of patients. A dramatic restoration of advanced glaucoma vision is possible in theory but remains unlikely based on the present evidence. --- What Is ER-100? ER-100 is an intravitreal gene therapy. A modified adeno-associated viral vector is injected into the vitreous cavity of one eye. The vector carries genetic instructions for producing OCT4, SOX2, KLF4, and a molecular switch that allows the treatment to be activated by oral doxycycline. Participants take doxycycline for 56 days. Doxycycline does not act as a conventional glaucoma drug. Its purpose in this system is to activate the genetic cassette that produces OSK in cells transduced by the vector. () The therapy is intended to deliver OSK primarily to retinal ganglion cells, the neurons whose axons form the optic nerve. ER-100 is not designed to edit the patient’s existing genes in the way that a gene-editing treatment would. Instead, it adds extra genetic instructions that may remain in cells without permanently changing the original genome. That distinction is important, but it does not make the treatment risk-free. Extra genetic material can still produce unwanted effects, and adeno-associated viral vectors can trigger inflammation, immune responses, or rare vector-related complications. --- Why OCT4, SOX2, and KLF4? OCT4, SOX2, and KLF4 are transcription factors. They do not simply turn one gene on or off. They bind DNA and influence large networks of genes involved in cell identity, chromatin structure, development, stress responses, and cellular repair. The original four-factor reprogramming cocktail also includes c-MYC, which can help convert adult cells into induced pluripotent stem cells. However, c-MYC is strongly associated with cell growth and cancer biology. ER-100 omits c-MYC. OCT4 OCT4 is a central regulator of cellular plasticity and developmental gene networks. In full cellular reprogramming, it helps push a mature cell toward a pluripotent state. In partial reprogramming, the goal is not to push the cell all the way back to an embryonic state. Instead, a brief or controlled amount of OCT4 may help loosen age-associated regulatory patterns and make older chromatin more accessible to remodeling. SOX2 SOX2 works with OCT4 and other factors to reorganize gene-regulatory networks. It is important in maintaining neural and stem-cell programs. In a retinal ganglion cell, controlled SOX2 activity could theoretically help reopen developmental programs related to axon growth, synaptic maintenance, and neuronal resilience. KLF4 KLF4 regulates chromatin accessibility, cell differentiation, stress responses, and cellular identity. It can help remodel the structure around DNA, allowing some previously silenced genes to become active. KLF4 is also part of the reason careful dosing is essential. It participates in both differentiation and cellular reprogramming, so excessive or prolonged expression could disturb the mature retinal ganglion cell state. Why the cell does not necessarily become a stem cell Full reprogramming requires strong and sustained activation of several factors, followed by major changes in cell identity and the acquisition of pluripotency. Partial reprogramming attempts to stop the process earlier. The proposed sequence is: OSK enters the retinal ganglion cell. OSK binds regulatory regions across the genome. Age-associated chromatin and DNA methylation patterns begin to change. Gene networks involved in neuronal maintenance and axon growth become more youthful. OSK expression is stopped before the cell crosses into a pluripotent state. The cell remains a retinal ganglion cell but operates in a more resilient, growth-competent state. This separation between rejuvenation and pluripotency is the central safety hypothesis. It is supported by mouse experiments showing no increase in retinal ganglion-cell proliferation and no obvious loss of retinal structure. However, “partial” does not mean perfectly controlled, particularly in humans with different vector distribution, genetics, disease severity, and immune responses. () --- What Does “Epigenetic Age” Mean? Cells can remain genetically similar while changing how their genes are used. This regulation is called epigenetics. Important epigenetic mechanisms include: DNA methylation, in which chemical groups attach to DNA and influence gene activity. Histone modification, which affects how tightly DNA is packaged. Chromatin organization. Regulatory proteins that determine which genes are accessible. Noncoding RNA and other gene-regulating systems. With age, these patterns become less precise. Some genes become abnormally silenced, while others become abnormally active. This accumulation of regulatory noise may contribute to inflammation, impaired energy production, weaker stress responses, and reduced regenerative ability. DNA methylation clocks estimate biological age by examining methylation at selected sites across the genome. These clocks are useful biomarkers, but they are not equivalent to a complete measurement of aging. Reversing a methylation clock does not automatically prove that every harmful feature of aging has been repaired. A 2024 review specifically cautioned that epigenetic-clock reversal and true functional rejuvenation should not be treated as identical concepts. () The strongest evidence that methylation changes may be functionally important comes from the original mouse study. Injury accelerated the methylation-age signature of retinal ganglion cells. OSK reversed this signature, and suppression of the DNA-demethylating enzymes TET1 and TET2 blocked much of the improvement in axon regeneration and visual function. () That does not prove that methylation is the only cause of glaucoma. It suggests that at least some age- and injury-associated methylation changes participate in the loss of neuronal function. --- The Scientific Path to ER-100 Early partial-reprogramming studies Earlier animal studies showed that temporary activation of reprogramming factors could reverse some age-associated traits in mice without producing the full eSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/a-new-glaucoma-gene-therapy-is-entering-human-trials-could-it-protect-vision-without-lowering-eye-pressureTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:A New Glaucoma Gene Therapy Is Entering Human Trials — Could It Protect Vision Without Lowering Eye Pressure? For more than a century, glaucoma treatment has focused on one central strategy: lower the pressure inside the eye. Pressure-lowering eye drops, laser treatment, and surgery can slow damage, but they do not directly make retinal ganglion cells more resistant to injury. Some patients continue to lose vision even when their eye pressure appears to be well controlled. ASP2767, an experimental gene therapy from Astellas, is designed around a different idea: deliver protective genes directly to retinal ganglion cells so that the cells may better survive glaucoma-related stress. The treatment is now entering its first human study, registered as NCT07770685, a combined Phase 1 and Phase 2 trial. The trial is important because it is specifically designed to test a neuroprotective treatment for progressive open-angle glaucoma, not simply another pressure-lowering drug. () The most likely interpretation of the available evidence is that ASP2767 is intended primarily to preserve surviving retinal ganglion cells and their function. It is not yet demonstrated to regenerate a damaged optic nerve, replace dead neurons, or restore established visual-field loss. The Bottom Line ASP2767 is an investigational intravitreal gene therapy. The first human trial plans to enroll approximately 156 adults with progressive open-angle glaucoma. The public trial record does not disclose the clinical vector, gene sequence, dose levels, or names of the anti-inflammatory preventive treatments. The strongest scientific trail connects ASP2767 to work from Quethera, a company acquired by Astellas in 2018. The best-matching preclinical program uses an adeno-associated virus type 2 vector to express both: Tropomyosin receptor kinase B, a receptor that supports retinal ganglion-cell survival. Mature brain-derived neurotrophic factor, a protein that activates that receptor. In mice and rats, the related construct preserved retinal ganglion cells and electrical measures of retinal ganglion-cell function after optic-nerve injury or experimentally elevated eye pressure. There is no public evidence yet that the treatment regenerates long-distance optic-nerve axons or restores permanent visual-field loss. If it works, ASP2767 would most likely be an add-on treatment used together with eye-pressure control, not a replacement for it. --- What Is ASP2767? Established facts ASP2767 is: Developed by Astellas Pharma. Intended for optic neuropathy caused by glaucoma. Administered by a single intravitreal injection into one eye. Being tested in adults with progressive open-angle glaucoma. Entering humans for the first time in the registered Phase 1/Phase 2 study. Listed in Astellas’ ophthalmology pipeline as a gene therapy for glaucoma. () The public-facing trial materials describe ASP2767 as a harmless-virus-based gene therapy. The delivered genes are expected to cause retinal nerve cells to produce proteins intended to protect them and slow further vision loss. () What has not been officially disclosed The publicly available clinical-trial listing does not identify: The exact adeno-associated virus type or engineered capsid used clinically. The promoter controlling gene expression. The exact genes or protein sequences in the clinical product. The vector dose levels. The number of patients in each Phase 1 dose cohort. The precise primary and secondary endpoint definitions. The identity and schedule of “Prophylactic Regimen A” and “Prophylactic Regimen B.” The clinical trial sites. Those omissions are normal for a newly registered first-in-human gene-therapy study. Some details may be available in the investigator brochure, regulatory submissions, or later registry updates but are not currently visible in the public record I could verify. --- The Strongest Reconstruction of ASP2767’s Mechanism Strongly supported inference: a dual tropomyosin receptor kinase B and mature brain-derived neurotrophic factor therapy The most important clue is the history of Quethera, a British gene-therapy company acquired by Astellas in 2018. Quethera’s glaucoma program used recombinant adeno-associated virus vectors to deliver protective genes to retinal cells. Astellas stated that the lead preclinical candidate significantly improved retinal ganglion-cell survival in experimental glaucoma models. () A later paper provides an unusually close match to that description. It was authored by researchers from: The University of Cambridge. Quethera. Astellas. Other institutions involved in glaucoma gene-therapy research. The paper describes a bicistronic adeno-associated virus vector that expresses two fully humanized components: Tropomyosin receptor kinase B, also called the TrkB receptor. Mature brain-derived neurotrophic factor. A short self-cleaving 2A peptide allows both proteins to be produced from a single genetic cassette. () The paper does not explicitly state that this published construct is identical to clinical ASP2767. Astellas may have modified the vector, promoter, capsid, protein sequences, or manufacturing process before entering human trials. Therefore: > Best-supported conclusion: ASP2767 is probably an optimized clinical version of the Quethera/Astellas dual tropomyosin receptor kinase B–mature brain-derived neurotrophic factor program. > What remains unproven: the exact identity of the clinical vector and genetic cassette. How the proposed pathway works Brain-derived neurotrophic factor is a natural support signal used by neurons. It binds to the tropomyosin receptor kinase B receptor on retinal ganglion cells and activates intracellular survival pathways, including: The protein kinase B pathway. The extracellular signal-regulated kinase pathway. Other pathways involved in cellular metabolism, synaptic maintenance, and resistance to programmed cell death. In glaucoma, injury near the optic nerve head can interfere with the normal transport of growth and survival signals between the brain and retinal ganglion cells. The cells may then become metabolically stressed and more vulnerable to pressure, mechanical strain, reduced blood supply, oxidative stress, and inflammation. The proposed treatment attempts to bypass part of that problem by making retinal ganglion cells produce both: More of the survival receptor. More of the receptor’s activating ligand. This dual approach is scientifically important because delivering brain-derived neurotrophic factor alone can lead to reduced receptor availability over time. The related research was designed to avoid that limitation by increasing both sides of the signaling system. () --- Why an Intravitreal Adeno-Associated Virus Vector? An intravitreal injection places the vector into the gel-filled cavity inside the eye. From there, the vector can contact the inner retina, including retinal ganglion cells. Adeno-associated virus type 2 has been widely studied for retinal ganglion-cell delivery because it can transduce inner-retinal neurons after intravitreal injection. However, it is not perfectly specific. Depending on the vector design and promoter, other retinal cells may also receive the genetic material. () The likely advantages are: A single injection rather than daily treatment. Local production of the protective proteins inside the eye. Long-lasting expression in nondividing retinal neurons. Theoretical activity even when eye pressure is already controlled. The likely disadvantages are: The vector cannot be easily removed after injection. Not every retinal ganglion cell may be transduced. Existing antibodies against the viral capsid may reduce delivery. Inflammation can damage the retina or optic nerve. Excessive or poorly controlled growth-factor signaling could have unintended effects. --- The Newly Registered Human Trial Trial identity The study is: Trial number: NCT07770685. Astellas study number: 2767-CL-0101. Sponsor: Astellas Pharma Global Development. Design: Phase 1, open-label, dose escalation followed by Phase 2, randomized, sham-controlled and masked. Planned enrollment: 156 participants. Treatment: One intravitreal injection in one study eye. Follow-up: Approximately 52 weeks after treatment. () As of August 25, 2026, public registry mirrors described the study as not yet recruiting, with a planned start in August 2026 and a primary completion date in July 2030. The patient-facing listing says enrollment is expected to begin during August 2026. No trial locations were publicly posted in the record available at that time. () Phase 1 Phase 1 is intended to: Test safety. Assess tolerability. Escalate through increasing doses. Identify the highest dose that can be given safely. Observe preliminary effects on visual function and retinal structure. Phase 1 is open-label, meaning the participants and investigators know that ASP2767 is being given. Participants in the dose-escalation portion must have relatively severe but not completely end-stage disease: Mean deviation between −12 and −20 decibels. Evidence of glaucomatous visual-field loss. Corresponding optic-nerve damage. At least one quadrant with remaining visual-field function. Support the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/gene-based-interventions-for-myocilin-associated-glaucoma-august-2026-first-in-human-learningsTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Gene-Based Interventions for Myocilin-Associated Glaucoma: August 2026 First-in-Human Learnings Evidence reviewed through August 24, 2026 Introduction Gene-based treatment for myocilin-associated glaucoma has moved from laboratory research into early human testing. The leading approach, called BD113, uses a virus-like particle to deliver a preassembled gene-editing system into the eye. Its goal is to disrupt the harmful form of the MYOC gene in the trabecular meshwork—the drainage tissue responsible for removing fluid from the eye. The early news is encouraging but extremely limited. A 2026 conference abstract reported sustained intraocular pressure reduction in one first-in-human participant without reported ocular or immune adverse events. A separate 2026 scientific review referred to two treated patients with normalized pressure and discontinuation of pressure-lowering medications. However, the full patient-level data—including exact pressure readings, duration of follow-up, visual-field results, editing measurements, and statistical analysis—have not been publicly reported. APAO 2026 abstract book Theranostics review () This distinction matters: a promising first human signal is not the same as proof of safety or effectiveness. As of August 24, 2026, the official ClinicalTrials.gov record still shows no posted study results and lists the trial’s status as unknown, although its last known status was recruiting. The original estimated study-completion date was December 2025. ClinicalTrials.gov: NCT06465537 () Why MYOC Is an Attractive Gene-therapy Target The MYOC gene provides instructions for making myocilin, a protein found in the trabecular meshwork and other eye tissues. Certain harmful MYOC variants cause the protein to fold incorrectly. The abnormal protein can accumulate inside trabecular meshwork cells, trigger stress in the endoplasmic reticulum, damage the cells, and reduce aqueous-fluid drainage. The result is often high intraocular pressure and progressive optic-nerve damage. Myocilin misfolding and glaucoma: a 20-year update CRISPR-Cas9-based treatment of myocilin-associated glaucoma () MYOC-related glaucoma is commonly inherited in an autosomal dominant pattern. It can cause juvenile-onset open-angle glaucoma, often with very high pressure at a young age, or adult-onset primary open-angle glaucoma. MYOC variants are estimated to account for approximately 3% to 4% of primary open-angle glaucoma and around 10% of juvenile-onset open-angle glaucoma, although the percentage varies among populations and study groups. MedlinePlus Genetics: MYOC APAO 2026 abstract book () The therapeutic logic is unusual. Many gene therapies replace a missing or defective gene. In MYOC-associated glaucoma, the proposed treatment instead aims to remove or silence a toxic, overactive gene product. Laboratory and animal studies support this strategy: disrupting mutant MYOC reduced abnormal protein accumulation, eased cellular stress, improved fluid outflow, lowered pressure, and preserved retinal ganglion cells in mouse models. CRISPR-Cas9-based treatment of myocilin-associated glaucoma () What Was Reported in Humans by August 2026? BD113: The Directly MYOC-Targeted Program BD113 is described in the clinical registry as an integration-defective lentiviral-derived virus-like particle carrying a guide ribonucleic acid and CRISPR-associated protein 9 as a preassembled ribonucleoprotein complex. The intended effect is to knock out or substantially reduce the harmful MYOC gene activity in trabecular meshwork cells. ClinicalTrials.gov: NCT06465537 () The public human evidence can be summarized as follows: For the full table, please open this article on visualfieldtest.com. The most important limitation is that the public reports do not provide the information needed to judge treatment magnitude. The available material does not specify the patient’s starting pressure, lowest pressure, pressure without medication, length of follow-up, number of glaucoma medicines before treatment, visual-field status, or whether the treatment prevented progression. The review’s reference to two patients also differs from the conference abstract’s reference to one patient. This may reflect later enrollment or reporting, but that is an inference rather than a confirmed final dataset. APAO 2026 abstract book Theranostics review () What Is Known About the Trial Design? The registered study planned to enroll approximately 6 to 9 adults at Beijing Tongren Hospital in China. Participants were divided into two broad groups: People with a study eye that had little or no useful vision, intended to provide an additional safety margin. People with useful vision in the study eye and a blood-confirmed MYOC mutation. Each participant was scheduled to receive one intracameral injection in the study eye. The planned follow-up was at least one year. ClinicalTrials.gov: NCT06465537 () The main planned pressure outcomes were: The proportion of participants with intraocular pressure of 21 millimeters of mercury or less. The proportion with at least a 20% pressure reduction from baseline. Ocular adverse events such as inflammation, bleeding, infection, corneal reaction, or damage to the anterior segment. In participants with useful vision, changes in visual acuity, visual fields, and retinal nerve-fiber-layer measurements. The threshold of 21 millimeters of mercury is a trial measurement, not a universal treatment goal. A safe target pressure depends on the amount of optic-nerve damage, the rate of progression, corneal thickness, age, and other factors. Delivery Route and Dose Intracameral Delivery BD113 is injected into the anterior chamber, the fluid-filled space between the cornea and iris. This is different from an intravitreal injection, which is placed farther back in the eye near the retina. The intracameral route is intended to expose the anterior segment and trabecular meshwork directly. In mouse experiments, the virus-like particle reportedly showed more selective delivery to the trabecular meshwork than conventional adeno-associated virus or lipid nanoparticles, which showed more dispersion toward the cornea. APAO 2026 abstract book () An intracameral injection is a familiar type of eye procedure, but it is not risk-free. Possible complications include: Temporary or persistent inflammation Bleeding in the anterior chamber Infection Corneal endothelial injury Pressure spikes or pressure that becomes too low Damage related to the injection itself The study registry specifically lists endophthalmitis, hypopyon, hyphema, and corneal injection-site reactions among the adverse events being monitored. ClinicalTrials.gov: NCT06465537 () Single Dose of 4 Micrograms of p24 Protein Equivalent The registered BD113 dose is 4 micrograms of p24 protein equivalent in a single intracameral injection. The p24 measurement reflects a viral-particle manufacturing and quantity assay. It is not directly equivalent to the amount of CRISPR-associated protein 9, the number of guide molecules, or the amount of conventional viral-vector genomes. ClinicalTrials.gov: NCT06465537 () The publicly available trial information does not describe a conventional multi-level dose-escalation table for BD113. Therefore, it is not yet possible to determine whether the reported pressure effect is dose-related or whether a lower dose might provide a better safety margin. Target Engagement: What Has and Has Not Been Shown? Target engagement means evidence that the treatment reached and changed the intended biological target. For a MYOC-editing treatment, the strongest evidence would include: Editing of the MYOC gene in treated trabecular meshwork cells. Lower levels of abnormal myocilin protein. Reduced endoplasmic-reticulum stress. Improved aqueous-fluid outflow. Lower intraocular pressure. Slower structural or functional glaucoma progression. Animal Evidence The BD113 abstract reported approximately 35% editing in cynomolgus macaques, even though the animals had pre-existing immunity against CRISPR-associated protein 9. This is important because it suggests that pre-existing immune recognition does not necessarily prevent editing. However, the result was reported in a conference abstract and does not substitute for human tissue evidence. APAO 2026 abstract book () Other recent preclinical approaches have produced measurable target engagement: A messenger-ribonucleic-acid lipid-polymer system produced approximately 18% MYOC editing in a mouse study, reduced abnormal protein accumulation, and lowered pressure within several weeks. No obvious ocular inflammation was seen during the reported observation period. PubMed: therapeutic messenger-ribonucleic-acid delivery of CRISPR-associated protein 9 () A 2026 lipid-nanoparticle base-editing study reported approximately 17% editing, approximately 46% lower mutant myocilin protein, reduced cellular stress, and rescue of the glaucoma phenotype in mice, without detected ocular toxicity or off-target editing in the reported experiments. PubMed: lipid-nanoparticle-mediated base editing () Human Target Engagement Remains Unconfirmed The BD113 clinical registry plans to measure p24 and CRISPR-associated proteiSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/smart-contact-lenses-for-iop-monitoring-august-2026-clinical-utility-resultsTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Smart Contact Lenses for IOP Monitoring: August 2026 Clinical Utility Results Evidence cutoff: August 23, 2026 Introduction Continuous intraocular pressure monitoring could reveal pressure changes that are easily missed during a routine eye examination—especially pressure increases during sleep, while lying down, or outside normal office hours. Standard clinic testing usually provides only a few measurements each year, most often while the patient is awake and seated. The technology has advanced substantially. However, the clinical evidence available by August 23, 2026 still supports smart contact lenses mainly as research and specialized monitoring tools, not as replacements for routine glaucoma examinations or as stand-alone devices for making treatment decisions. The most important distinction is between: Analytical validity: whether the device detects pressure-related changes. Clinical validity: whether those patterns are associated with glaucoma progression or treatment response. Clinical utility: whether using the device improves treatment decisions and patient outcomes. By August 2026, analytical validity is promising for several devices. Clinical validity is emerging. Clinical utility—particularly fewer visual-field losses, fewer urgent visits, or better long-term glaucoma control—has not yet been proven. Executive Summary The newest peer-reviewed clinical report, published June 23, 2026, described a soft contact lens with a sleep-mask reader that detected posture-related and closed-eye pressure changes. Human testing was very small and did not establish overnight adherence, data completeness, or treatment benefit. PubMed () A newer human accuracy study involving 80 eyes found that a contact lens sensor had generally favorable agreement with Goldmann applanation tonometry and supine Perkins tonometry. More than 80% of comparisons were within 5 millimeters of mercury, but the study was short-term and did not evaluate treatment outcomes. Full text () The United States Food and Drug Administration-authorized SENSIMED Triggerfish detects relative ocular dimensional changes, not a directly interchangeable Goldmann pressure value. Its intended clinical role is to identify potentially important pressure-related time periods for follow-up testing. United States Food and Drug Administration review () In an early observational Triggerfish study, 13 of 15 patients, or 87%, completed 24-hour monitoring, and treatment was changed in 11 of 15 patients, or 73%, after the tracing was reviewed. These were clinician decisions after reviewing a completed recording—not responses to validated real-time alerts. PubMed Study report () No publicly available August 2026 study demonstrated that an automated contact lens alert improved visual-field preservation, reduced glaucoma progression, or reliably changed management through a predefined alert protocol. Home rebound tonometry remains more clinically established than experimental smart lenses because it provides a conventional pressure number. It is intermittent, requires training, and still cannot replace clinic-based assessment. European Glaucoma Society guideline () What the August 2026 Evidence Actually Shows For the full table, please open this article on visualfieldtest.com. The Japanese study registry is important because it represents a relatively larger contemporary clinical dataset. However, the publicly available record reports enrollment and safety information rather than detailed pressure curves, Goldmann agreement, management changes, or visual outcomes. Japanese registry record () Correlation With Goldmann Applanation Tonometry Triggerfish: useful for timing, not direct pressure substitution The Triggerfish system uses a soft contact lens containing a strain-sensitive circuit near the edge of the lens. The circuit detects changes in the shape or circumference of the eye that are believed to accompany pressure changes. Its output is usually reported in electrical units or relative signal changes. It does not provide a conventional pressure value that can automatically be substituted for a Goldmann reading. The United States Food and Drug Administration review cited a strong correlation between the average 24-hour Triggerfish curve and a fellow-eye pressure curve in 30 healthy participants. However, this supports recognition of a 24-hour pattern, not point-by-point interchangeability with Goldmann applanation tonometry. The agency described the device as a way to identify the time window when a clinician should perform conventional pressure measurement. United States Food and Drug Administration review () This limitation is clinically important. A large signal peak does not automatically mean that the pressure is 30 or 40 millimeters of mercury. The signal may also be influenced by: Lens fit Corneal curvature Corneal thickness and biomechanics Blinking and eye movement Temperature Eyelid pressure Posture Differences between individual disposable lenses Earlier research also found that Triggerfish output did not consistently correlate with Goldmann pressure before and after pressure-lowering treatment. This is why the device is best interpreted as a patient-specific pattern monitor, not as a stand-alone tonometer. Review of Triggerfish evidence () Newer sensors are moving toward absolute pressure The 2022 Purdue smart soft contact lens was designed to provide calibrated absolute pressure values. In three human participants, the sensor showed a reported linear calibration with an R² value of 0.91 when compared with iCare Home measurements. During a six-hour ambulatory test, its pressure trend was closer to Goldmann measurements than the iCare comparison in that small experiment. Full study () A separate human study involving 80 eyes found that the newer contact lens sensor had generally good agreement with Goldmann and Perkins measurements. All pressure differences were reported as being within ±2 millimeters of mercury in the analyzed comparisons. More than 80% of Bland–Altman comparisons were within ±5 millimeters of mercury, and more than 60% were within ±3 millimeters of mercury. However, this was a short, cross-sectional study and did not demonstrate reliable home use, natural sleep monitoring, or improved outcomes. Full study () The June 2026 nocturnal sensor paper reported that sensor-derived trends closely matched both Goldmann and iCare measurements during tested conditions. Its human testing was still a pilot rather than a large validation trial. PubMed Publisher report () Diurnal and Nocturnal Pressure Patterns Why sleep monitoring matters Intraocular pressure often changes with posture and time of day. When a person lies down, changes in episcleral venous pressure, fluid distribution, and aqueous humor outflow may increase pressure. These changes can be especially important for people whose daytime clinic pressure appears controlled but whose glaucoma continues to worsen. In the early 15-patient Triggerfish study: 9 of 13 patients with complete recordings, or 69%, had their highest signal during the nighttime period. Prolonged pressure-related peaks were reported in 12 of 15 patients, or 80%. The pattern was often most informative outside normal clinic hours. PubMed Study report () A separate study involving 40 treated glaucoma patients found that participants who were progressing despite controlled daytime pressure were more likely to have a nighttime pressure-related peak than stable participants. The study included 19 progressors and 21 nonprogressors, and the association was statistically significant. This is clinically interesting, but it shows an association, not proof that eliminating the nighttime peak prevents vision loss. Full study () What the newest 2026 sensor adds The June 2026 soft lens study focused on a major weakness of older sensors: difficulty measuring accurately with the eye closed and the patient lying down. The new lens was tested with: A reader integrated into a sleep mask Closed-eye conditions Recumbent and posture-transition testing Healthy participants A participant with pigmentary glaucoma The glaucoma participant showed a sustained pressure elevation during the supine, closed-eye period that mimicked sleep. The lens also remained comfortable in the small human pilot, with reported comfort ratings generally above 90 on the study's 0-to-100 comfort scale. Publisher report () The limitation is that the study did not yet evaluate fully unconstrained natural sleep in a large patient population. It also did not report how often the sensor failed to collect usable data, how many patients would tolerate repeated overnight use, or whether the findings changed treatment. Adherence, Comfort, and Data Completeness Triggerfish experience The strongest published adherence data remain from older Triggerfish studies rather than the newest experimental lenses. In the 15-patient initial clinical report: 87% completed the full 24-hour recording. One patient stopped because of device intolerance. One recording was incomplete because of technical malfunction. Average comfort was reported as 7 out of 10. No serious adverse events were reported. PubMed () In a larger 40-patient reproducibility study, common temporary effects inSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/dry-eye-disease-august-2026-phase-ii-iii-results-for-novel-mechanismsTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Dry Eye Disease: August 2026 Phase II/III Results for Novel Mechanisms Evidence cutoff: August 22, 2026 Introduction Dry eye disease treatment is moving beyond “replace the tears” with artificial tears. Newer therapies are attempting to stimulate the eye’s own tear reflex, restore the mucin layer, slow tear evaporation, improve meibomian gland function, or target inflammation in genetically selected patients. A date clarification is important: there was not one single August 2026 wave of completed Phase II or Phase III dry eye readouts covering all of these mechanisms. The most important recent human data available by August 22, 2026 include: The May 2026 publication of Phase III results for acoltremon, now marketed in the United States as Tryptyr. A 2026 randomized study of the mucin secretagogues diquafosol and rebamipide, showing effects within 30 minutes. A July 2026 randomized study of lipid-containing artificial tears in people with a thin tear-film lipid layer. Continuing Phase II/III programs for AZR-MD-001, licaminlimab, PL9643, and platelet-lysate biologics, for which definitive August 2026 efficacy results were not publicly posted. An August 8, 2026 publication involving troxipide nanoparticles applied through the eyelid was preclinical animal research, not a human Phase II or Phase III trial. It should not be interpreted as proof of clinical benefit in patients. Troxipide nanoparticle study () How to Interpret Dry Eye Trial Results Clinical trials usually measure both symptoms and signs: Symptoms Assessment iN Dry Eye, or SANDE, measures the frequency and severity of symptoms on a 0-to-100 scale. Higher scores indicate worse symptoms. Ocular Surface Disease Index, or OSDI, measures symptoms and their effect on daily activities. Higher scores indicate worse disease. Tear break-up time, often called TBUT, measures how long the tear film remains stable after a blink. A longer time is generally better. Corneal fluorescein staining measures damage to the surface cells of the cornea. A lower score is better. Schirmer testing estimates tear production using a paper strip. A larger increase suggests more aqueous tear production. These measures do not always improve together. A patient may have less burning but little change in staining, or may produce more tears without feeling much better. This symptom–sign mismatch is one of the major difficulties in dry eye research. Results also cannot be compared directly across studies unless the trial populations, control groups, dosing schedules, and measurement methods are similar. Summary of the Most Relevant 2026 Evidence For the full table, please open this article on visualfieldtest.com. Neurosensory Modulation: Acoltremon, or Tryptyr Mechanism and treatment concept Tryptyr contains acoltremon, a transient receptor potential melastatin 8 agonist. Transient receptor potential melastatin 8 channels are found on cold-sensitive sensory nerves in the cornea and eyelids. Activating these nerves can stimulate a reflex pathway involving the lacrimal gland and increase tear production. The mechanism is different from anti-inflammatory drugs such as cyclosporine and lifitegrast. It also differs from Miebo, which is designed primarily to reduce evaporation. The Food and Drug Administration review noted that acoltremon’s tear-producing effect is greatly reduced under topical anesthesia, supporting the importance of an intact sensory nerve pathway. Food and Drug Administration integrated review () Tryptyr was approved by the Food and Drug Administration on May 28, 2025, at a dose of one drop in each eye twice daily. Food and Drug Administration Drug Trials Snapshot for Tryptyr () Tear production The two pivotal Phase III studies, COMET-2 and COMET-3, enrolled a combined 931 patients. The primary endpoint was the percentage of patients achieving at least a 10-millimeter increase in unanesthetized Schirmer testing on day 14: COMET-2: 42.6% with acoltremon versus 8.2% with vehicle. COMET-3: 53.2% with acoltremon versus 14.4% with vehicle. Both differences were statistically significant. Increased tear production was also observed after the first dose and remained detectable through day 90 when the test was performed after dosing. Acoltremon Phase III publication Tryptyr prescribing information () Symptoms In COMET-2, the key secondary endpoint, change in the global SANDE score at day 28, favored acoltremon: Acoltremon: least-squares mean change of −19.7 points Vehicle: least-squares mean change of −14.7 points Difference: −5.1 points However, the same SANDE endpoint was not statistically significant in COMET-3, the replication study. The Food and Drug Administration also noted that day-90 symptom endpoints were not met and that the evidence for replicated symptom relief was weaker than the evidence for increased tear production. Food and Drug Administration review () Clinical interpretation: Tryptyr clearly stimulates tear production, but the size and consistency of symptom improvement may vary. It should not be presented as a guaranteed rapid pain-relief treatment for every patient. Corneal staining and tear-film stability The published Phase III report found greater reductions in total corneal fluorescein staining on days 28 and 90 and greater reductions in conjunctival staining across study visits. However, the regulatory approval was primarily based on the tear-production endpoint rather than a replicated symptom endpoint. Tear break-up time was measured in the trial program, but a replicated, clinically persuasive tear break-up time benefit was not the central basis for approval. The Food and Drug Administration review also raised uncertainty about how long the tear-stimulation effect lasts between the post-dose measurement and the next dose 12 hours later. () Onset of action Tryptyr appears to act very quickly on tear production: A significant effect was observed on day 1. The post-dose Schirmer test was started only a few minutes after instillation. The study does not prove that patients experience meaningful symptom relief within a few minutes. The duration of effect throughout the entire 12-hour dosing interval has not been clearly established. The practical expectation is therefore rapid stimulation of tearing, with symptom and surface improvements potentially requiring continued use. Safety and tolerability The main tolerability problem is burning or stinging immediately after use: Instillation-site pain occurred in approximately 50% of patients. Most events were mild. Less than 1% of patients discontinued treatment because of burning or stinging. No major drug-related safety signal was identified in the pivotal trials. Tryptyr is packaged in single-dose vials. One vial can be used for both eyes, but it must be discarded after use. Contact lenses should be removed before dosing and may be reinserted after 15 minutes. Tryptyr prescribing information () Likely responder phenotype The best mechanistic fit may be patients with: Low tear production. Preserved corneal sensory nerve function. A functioning reflex-tear pathway. Mixed disease with an aqueous-deficient component. This is a mechanism-based inference, not a validated clinical responder rule. The COMET trials did not establish that Tryptyr is superior in a clearly defined aqueous-deficient subgroup or inferior in evaporative disease. Patients with severe corneal nerve dysfunction, prominent neuropathic pain, or symptoms that are very poorly matched to clinical signs may respond unpredictably. Mucin Secretagogues: Diquafosol and Rebamipide Why mucin matters The tear film is not simply water. It includes: An aqueous component. A lipid component that reduces evaporation. A mucin component that helps tears spread across the ocular surface. The gel-forming mucin mucin 5AC, produced mainly by conjunctival goblet cells, helps lubricate the eye and maintain tear-film stability. 2026 randomized study A 2026 prospective paired-eye study compared 3% diquafosol with 2% rebamipide. This was not a large registration Phase III trial, but it provides unusually useful information about early pharmacologic effects. Thirty minutes after instillation: Both agents significantly increased tear mucin 5AC. Both improved symptoms and tear break-up time. The difference in tear break-up time between the two agents was not statistically significant. Diquafosol produced a greater improvement in the visual analog symptom score than rebamipide. Mucin 1, a membrane-associated mucin, did not change significantly during this short observation period. The study therefore supports a rapid tear-film and mucin effect, especially for patients with short tear break-up time or suspected mucin dysfunction. 2026 diquafosol and rebamipide study () Safety and tolerability Reported short-term symptoms were relatively common but generally mild: Burning was reported by approximately 20% of patients with diquafosol and rebamipide. Foreign-body sensation occurred in approximately 17% to 20%. Dryness was reported by approximately 13% with diquafosol and 23% with rebamipide. No significant tolerability difference was found between the treatments. Likely responder phenotype Mucin secretagogues may be most useful for patients with: Short tear break-up time. OcSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/teleophthalmology-for-rural-and-underserved-populations-august-2026-outcomes-trialTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Teleophthalmology for Rural and Underserved Populations: August 2026 Outcomes Trial Evidence snapshot: August 19, 2026 Teleophthalmology can bring retinal imaging, optical coherence tomography, visual acuity testing, eye pressure measurement, specialist review, care navigation, and referral coordination closer to where patients live. This is especially important in rural communities, Federally Qualified Health Centers, Indigenous communities, and low-income areas where travel distance, cost, limited transportation, and shortages of ophthalmologists can delay care. However, an important evidence limitation should be stated clearly: I could not verify a single completed August 2026 randomized or stepped-wedge trial that enrolled rural or underserved patients and followed glaucoma, diabetic retinopathy, and age-related macular degeneration from screening through treatment initiation while also measuring vision outcomes, preventable complications, costs, and satisfaction. Reporting such a trial as if it existed would require inventing results. The available evidence is therefore best understood as a 2026 evidence set made up of several complementary trials and programs. Together, these studies show that teleophthalmology can improve screening participation, reduce unnecessary urgent referrals, shorten specialist waiting times, and achieve high patient satisfaction. They also show that the strongest remaining weakness is the “last mile” between a positive screen and completed treatment. Key Findings The strongest completed end-to-end randomized evidence comes from the United Kingdom community optometry trial known as the HERMES study. Teleophthalmology reduced unnecessary urgent referrals and shortened the average time to specialist consultation from 89 days to 53 days. The same trial showed a clinically shorter average time from the initial community visit to treatment—55 days compared with 90 days—although the difference was not statistically significant. In the Michigan Screening and Intervention for Glaucoma and eye Health through Telemedicine study, 99% of participants were satisfied or very satisfied, and the program cost approximately $110.99 per participant served. In rural Alabama, teleophthalmology detected substantial levels of glaucoma-related disease and diabetic retinopathy. Among referred participants in the initial Alabama cohort, 76.7% attended follow-up, including 92% of those referred for glaucoma. Randomized diabetic retinopathy evidence shows that telemedicine can substantially increase completion of screening, but available trials have not directly quantified the number of cases of blindness prevented. Randomized age-related macular degeneration evidence suggests that teleophthalmology can identify new suspected disease without worsening visual outcomes, but remote monitoring of recurrence may delay treatment unless the pathway includes rapid escalation. A sustainable model requires local imaging staff, remote eye specialists, care navigators, local treatment partners, interoperable electronic health records, and strong cybersecurity controls. What the Available Trials Actually Tested For the full table, please open this article on visualfieldtest.com. The United Kingdom HERMES trial is the closest match to a complete referral pathway. The rural American studies are more relevant to health equity and community implementation, but they generally functioned as screening-plus-navigation programs rather than randomized comparisons of screening through treatment. () Effects on Time to Diagnosis and Treatment The strongest evidence: faster specialist consultation In the United Kingdom cluster randomized trial, patients referred through a teleophthalmology pathway reached hospital consultation faster than patients using standard referral: Teleophthalmology pathway: approximately 53 days Standard pathway: approximately 89 days Difference: approximately 36 days faster For urgent referrals, the average time to consultation was approximately 23 days with teleophthalmology versus 53 days with standard referral. The pathway also shortened the average time from the initial community optometry visit to treatment from approximately 90 days to 55 days, although the treatment difference did not reach statistical significance. () The trial also found that 62 participants required treatment. Among those who attended consultation, treatment was required in 55.2% of teleophthalmology participants compared with 28.9% of standard-care participants. This does not mean teleophthalmology caused more disease. It more likely indicates that remote specialist triage directed a greater proportion of appropriate patients toward specialist care while reducing unnecessary visits. () Diabetic retinopathy: better screening access, incomplete time-to-treatment evidence The Tribal Vision Project randomized 567 participants and found that telemedicine greatly increased the likelihood of completing diabetic retinopathy screening: Within six months: 94.6% with telemedicine versus 43.9% with traditional surveillance Between more than six and 18 months: 53.0% versus 33.2% Over approximately four years, diabetic retinopathy worsened by at least two stages in 8.5% of participants and improved by at least two stages in 1.2%. Overall, disease severity remained generally stable. However, the study did not provide a definitive estimate of how many cases of severe visual loss or blindness were prevented through telemedicine. () A 2026 stepped-wedge randomized quality-improvement trial involving 5,665 adults with type 2 diabetes found that electronic health record “bulk orders” increased the odds of completing diabetic retinopathy screening by approximately 78%. The six-month completion rate was 17.5%, and the median time from the bulk order to a retinal imaging appointment was 79 days. This result shows that teleophthalmology infrastructure alone is not enough; scheduling access and patient follow-through remain major bottlenecks. () Age-related macular degeneration: initial referral was comparable, recurrence monitoring required caution In a randomized clinical trial of teleophthalmology for suspected neovascular age-related macular degeneration: Referral to diagnostic imaging took 22.5 days with teleophthalmology versus 18.0 days with routine care. Diagnostic imaging to treatment took 16.4 days versus 11.6 days. Neither difference was statistically significant. For recurrence monitoring, treatment reinitiation took approximately 13.6 days with teleophthalmology versus almost immediate treatment in the routine group. Despite the delay in recurrence treatment, there was no difference in final visual acuity. These results support teleophthalmology for initial triage when there is a reliable escalation system. They also warn against allowing remote monitoring to become a passive process. Patients with suspected recurrence need rapid clinical review and, when necessary, immediate injection scheduling. () Outcomes by Eye Disease Glaucoma Glaucoma is particularly challenging for teleophthalmology because diagnosis and treatment usually require more than a photograph. A useful pathway may include: Visual acuity measurement Intraocular pressure Central corneal thickness Optic nerve photographs Optical coherence tomography of the retinal nerve fiber layer Visual field testing when feasible Medical and family history Remote specialist review In-person confirmation and treatment planning The Michigan community program identified glaucoma or suspected glaucoma in 22.4% of 3,709 participants. It identified diabetic retinopathy in 4.7% and macular degeneration in 1.7%. Among participants who screened positive for glaucoma or suspected glaucoma and were randomized to receive either written education or personalized education with health coaching, follow-up attendance was similar: 61% versus 59%. () In the three Screening and Intervention for Glaucoma and eye Health through Telemedicine sites, glaucoma or suspected glaucoma was detected in: 18.6% of Alabama participants 24.0% of Michigan participants 26.7% of New York City participants In-office referral rates were 47.3% in Alabama, 42.8% in Michigan, and 66.1% in New York City. The variation partly reflects differences in screening equipment, referral criteria, and whether refractive error was treated locally or referred elsewhere. () The Michigan program also reported modest improvement in presenting visual acuity among the 943 participants who returned for repeat screening. Worse-eye visual acuity improved from a mean logarithm of the minimum angle of resolution value of 0.25 to 0.21, while vision-related quality of life improved from 81.1 to 86.4. These findings are encouraging, but the repeat-screening group was not a randomized sample, and many participants received glasses or other care. The results therefore cannot be interpreted as proof that teleophthalmology prevented glaucoma progression. () What remains unproven in glaucoma No completed rural randomized trial identified in this evidence review demonstrated reductions in: Visual field loss Glaucoma progression Emergency glaucoma surgery Medication failure Irreversible blindness Teleophthalmology appears effective forSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/smart-contact-lenses-for-iop-monitoring-august-2026-clinical-utility-resultsTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Smart Contact Lenses for Intraocular Pressure Monitoring: August 2026 Clinical Utility Results Evidence reviewed through August 18, 2026. Introduction Smart contact lenses and other wearable sensors aim to solve a major problem in glaucoma care: eye pressure is measured only occasionally in most clinics, even though it changes throughout the day and may rise during sleep or while lying down. The August 2026 evidence is promising but more limited than some headlines suggest. The newest soft contact lens studies show that overnight and closed-eye monitoring is technically feasible. However, there is still no large, peer-reviewed clinical trial showing that an external smart contact lens improves vision, slows glaucoma progression, or reliably changes treatment based on automated alerts. The strongest real-world evidence for remote treatment decisions comes from implantable telemetric sensors and, to a lesser degree, home rebound tonometry rather than from external smart contact lenses. Nocturnal soft contact lens study Ongoing smart contact lens trial Implantable sensor progression study Executive Summary New soft contact lens technology: The 2026 nocturnal sensor demonstrated closed-eye and recumbent monitoring in a very small human pilot involving a healthy participant and a participant with pigmentary glaucoma. It reported encouraging comfort and signal stability, but no cohort-level adherence, data-completeness, treatment-change, or vision-outcome results. Advanced Materials report Triggerfish: The commercially available SENSIMED Triggerfish detects changes in ocular dimensions related to pressure, rather than directly reporting pressure in millimeters of mercury. It can identify the likely timing of pressure peaks, but its United States authorization limits clinical use to helping identify when conventional pressure measurement should be performed. United States Food and Drug Administration United States Food and Drug Administration review Implantable EyeMate sensors: These devices provide the most mature continuous telemetric data. In one remote-monitoring study, data led to treatment changes in 5 of 34 patients who submitted measurements, while treatment changes were considered in another 5 patients. Remote telemetric monitoring study Home tonometry: iCare HOME2 offers a more practical alternative for intermittent home measurements. In a 75-patient prospective cohort, 65% obtained at least six measurements per day, while 19% obtained fewer than two per day. The device identified maximum pressure outside clinic hours in 36% of patients. Home tonometry cohort Payer position: Publicly available 2026 policies from Aetna and Anthem classify continuous pressure monitoring and home tonometry as investigational, unproven, or not medically necessary for routine glaucoma care. Aetna policy Anthem policy What the Devices Actually Measure External smart contact lenses There are two broad approaches: Relative-signal sensors, such as Triggerfish, detect changes in corneal or corneoscleral shape that are believed to reflect pressure changes. Quantitative sensors, such as the newer Purdue-developed soft lenses, attempt to convert mechanical deformation into an absolute pressure estimate in millimeters of mercury. This distinction is clinically important. A relative signal may show that a patient’s pressure-related ocular changes increased overnight, but it does not necessarily mean that a reading of “higher” corresponds to a specific pressure such as 25 millimeters of mercury. Calibration can vary with lens fit, corneal curvature, corneal thickness, posture, eyelid position, and individual ocular biomechanics. NICE technology review Triggerfish clinical review Implantable telemetric sensors EyeMate sensors are implanted inside the eye and are read by an external handheld or wearable reader. Unlike Triggerfish, the implant is designed to measure actual intraocular pressure rather than only an indirect dimensional signal. The disadvantage is that implantation requires intraocular surgery, generally at the time of glaucoma or cataract surgery. EyeMate-SC trial EyeMate-IO trial Home rebound tonometry The iCare HOME and iCare HOME2 devices do not continuously monitor pressure. Instead, the patient takes individual measurements at selected times, often several times per day. This makes them less passive than a contact lens but substantially easier to validate, replace, and interpret against Goldmann applanation tonometry. August 2026 Contact Lens Evidence 2026 nocturnal soft contact lens The newest peer-reviewed study, published online in June 2026, evaluated a soft contact lens with an embedded wireless pressure sensor and a reader integrated into a sleep mask. The design specifically addressed two limitations of earlier devices: closed-eye operation and stable sensing while lying down. Nocturnal intraocular pressure monitoring study The study demonstrated: Stable sensing with the eye open and closed. Monitoring during sitting and recumbent postures. Resistance to moderate eye and head movement. Ex vivo sensitivity of approximately 0.163 megahertz per millimeter of mercury, with a calibration coefficient of R² = 0.977. Human testing in a healthy participant and a participant with pigmentary glaucoma. Comfort ratings generally above 90 on the study’s 0–100 comfort scale after transition to a recumbent, eyes-closed posture. No meaningful subjective visual distortion, although mild regional visual-field reductions were observed in testing and remained within functional limits. Advanced Materials full report What the 2026 study did not show The study did not establish: Agreement with Goldmann applanation tonometry in a clinical cohort. A validated conversion equation applicable across patients. Overnight wear adherence in a larger population. The percentage of usable or missing data during sleep. The sensitivity or specificity of automated alerts. Treatment changes caused by sensor readings. Reduced visual-field loss or slower glaucoma progression. Therefore, it should be regarded as a human feasibility and engineering-validation study, not as a clinical utility trial. Earlier smart soft contact lens data A 2022 Nature Communications study evaluated a different soft contact lens design in three adult contact-lens users. One participant had mild ocular hypertension. The lens produced a pressure-related signal that correlated with reference measurements across different postures, with a reported calibration fit of R² = 0.91. Its readings agreed more closely with the iCare Home device and Goldmann applanation tonometry than did the Triggerfish signal in the same testing environment. Smart soft contact lens study Comfort was favorable compared with Triggerfish, although the comparison used only three participants: Smart soft lens after adaptation: 12.7 ± 5.4 on a scale where lower scores indicated less discomfort. Bare soft contact lens: 4.0 ± 4.2. Triggerfish insertion: 46.7 ± 30.1. Triggerfish removal: 68.3 ± 6.2. The authors demonstrated 24-hour monitoring in a dog, but the human component involved short-term, in-clinic testing rather than overnight human monitoring. No adherence, data-completeness, management-change, or glaucoma-progression data were reported. Smart soft contact lens study A United States clinical trial of smart soft contact lenses began in October 2025 and is planned to enroll approximately 120 participants, with estimated completion in September 2028. As of August 18, 2026, the trial registry did not show mature clinical utility results. ClinicalTrials.gov study record Correlation With Goldmann Applanation Tonometry Triggerfish: useful for timing, not interchangeable pressure values Triggerfish does not directly provide a conventional pressure value in millimeters of mercury. Its output is an electrical signal representing changes in ocular dimensions. The United States Food and Drug Administration authorized it to identify the likely time window of peak pressure so that a clinician can perform conventional measurement at a more informative time. The regulatory review specifically states that treatment and diagnostic decisions should continue to rely on traditional clinical methods. United States Food and Drug Administration United States Food and Drug Administration review In a repeated 24-hour study of 40 glaucoma suspects and glaucoma patients: Blurred vision occurred in 82.5%. Conjunctival redness occurred in 80.0%. Superficial punctate keratitis occurred in 15.0%. Mean discomfort scores were approximately 27 and 24 on a 0–100 scale during two sessions. The correlation between repeated pressure-related profiles was approximately 0.59, indicating fair reproducibility rather than highly precise repeatability. Triggerfish safety and reproducibility study The central limitation is that a reproducible relative pattern is not the same as an accurate absolute pressure measurement. Lens position, corneal shape, and pressure-independent changes in ocular biomechanics can influence the signal. New quantitative lenses The newer soft lenses are designed to generate absolute pressure estimates. The available human evidence is encouraging, but the numbers come from very small studies. The 2022 human stuSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/a-new-target-for-protecting-the-optic-nerve-human-glaucoma-study-strengthens-the-case-against-galectin-3Test your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:A New Target for Protecting the Optic Nerve? Human Glaucoma Study Strengthens the Case Against Galectin-3 Introduction Galectin-3 inhibition is becoming one of the more credible new neuroprotective strategies in glaucoma—but it is not yet a proven treatment, and it is not ready to replace intraocular pressure lowering. The reason for the growing interest is that Galectin-3 sits at the intersection of several processes implicated in glaucoma: Microglial activation Müller glial stress responses Astrocyte reactivity Neuroinflammation Phagocytosis and debris clearance Metabolic dysfunction Retinal ganglion-cell and optic-nerve injury Earlier animal studies showed that genetic removal or pharmacological inhibition of Galectin-3 could preserve retinal ganglion cells and their axons despite continued ocular hypertension. A later rat study confirmed that intravitreal TD139, a small-molecule Galectin-3 inhibitor, protected retinal ganglion cells without lowering intraocular pressure. () The important new development is the demonstration that Galectin-3 is strongly associated with Müller glia in human glaucomatous retinas, rather than being merely a marker of activated microglia in experimental animals. The human finding makes the target more biologically relevant to patients, but it also makes the biology more complicated: Galectin-3 may be harmful in some disease-associated microglia while supporting beneficial Müller-cell functions in other circumstances. An Important Evidence Check: What Was Actually Published? As of August 17, 2026, the directly verifiable record matching the human Müller-glia finding is an EVER 2025 abstract by Anne Rombaut and colleagues titled Galectin-3 is associated with Müller cells in glaucoma. I could not independently verify the exact full-text August 2026 Acta Neuropathologica Communications citation described in the prompt through the indexed records available for this review. That distinction matters. The abstract provides the central findings, but it does not provide all the information normally expected from a complete research article, such as the full donor characteristics, exact sample sizes, fold changes, complete statistical tables, and detailed limitations. The conclusions below therefore separate: Human tissue findings that are directly reported in the abstract Animal treatment findings from peer-reviewed studies Reasonable but still unproven interpretations The human findings are nevertheless important because they connect the Galectin-3 pathway to the cell type that spans almost the entire retina and supports retinal ganglion-cell metabolism and homeostasis. () What Researchers Found in Human Glaucomatous Retinas Galectin-3 increased in association with glial markers Rombaut and colleagues examined Galectin-3 staining in: A rat bead model of ocular hypertension at an early time point and an early degenerative time point Donor human retinas with late-stage glaucoma Cell cultures of human MIO-M1 Müller glial cells They compared Galectin-3 with: Iba-1, a marker used to identify microglia and infiltrating monocyte-lineage cells Glial fibrillary acidic protein, a marker expressed by reactive astrocytes and Müller glia In the experimental rat retinas, the volume of Galectin-3 staining and its overlap with both the microglial marker and the glial fibrillary acidic protein marker increased. In the human retinas, however, Galectin-3 was more strongly associated with the glial fibrillary acidic protein-positive compartment. This Galectin-3–glial fibrillary acidic protein association was present in both control and glaucomatous retinas but was significantly greater in glaucoma. The authors interpreted this as evidence of a strong Müller-glial response. () What about microglia and astrocytes? The findings do not mean that microglia or astrocytes are irrelevant. Previous glaucoma studies have shown: Microglial activation in human glaucomatous retinas and optic nerves Increased Galectin-3 expression in disease-associated microglia in experimental glaucoma Increased astrocyte reactivity and Galectin-3 expression in the optic nerve head Increased Galectin-3 in human glaucomatous optic nerve head tissue and trabecular meshwork In the human Müller-cell study, glial fibrillary acidic protein was used as a combined marker for astrocytes and Müller glia. Therefore, glial fibrillary acidic protein staining alone cannot perfectly separate these two cell types. Morphological localization and the authors’ interpretation support a major Müller-glial contribution, but the full paper should provide more definitive cell-specific confirmation using markers such as retinaldehyde-binding protein 1, glutamine synthetase, cellular retinaldehyde-binding protein, or other Müller-cell markers. () The most important human observation The key observation is not simply that “Galectin-3 is higher in glaucoma.” It is that Galectin-3 appears to be redistributed toward Müller glia in human glaucoma, while also being associated with microglia and astrocytes. That is important because Müller glia: Extend through almost the full thickness of the retina Regulate potassium and water balance Remove excess glutamate Provide metabolic substrates to neurons Support the blood-retinal barrier Respond rapidly to mechanical, metabolic, and inflammatory stress Communicate with retinal ganglion cells, microglia, blood vessels, and other retinal cells A dysfunctional Müller cell can therefore influence many retinal systems at once. () Why the Müller-Glia Association Matters Müller glia can protect retinal ganglion cells—or amplify injury Healthy Müller glia are essential support cells. They help maintain the environment in which retinal ganglion cells function. In glaucoma, this support system can become disturbed. Experimental and review literature suggests that stressed Müller glia may: Release adenosine triphosphate, which can activate purinergic receptors Increase inflammatory signaling Alter glutamate handling Lose efficient potassium buffering Change their metabolism Release tumor necrosis factor alpha and interleukin-6 Promote microglial activation Contribute to a feed-forward inflammatory loop Müller-glia-derived adenosine triphosphate can act directly on retinal ganglion cells or stimulate microglia to release inflammatory mediators. This provides a possible route through which Müller glia could contribute to retinal ganglion-cell dysfunction even before extensive neuronal death has occurred. () Galectin-3 could be a signaling amplifier Galectin-3 is a carbohydrate-binding protein that can function inside cells, on cell surfaces, or in the extracellular environment. It can influence: Cell adhesion Cell migration Immune activation Phagocytosis Cell survival Fibrosis Cytokine signaling Receptor clustering and signaling In disease-associated microglia, Galectin-3 is often part of a broader program involving apolipoprotein E, lysosomal activity, phagocytosis, and inflammatory remodeling. In glaucoma models, Galectin-3 appears to help maintain a microglial state that can damage retinal ganglion cells. () The Müller-cell response may not be conventionally inflammatory One of the most interesting findings from the Rombaut group’s cell-culture experiments was that recombinant Galectin-3 caused morphological changes in MIO-M1 Müller cells consistent with gliosis. However, the molecular response was different from the response caused by a mixture of tumor necrosis factor alpha, interleukin-1 alpha, and complement component 1q. The inflammatory control mixture produced extensive inflammatory gene activation. Galectin-3 caused more modest changes, including effects that appeared to reduce some inflammatory signaling and alter Müller-cell homeostatic responses. This suggests that Galectin-3 may not simply be a conventional inflammatory trigger in Müller cells. It may instead act as a stress-response regulator, changing the behavior of Müller glia in ways that can be protective, maladaptive, or both depending on disease stage and cellular context. () Is Galectin-3 Harmful, Protective, or Merely a Marker? The most accurate answer is: potentially all three, depending on where, when, and how it is expressed. Evidence that Galectin-3 can be harmful In experimental glaucoma: Galectin-3 is increased in activated, disease-associated microglia Genetic deletion of the Galectin-3 gene protects retinal ganglion cells TD139 protects retinal ganglion cells despite continued ocular hypertension Galectin-3 inhibition can protect optic-nerve axons in mouse models These intervention studies support more than a simple marker role. They indicate that at least some forms of Galectin-3 signaling contribute causally to neurodegeneration. () Evidence that Galectin-3 can also be protective Other retinal studies show that Galectin-3 helps Müller glia perform clearance phagocytosis through the MERTK receptor pathway. In those studies, Galectin-3 deficiency worsened Müller-cell activation and aggravated retinal degeneration in inherited and chemically induced retinal injury models. This is an important warning. Completely eliminating Galectin-3 from every retinal cell may not be beneficial. MüSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/nicotinamide-b3-gets-surprisingly-strong-human-glaucoma-evidenceTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Nicotinamide/B3 Gets Surprisingly Strong Human Glaucoma Evidence What the 2026 studies show about vitamin B3, nicotinamide, glaucoma prevention, neuroprotection, dosage and safety Introduction As of August 13, 2026, the evidence linking nicotinamide, a form of vitamin B3, with glaucoma protection has become substantially more persuasive—but it still has not crossed the threshold required to change routine treatment. Two new human studies are driving the renewed interest: A July 9, 2026, JAMA Ophthalmology cohort study found that patients with ocular hypertension who had documented systemic nicotinamide exposure were much less likely to receive a later diagnosis of primary open-angle glaucoma. An August 2026 American Journal of Ophthalmology analysis of the Rotterdam Study found that higher dietary intake of niacin, the broader vitamin B3 category, and vitamin B12 was associated with a lower risk of developing open-angle glaucoma. These findings reinforce earlier randomized trials showing that nicotinamide may improve certain measures of retinal function in people who already have glaucoma. They also fit a biologically plausible theory: aging, elevated eye pressure and oxidative stress may deplete nicotinamide adenine dinucleotide, or NAD+, leaving retinal ganglion cells less able to produce energy and survive stress. However, the most dramatic prevention result is observational, not randomized. High-dose nicotinamide also carries a real—although probably uncommon—risk of liver injury. The evidence is promising enough to justify large clinical trials, but not yet strong enough to replace pressure-lowering treatment or support unsupervised high-dose supplementation. () The central new finding: lower glaucoma conversion in ocular hypertension What the JAMA Ophthalmology study examined The study used deidentified electronic health-record data from 67 United States health care organizations, covering March 2006 through March 2026. Researchers identified people with ocular hypertension but no previous open-angle glaucoma, laser treatment or glaucoma eye-drop therapy. The analysis compared: 1,460 patients with documented systemic nicotinamide exposure 1,460 propensity-matched control patients with no recorded use of nicotinamide or niacin The groups were followed for an average of 3.7 years. The study was published online on July 9, 2026. () Primary open-angle glaucoma diagnosis A subsequent diagnosis of primary open-angle glaucoma occurred in: For the full table, please open this article on visualfieldtest.com. The reported hazard ratio of 0.34 corresponds to approximately a 66% lower hazard of diagnosis during follow-up. The absolute difference was 5.5 percentage points, with a 95% confidence interval of 3.8 to 7.3 percentage points. If the association were causal, a simple calculation would suggest that roughly 18 similar ocular-hypertension patients would need to receive nicotinamide to prevent one additional diagnosis over approximately four years. That number was not reported by the investigators and should not be interpreted as a treatment recommendation. () Fewer glaucoma treatments and laser procedures The study also found lower rates of treatment escalation: Topical eye-pressure-lowering treatment: 13.6% with nicotinamide versus 21.2% in controls Hazard ratio: 0.57 Laser trabeculoplasty: 0.8% with nicotinamide versus 1.9% in controls Hazard ratio: 0.38 These findings suggest that nicotinamide exposure was associated not only with fewer glaucoma diagnoses, but also with fewer downstream treatment decisions. However, medication initiation and laser treatment are influenced by clinician judgment, follow-up patterns, coding and patient preferences. They are useful supporting outcomes, but they are not direct measurements of retinal ganglion-cell survival. () Is the apparent effect unusually large? Numerically, yes. The size of the association is striking because it resembles the benefit of the best-established prevention strategy for ocular hypertension: lowering intraocular pressure. In the randomized Ocular Hypertension Treatment Study, five-year primary open-angle glaucoma incidence was: 4.4% in patients assigned to pressure-lowering eye drops 9.5% in patients assigned to observation That corresponded to a hazard ratio of approximately 0.40 and an absolute risk reduction of 5.1 percentage points. () The nicotinamide cohort reported: 3.5% versus 9.0% Hazard ratio 0.34 Absolute risk reduction 5.5 percentage points Therefore, the observed nicotinamide association was at least as large numerically as the Ocular Hypertension Treatment Study result. But the comparison is not proof that nicotinamide works as well as eye-pressure-lowering medication. The studies differed in several important ways: The Ocular Hypertension Treatment Study was randomized; the nicotinamide study was observational. The follow-up periods were different. The participants may have had different levels of baseline risk. The glaucoma outcomes were identified differently. The nicotinamide study did not provide the same detailed, standardized measurements of eye pressure, corneal thickness, optic-nerve appearance and visual fields. The correct interpretation is that the magnitude deserves urgent randomized testing, not that nicotinamide has already matched established treatment. Why the JAMA study cannot establish causation Propensity matching can make groups look similar using recorded information, but it cannot reproduce randomization. Several explanations other than a direct protective effect remain possible. Exposure was documented, not directly measured The study evaluated documented systemic nicotinamide exposure. Electronic records may not show: The actual dose The product formulation How long the patient took it Whether the patient took it consistently Whether the product was prescribed, purchased over the counter or obtained elsewhere A patient with a documented nicotinamide prescription may therefore differ considerably from a person taking a low-dose supplement intermittently. Residual confounding remains possible The records may not have fully captured important glaucoma risk factors, including: Family history Central corneal thickness Detailed baseline eye pressure Optic-nerve structure Visual-field status Genetic susceptibility Smoking, exercise and dietary patterns Health literacy and access to specialist care Even after statistical adjustment, unmeasured differences can remain. Healthy-user bias is a serious possibility People who take supplements may also be more likely to: Attend preventive medical visits Follow eye-care recommendations Exercise and eat a healthier diet Avoid smoking Seek care earlier Have better access to specialists Any of these factors could reduce the likelihood of glaucoma diagnosis or treatment escalation independently of nicotinamide. Diagnosis and treatment are not identical to disease biology A lower rate of glaucoma coding could reflect a lower rate of disease, but it could also reflect differences in: Follow-up frequency Provider documentation Testing intensity Access to glaucoma specialists Thresholds for labeling ocular hypertension as glaucoma Likewise, fewer prescriptions or laser procedures could reflect clinician preference rather than less retinal damage. The study did not prove a dose-response relationship A strong causal argument would be strengthened if higher doses, longer exposure or higher blood nicotinamide levels were associated with progressively greater protection. The available cohort result does not establish that relationship. The study did not prove an intraocular-pressure-independent effect The study did not establish whether nicotinamide users had lower eye pressure over time. It is therefore impossible to determine whether the association reflects: Direct retinal neuroprotection, Lower eye pressure, Better treatment adherence, Healthier behavior, or A combination of these factors. These limitations are especially important because the apparent benefit was large. Large effects from observational studies are valuable signals, but they are also particularly vulnerable to bias. () What the August 2026 Rotterdam Study adds The Rotterdam Study provides a different kind of evidence. Rather than examining high-dose supplements, investigators assessed usual dietary intake of several B vitamins in people initially free of open-angle glaucoma. The analysis included: 6,742 participants Mean age: 62.4 years 58.2% women 162 new cases of open-angle glaucoma The analysis adjusted for at least age, sex, total calorie intake, diet quality and follow-up time. () Niacin, or dietary vitamin B3 Higher dietary niacin intake was associated with lower incident open-angle glaucoma: Odds ratio per additional milligram per day: 0.94 Highest intake group: approximately 23.27 milligrams per day Lowest intake group: approximately 9.98 milligrams per day Highest versus lowest intake groups: odds ratio 0.43 Trend across groups: P = .02 This is consistent with a potentially protective role for vitamin B3-related nutrition. However, dietary niacin is not the same intervention as taking one to three grams of purified nicotinamide daily. Food-based measures generally combine different sources and forms of vitamin Support the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/can-glaucoma-damage-be-reversed-first-human-epigenetic-reprogramming-trial-targets-the-optic-nerveTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Can Glaucoma Damage Be Reversed? First Human Epigenetic Reprogramming Trial Targets the Optic Nerve Updated August 11, 2026 Bottom line ER-100 is the first human clinical trial of a partial epigenetic reprogramming therapy, but it is not yet evidence that glaucoma damage can be reversed in people. Life Biosciences is testing ER-100 in a small, first-in-human Phase 1 study involving adults with open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy. The treatment delivers genetic instructions for three transcription factors—OCT4, SOX2, and KLF4, collectively called OSK—to retinal ganglion cells using an adeno-associated virus type 2 vector. Oral doxycycline is then used for eight weeks to activate the therapeutic genes. [ClinicalTrials.gov study record] () The scientific idea is fundamentally different from conventional glaucoma treatment. Instead of lowering intraocular pressure, ER-100 is intended to make damaged but living retinal ganglion cells behave more like younger, healthier cells. The preclinical evidence is unusually ambitious: studies in mice reported retinal ganglion cell survival, optic nerve axon growth, improved electrical retinal responses, and improved visual behavior. Company-presented nonhuman-primate data reported recovery of pattern electroretinogram responses and improved optic nerve axon survival after an experimental optic nerve stroke. However, the primate findings have been publicly described mainly through company disclosures and a 2023 Association for Research in Vision and Ophthalmology presentation rather than a detailed, independent, peer-reviewed clinical-efficacy publication. [Nature study] () [Life Biosciences primate disclosure] () As of August 11, 2026, no human vision benefit, epigenetic reset, retinal ganglion cell regeneration, or long-term safety result has been publicly reported. Life Biosciences has confirmed that the first participant was dosed, but the trial remains an early safety study with no results posted on ClinicalTrials.gov. [Life Biosciences first-dose announcement] () [ClinicalTrials.gov record] () The fairest conclusion is: > Glaucoma has not yet entered the era of proven optic-nerve restoration. It has entered the era of the first credible human experiment testing whether optic-nerve cells can be rejuvenated rather than merely protected. --- Why current glaucoma treatments do not reverse damage Glaucoma damages retinal ganglion cells, the nerve cells that collect visual information from the retina. Their long axons form the optic nerve and carry signals to the brain. Once retinal ganglion cells and their axons are permanently lost, current treatments cannot replace them. Standard treatments—including eye drops, laser treatment, and glaucoma surgery—primarily reduce intraocular pressure. Lowering pressure can slow or prevent additional optic nerve damage, but it does not normally restore lost visual field. [National Eye Institute] () [American Academy of Ophthalmology patient information] () This is why glaucoma care is generally described as preservation rather than restoration. Lowering pressure remains the only proven treatment strategy for controlling ordinary open-angle glaucoma, although disease progression can sometimes continue even when pressure is considered acceptable. [National Institute for Health and Care Excellence] () The difficulty is not only that retinal ganglion cells die. Their axons must also travel through the optic nerve and connect with appropriate visual centers in the brain. The National Eye Institute has emphasized that the failure of adult human retinal ganglion cells to regenerate and reconnect explains much of the irreversibility of optic-nerve-related vision loss. [National Eye Institute optic-nerve regeneration report] () ER-100 is designed to intervene at a different level: Conventional treatment: reduce the mechanical stress caused by intraocular pressure. ER-100: alter gene regulation inside retinal ganglion cells. Potential goal: preserve stressed cells, restore the function of injured cells, and possibly reactivate some regenerative capacity. ER-100 is therefore not a replacement for pressure control. Even if it works, a person with glaucoma would still be expected to need standard treatment to reduce the original disease stress. --- What ER-100 is ER-100 is described by Life Biosciences as AAV2-OSK: an adeno-associated virus type 2 vector carrying genetic instructions for OCT4, SOX2, and KLF4. The vector is administered by an intravitreal injection, meaning an injection into the gel-like vitreous cavity inside the eye. [Life Biosciences] () The vector is intended to deliver the OSK instructions mainly to retinal ganglion cells. It is not designed to edit the patient’s existing DNA sequence in the way a genome-editing system would. However, that does not mean it carries no genetic or biological risk: the vector can persist in cells, transgene expression may vary, and rare vector-genome integration is a general consideration in gene therapy. The treatment includes a separate control mechanism. According to the ClinicalTrials.gov record: The patient receives a single dose of ER-100. The viral vector remains in the eye. The patient takes oral doxycycline for 56 days. Doxycycline activates OSK expression through an inducible genetic switch. Doxycycline is stopped after eight weeks. The exact numeric vector doses for the dose-escalation groups have not been publicly listed in the main ClinicalTrials.gov record. The trial states that at least two dose levels will be assessed in the open-angle glaucoma cohort. [ClinicalTrials.gov] () What “epigenetic reprogramming” means The epigenome consists of chemical and structural controls that influence which genes are turned on or off. These controls include DNA methylation, chemical changes to histone proteins, and changes in how DNA is packaged. Epigenetic reprogramming does not necessarily change the underlying DNA letters. Instead, it attempts to alter the instructions that determine how the cell reads its existing genome. The theory behind ER-100 is that aging and injury gradually disturb the gene-regulation program that keeps retinal ganglion cells functional. According to this model, some of the damage may be a loss of youthful cellular information rather than irreversible destruction of every component of the cell. OSK is intended to push the cell toward a younger gene-expression state without converting it completely into a stem cell. --- How OCT4, SOX2, and KLF4 are supposed to rejuvenate retinal ganglion cells The three factors are transcription factors. They bind DNA and influence large networks of other genes. OCT4 OCT4 is a major regulator of cell identity and cellular reprogramming. In the original induced-pluripotent-stem-cell experiments, OCT4 helped activate a developmental program that could return adult cells to a stem-cell-like state. In ER-100, the aim is not to drive retinal ganglion cells all the way back to pluripotency. Instead, OCT4 is intended to help reopen or reorganize portions of the gene-regulatory landscape associated with cellular repair and youthfulness. SOX2 SOX2 is another key reprogramming factor. It helps alter chromatin accessibility—the degree to which DNA can be reached by gene-regulating proteins. In retinal ganglion cells, this may help reactivate genes involved in neuronal maintenance, axon growth, stress resistance, and synaptic function. The exact human retinal ganglion cell targets of ER-100 remain unproven. KLF4 KLF4 is involved in cell identity, chromatin regulation, stress responses, and reprogramming. It works together with OCT4 and SOX2 to alter gene-expression networks. The intended result is not simply a lower “epigenetic age” on a laboratory test. The therapeutic claim is that the cells should function better: maintaining axonal transport, resisting injury, and potentially regaining some ability to extend or repair axons. The proposed sequence of events The proposed mechanism can be summarized as: Age or injury alters gene regulation in retinal ganglion cells. These cells become less able to maintain axons and respond to stress. OSK temporarily changes transcription and chromatin organization. DNA methylation patterns and gene expression move toward a more youthful state. The retinal ganglion cells become more resilient or regain some regenerative capacity. Visual signaling improves if enough cells and axons remain connected. The mouse work supports several steps in this chain, but the complete sequence has not been demonstrated in humans. The original Nature study reported that OSK restored youthful DNA methylation patterns and gene-expression profiles in mouse retinal ganglion cells, and that the effect required the DNA-demethylation machinery involving TET1, TET2, and TDG. This is stronger evidence than merely showing that a methylation clock changed, but it still does not prove that aging in human glaucoma is primarily caused by epigenetic information loss. [Nature study] () --- Why ER-100 uses three factors rather than all four Yamanaka factors The original four-factor reprogramming combination is: OCT4 SOX2 KLF4 c-MYC The four-factor combinatioSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/why-visual-fields-matter-from-silent-loss-to-real-world-functionTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Why Visual Fields Matter: From Silent Loss to Real-World Function A person can read the smallest line on an eye chart and still have a serious problem with peripheral vision. This is especially common in glaucoma, where vision loss often begins slowly at the sides of the visual field while sharp central vision remains clear. That is why visual field testing matters. It measures not only how clearly a person sees, but also where vision is missing, how sensitive each area is, and whether the pattern is changing over time. In many patients, the test detects functional loss long before they recognize a problem in daily life. () What a Visual Field Test Measures A standard eye chart measures central visual acuity—the ability to see small letters or details directly in front of you. A visual field test measures the wider area that can be seen while the eyes remain fixed on one point. During standard automated perimetry, one eye is tested at a time. The patient looks at a central target and presses a button whenever a flash of light is seen. The machine presents lights of different brightness at many locations and estimates the dimmest light visible at each point. The result is a map of visual sensitivity across the field. () A report may include: A grayscale map, which gives a visual impression of missing or reduced areas. A total deviation map, comparing the result with people of the same age. A pattern deviation map, which helps identify localized defects despite generalized blur from conditions such as cataract or a small pupil. Mean deviation, an age-adjusted summary of overall field loss. More negative values generally indicate more loss. Visual field index, a percentage estimate of remaining age-adjusted field function, with greater emphasis on points near central vision. Pattern standard deviation, which highlights localized, irregular defects. These numbers are useful, but they should not be interpreted alone. The pattern, location, reliability, structural examination of the optic nerve, and the results from previous visits are all important. () Why Patients Often Do Not Notice Visual Field Loss Loss usually begins outside the center In chronic open-angle glaucoma, damage is usually gradual and often begins in the peripheral field. Early disease may produce small blind spots or areas of reduced sensitivity that do not interfere with ordinary tasks. The National Eye Institute notes that early glaucoma often has no symptoms, and many people do not notice that their side vision is changing until the disease is more advanced. () This creates a dangerous mismatch: The optic nerve may already be losing function. The eye chart may still show good central vision. The patient may still feel that vision is “normal.” A visual field test may reveal the problem before everyday symptoms become obvious. The two eyes can compensate for each other Most people do not routinely compare one eye with the other. If a defect affects one eye more than the other, the better eye may help cover the missing area. When the visual fields from both eyes are combined, some defects may be less noticeable than they are during one-eye-at-a-time testing. Research has shown that a person may have measurable defects in each eye while the combined binocular field appears relatively preserved. This is one reason that both monocular results and the likely binocular effect must be considered. () The brain adapts to slowly changing vision A slowly developing blind spot does not produce the same sudden warning as a new loss of vision. Patients may unconsciously turn the head more, scan the environment more often, walk more cautiously, or rely on familiar surroundings. These adjustments can hide the problem until the remaining field becomes much smaller. Adaptation is helpful, but it can also create false reassurance. A person may function adequately in a familiar home while struggling in a crowded store, on an unfamiliar street, in dim lighting, or behind the wheel. How Field Defects Affect Daily Activities The effect of visual field loss depends on where the defect is located, whether it affects one or both eyes, how severe it is, and how quickly it developed. No single field score predicts every real-world ability. For the full table, please open this article on visualfieldtest.com. The relationship is not always predictable. Studies comparing central and far peripheral loss have found that central damage is more closely associated with several measures of quality of life and daily activity, while far peripheral damage may be especially important for stride length, gait variability, and hazard detection. () Driving Driving requires more than reading road signs. It requires: Detecting vehicles, pedestrians, cyclists, and objects approaching from the side Maintaining lane position Responding quickly to unexpected hazards Searching mirrors and intersections Managing glare and low-light conditions Dividing attention between several parts of the visual environment Moderate or severe visual field loss—particularly when it affects both eyes—has been associated with slower responses to road hazards, poorer lane maintenance, greater difficulty driving at night, increased self-restriction, and a greater likelihood of stopping driving. Recent review evidence also links more severe bilateral field loss with poorer driving performance and a higher risk of motor-vehicle collisions. () A visual field test is important for counseling, but it is not the same as a driving test. Safe driving also depends on visual acuity, contrast sensitivity, attention, reaction time, cognition, neck movement, medications, and experience. Driver-licensing standards are jurisdiction-specific, so patients should check their state requirements and ask about a formal driving evaluation when appropriate. State agencies may impose different restrictions or medical-review requirements for people with reduced vision. () Walking, mobility, and falls Peripheral vision helps a person notice objects approaching from the side. Central vision helps identify steps, uneven surfaces, and details in the walking path. Losing either part of the field can cause a person to slow down, shorten steps, widen the base of support, or become more cautious. Research in glaucoma has linked visual field loss with: Greater fear of falling Shorter steps and strides Greater variation from one step to the next Fewer daily steps Difficulty with instrumental activities such as shopping and navigating unfamiliar places Increased mobility restriction Faster rates of binocular visual field loss have also been associated with a greater history of falls, even after considering the existing severity of the field defect. () This is why a patient who says, “I can still see,” should also be asked: Have you stumbled recently? Do you avoid stairs or uneven ground? Do you bump into objects? Do you feel unsafe crossing a street? Have you reduced outdoor activities? Do you need brighter lighting at home? Reading Reading depends on clear central vision, but it also depends on the ability to process several letters at once and move smoothly from one line to the next. Defects near fixation or in the central visual field can reduce the visual span—the amount of text recognized during one glance. People with bilateral glaucoma may read more slowly, lose their place, skip lines, struggle with small or low-contrast print, and become tired during prolonged reading. These problems may occur even when visual acuity remains relatively good. In one study, glaucoma was associated with slower oral and silent reading, and sustained silent reading was particularly affected. () Reading difficulty is therefore not always corrected by stronger glasses. Helpful strategies may include better lighting, larger print, higher contrast, magnification, electronic reading devices, and vision rehabilitation. Visual Fields and Quality of Life Clinical measurements and patient experience are related, but they are not identical. Two people with similar visual field scores may have very different lifestyles, work demands, home environments, coping strategies, and levels of disability. Patient-reported measures Several questionnaires help measure the effect of visual loss on daily life: The Glaucoma Quality of Life-15 questionnaire focuses on central and near vision, peripheral vision, glare and dark adaptation, and outdoor mobility. The National Eye Institute Visual Function Questionnaire-25 covers areas such as general vision, near and distance activities, driving, social functioning, role difficulties, dependence, and mental health. General disability and activity questionnaires may assess walking, shopping, reading, household activities, and independence. Studies consistently show that quality of life tends to worsen as binocular visual field loss becomes more severe. Faster visual field decline is also associated with worse later vision-related quality of life, even when two patients have similar amounts of damage at a single visit. () Objective functional measures Research can also measure function directly, using: Reading speed Number of daily steps Walking speed and stride variability Simulated shopping or object-finding tasks Falls Driving restriction or driving cSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/do-more-data-points-reveal-clearer-trends-power-and-noise-in-vf-progressionTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Do More Data Points Reveal Clearer Trends? Power and Noise in Visual Field Progression Introduction In glaucoma, visual field testing is used to determine whether vision is stable or gradually worsening. The challenge is that each test contains some noise. Attention, fatigue, learning, cataract, dry eye, fixation, and the patient’s underlying level of damage can all affect the result. Testing more often usually makes a true trend easier to recognize. However, the benefit is not proportional. Moving from one test per year to two often provides a meaningful gain. Moving from two to three tests per year may help, but the additional benefit is smaller. Testing too often can also create more apparent “changes” that later disappear, especially when statistical thresholds are applied repeatedly. The practical goal is therefore not to collect the largest possible number of visual fields. It is to collect enough high-quality tests, spaced appropriately, to detect clinically important progression without creating unnecessary burden or false alarms. Current glaucoma guidance supports at least annual testing for established glaucoma, with more frequent testing during the first two years after diagnosis or when the risk of rapid progression is high. () Why visual field progression is difficult to detect A visual field test measures light sensitivity at many locations. The result is not a direct photograph of the optic nerve. It is a behavioral measurement that depends on the patient noticing and responding to visual stimuli. A simple way to describe a visual field series is: > Observed result = true visual function + measurement noise The true glaucoma signal may be a gradual decline of only a fraction of a decibel per year, while the variation between individual tests can be several decibels at some locations. Test–retest variability tends to be greater in eyes with more advanced damage, lower sensitivity, peripheral defects, and certain defect patterns. () Mean deviation Mean deviation is a single summary number describing the overall visual field compared with an age-adjusted normal field. A negative number indicates loss; a more negative number indicates greater overall loss. Mean deviation is useful because it averages information across the field and is relatively easy to follow over time. A clinician can plot mean deviation against time and calculate a slope, such as: −0.3 decibels per year: slow change −1.0 decibel per year: moderate change −2.0 decibels per year: rapid change However, mean deviation can miss localized progression if the damaged area is small. It can also be influenced by diffuse factors such as cataract or other media opacity. () Pointwise slopes Pointwise linear regression evaluates each test location separately. It can show that a particular cluster of locations is worsening at, for example, −1.2 decibels per year. This approach can detect localized or paracentral progression that is diluted within a whole-field average. Its disadvantages are that individual locations are noisier than the overall mean, many locations are tested simultaneously, and the chance of at least one apparently significant result increases as more locations and more visits are examined. () How increasing test frequency improves signal-to-noise For a trend analysis, additional tests help in two ways: They provide more observations, reducing uncertainty about the estimated slope. They show whether a change is persistent, rather than a single unusually poor result. The timing of the tests also matters. A slope is estimated more precisely when tests are distributed across a longer time span. Three tests performed within a few weeks provide a better estimate of short-term repeatability, but three tests spaced over a year provide more information about long-term decline. This is why two baseline tests close together can be useful for learning and repeatability, while later tests should usually be spread across the follow-up period. The European Glaucoma Society emphasizes that determining an individual rate of progression generally requires at least two years and enough reliable visual fields. () Simulation evidence: the largest gains occur early Mean deviation: one versus two versus three tests per year Wu and colleagues used real visual field variability from 1,072 eyes and reconstructed visual field series through computer simulation. Their analysis required two baseline tests and a confirmatory test before progression was counted. The estimated time required to detect progression in 80% of eyes was: () For the full table, please open this article on visualfieldtest.com. These results show two important principles: Increasing testing from once to twice yearly produced a substantial improvement. Increasing testing from twice to three times yearly produced a smaller improvement. For a rapidly progressing eye losing −2.0 decibels per year, moving from annual to six-monthly testing shortened modeled detection time by approximately 0.9 years. Moving from six-monthly to four-monthly testing shortened it by only about 0.3 years. For a slower eye losing −0.5 decibels per year, even three tests per year required approximately five years to achieve 80% detection power. More frequent testing helps, but it cannot completely overcome a very small signal or high measurement variability. () An earlier practical analysis reached a similar conclusion. For an eye with average variability, approximately three tests per year were estimated to be needed to detect a four-decibel mean deviation decline over two years with 80% power. The authors recommended six reliable examinations during the first two years to establish a baseline and identify unusually rapid progression. () Pointwise slopes: greater sensitivity, but more false alarms Gardiner and Crabb developed a “virtual eye” simulation in which a test location was either stable or deteriorating at a known rate. When a location was truly worsening at 2 decibels per year, more frequent testing allowed pointwise linear regression to identify progression sooner. But when the simulated location was stable, increasing test frequency also increased the number of series falsely labeled as progressing during the early years. Their conclusion was that three tests per year provided a practical compromise between sensitivity and specificity for pointwise linear regression. () This is an important qualification: more data improve the chance of detecting a real trend, but they also create more opportunities to observe an unusual sequence of results. Statistical methods therefore need confirmation rules and appropriate thresholds. What real-world visual field series show The Advanced Glaucoma Intervention Study Nouri-Mahdavi and colleagues analyzed 468 eyes from the Advanced Glaucoma Intervention Study. They compared the original, more frequent visual field series with a version in which approximately half of the later tests had been removed. The high-frequency series had a median interval of about six months, compared with approximately 11.3 months in the lower-frequency series. Progression based on mean deviation was detected in: 43.6% of eyes with the more frequent series 34.2% of eyes with the less frequent series Using pointwise linear regression, progression was detected in: 39.5% of eyes with the more frequent series 35.7% of eyes with the less frequent series The hazard of detecting mean deviation progression was 1.69 times higher with more frequent testing. For pointwise linear regression, the hazard was 1.52 times higher. The benefit was particularly evident with global mean deviation analysis. () This real-world analysis supports the simulation findings: six-monthly testing generally detects progression earlier than approximately annual testing, but the gain is larger for mean deviation than for pointwise slopes. Real-world testing in the United States A more recent study used real-world visual field variability from the Duke Glaucoma Registry and simulated progression at testing frequencies observed in a large United States insured population. For modeled progression rates of −0.5 or −1.0 decibels per year, the time required to detect progression in 80% of eyes was estimated as follows: () For the full table, please open this article on visualfieldtest.com. These numbers are modeled estimates, not a prediction for every patient. They nevertheless demonstrate how infrequent testing can delay recognition of progression for many years. The study also found that more than three-quarters of patients in the underlying nationwide cohort received fewer than one visual field test per year. () Frontloading tests A 2024 simulation study used progression rates and baseline characteristics from Swedish and Canadian glaucoma cohorts. It compared one visual field test per visit with a “frontloaded” strategy involving two tests per visit. When visits occurred every six months, frontloading detected progression approximately one to one-and-a-half years earlier in many scenarios. At four years, it increased the proportion of detected progressors by roughly 27% to 32%, depending on the amount of missing data. The simulated eyes also had less visual field loss when progression was detected. () FrontSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/patient-education-to-improve-vf-performance-and-reduce-anxietyTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Patient Education to Improve Visual Field Test Performance and Reduce Anxiety Visual field testing—also called perimetry—is essential for detecting and monitoring glaucoma, optic nerve disease, retinal disease, and some neurological conditions. During standard automated perimetry, one eye is tested at a time while the patient looks at a central target and presses a button whenever a light is seen in the surrounding area. The test estimates how sensitive different parts of the visual field are. () Because the test depends on attention, understanding, fixation, and timely responses, patient education can directly affect the quality of the result. Anxiety, fatigue, unfamiliarity, incorrect responses, and difficulty maintaining fixation may lead to unreliable findings or unnecessary repeat testing. In a prospective study, higher pre-test anxiety was associated with greater visual field unreliability, while patients who had completed more than 10 previous tests reported substantially less anxiety. () Why Patient Education Matters A patient does not need to see every light to perform well. The goal is to respond accurately to the lights that are visible and to avoid pressing the button simply because a light is expected. Education helps patients understand that: The lights vary in brightness. Some lights will be too dim to see. Missing occasional lights is expected. The patient should look at the central fixation target rather than chase peripheral lights. Blinking is allowed. A short pause can usually be requested if the patient becomes tired or uncomfortable. The test is not an examination that can be “failed” through one or two missed responses. A learning curve is common. Repeated testing can improve attention, response timing, and understanding of the procedure, although a better result after practice does not necessarily mean that the eye itself has improved. () Educational Interventions That Improve Performance Short Educational Videos A three- to five-minute video can show the patient what the instrument looks like, where to look, how the button works, and what the flashes will feel like during the test. A randomized study of 244 patients undergoing their first automated visual field test used a 4.5-minute educational video. Reliable results in both eyes were obtained in: 75.9% of patients who watched the video 61.4% of patients who received usual instruction without the video This was an absolute improvement of 14.5 percentage points. The main benefit occurred in the second eye tested: reliability was 86.6% with the video versus 73.5% without it. () A later quality-improvement audit used a 4.5-minute video in patients with no previous experience of standard automated perimetry. Reliability increased from 66.7% before the intervention to 87.5% afterward, an improvement of 20.8 percentage points. The video explained fixation, blinking, the changing brightness of the lights, and when to request a pause. () The video should be: Short enough to watch immediately before testing Available in the patient’s preferred language Demonstrated from the patient’s viewpoint Focused on behavior rather than disease terminology Followed by an opportunity to ask questions Interactive Demonstrations An interactive demonstration can be more effective than spoken instructions alone because it allows the patient to see and rehearse the exact task. A useful demonstration may include: A central fixation target A simulated peripheral flash A button response Examples of lights that are easy to see and lights that are barely visible A brief example showing that the patient should not move the eyes toward the flash A demonstration of normal blinking and pausing Direct research on a separate interactive perimetry simulator is still limited. However, studies comparing video and spoken instruction consistently suggest that visual explanation improves understanding and confidence. In one prospective study of 120 patients with no previous experience of the test, patients receiving video instruction had better reported relaxation and motivation than those receiving verbal instruction alone. () Teach-Back and Short Practice Questions After a video or demonstration, the technician can ask the patient to explain the procedure in their own words. This is called teach-back. Useful questions include: “Where will you look during the test?” “When should you press the button?” “What should you do if you do not see a light?” “Are you allowed to blink?” “What should you do if you become tired?” In the 2022 educational-video audit, patients completed a seven-question assessment. Among patients with unreliable tests, 76.9% scored fewer than four correct answers. Every patient who scored more than four correct answers had a reliable result. This finding shows a strong association between understanding and test quality, although it does not prove that the quiz alone caused the improvement. () Practice Tests A short practice exercise can reduce the unfamiliarity that makes the first test stressful. A practice exercise should be clearly labeled as training only, not as a clinical result. In a study of 55 healthy adults with no previous perimetry experience, the median test duration decreased from: 5.7 minutes during the first test 5.3 minutes during the second test False-negative responses also decreased from a median of 2% to 0%. Sensitivity increased during the second test, particularly in peripheral locations. () Practice should be brief. A full additional threshold test may create fatigue and may alter the patient’s performance through learning. For most patients, a short demonstration or practice block is preferable to repeatedly performing a complete clinical test before the actual measurement. Combined Video and Verbal Instruction Video appears to work best when it reinforces, rather than replaces, a clear explanation from the technician. In a study of 90 patients, three instruction methods were compared: Verbal instruction alone Video instruction alone Video followed by verbal instruction The combined video-and-verbal approach resulted in the fewest repeat tests. Both video instruction and combined instruction produced more reliable fields than verbal instruction alone. () The technician should use a consistent script. Instructions that are too strict may cause patients to withhold responses; instructions that encourage excessive guessing may increase false-positive responses. The patient should follow the instructions for the specific instrument and testing algorithm being used. Quantified Effects on Reliability and Test Duration The available studies show a clearer improvement in reliability than in test duration. For the full table, please open this article on visualfieldtest.com. Important Limitations These percentages should not be combined as if they came from one large trial. The studies used different: Patient populations Visual field instruments Testing algorithms Definitions of a “reliable” test Instruction methods Study designs Some studies were randomized, while others were audits or before-and-after comparisons. Reliability indices such as fixation losses, false-positive responses, and false-negative responses are useful, but they should not be interpreted in isolation. Modern interpretation also considers the gaze trace, the pattern of loss, test duration, disease severity, and whether the result makes clinical sense. () A Practical Structured Coaching Protocol A clinic can provide structured coaching in approximately five to eight minutes. Step 1: Set Expectations Use simple language: > “This test measures how sensitive different parts of your vision are. You will not see every light. Missing some lights is normal.” This reduces the fear that a patient must respond perfectly. Step 2: Show the Procedure Use a video, tablet demonstration, or printed illustration to show: The central fixation target The surrounding flashes The response button The covered eye How the patient should sit How the technician monitors fixation Step 3: Demonstrate the Correct Response Tell the patient: Look steadily at the central target. Press only when a light is seen. Do not move the eyes toward the light. Blink normally. Do not try to predict when the next flash will appear. Ask for a pause if needed. The exact response instruction should match the instrument’s protocol. Step 4: Use Teach-Back Ask the patient to explain the procedure. Correct misunderstandings before testing begins. Step 5: Offer a Brief Practice A short non-diagnostic practice sequence can familiarize the patient with the button and the changing brightness of the lights. The practice result should not be used as the patient’s clinical baseline. Step 6: Use Neutral Support During Testing The technician should monitor the patient’s position, alertness, and fixation without repeatedly giving performance-related comments. Overly frequent prompts may distract the patient or alter responses. A standardized script and consistent technician approach are preferable because technician instructions can influence perimetry results. () In-Clinic Tutoring Versus Application-Based Home Modules What In-Clinic Tutoring Does Best In-clinic tutoring is strongest when: The patient is taking the test for the first time. TSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/who-should-get-visual-field-testing-a-population-based-frameworkTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Who Should Get Visual Field Testing? A Population-Based Framework Visual field testing measures how well a person sees across the central and peripheral parts of the visual field. It is especially important because many eye and brain disorders damage peripheral vision gradually, without causing obvious symptoms at first. However, routine visual field testing is not necessary for every healthy, asymptomatic adult. The highest value comes from testing people whose examination, medical history, medication use, or disease pattern creates a meaningful risk of developing or worsening field loss. This targeted approach helps detect silent damage while limiting false-positive results, unnecessary anxiety, and avoidable testing. What Visual Field Testing Detects Most clinical visual field tests use automated static threshold perimetry. One eye is tested at a time while the patient looks at a central target and presses a button whenever a spot of light is seen. The test can identify: Peripheral blind spots caused by glaucoma Central or paracentral defects affecting reading or fixation Bitemporal defects associated with pituitary or other chiasmal disease Altitudinal defects associated with ischemic optic neuropathy Enlargement of the blind spot associated with papilledema Concentric peripheral loss caused by some toxic retinal disorders Hemifield loss after stroke or damage to the visual pathways Visual field testing is different from a visual acuity test. A person may still read the eye chart well while having important peripheral field loss. The two eyes also overlap, allowing one eye to compensate for defects in the other. Because visual field testing depends on attention, learning, fatigue, and response consistency, one abnormal result should usually be confirmed unless the pattern is clearly urgent. National Institute for Health and Care Excellence glaucoma guideline () The Population-Based Principle: Targeted Testing Rather Than Universal Screening The United States Preventive Services Task Force has found insufficient evidence to recommend routine population-wide screening for primary open-angle glaucoma in asymptomatic adults. This does not mean that visual field testing is unhelpful. Rather, it means that testing is more useful when directed toward people with identifiable risk factors or suspicious findings. United States Preventive Services Task Force recommendation () A comprehensive eye examination is still important, particularly as people get older or develop medical risk factors. The American Academy of Ophthalmology recommends a baseline comprehensive eye examination around age 40, with follow-up based on individual risk. Visual field testing should then be added when there is a suspicious optic nerve, elevated intraocular pressure, a relevant medication exposure, visual symptoms, or a disorder affecting the optic nerve or brain. American Academy of Ophthalmology glaucoma screening information () The groups most likely to benefit from routine or repeated testing are: Glaucoma suspects People with ocular hypertension People with established glaucoma Patients with neuro-ophthalmic disease Patients taking medications that can injure the retina or optic nerve Evidence on Asymptomatic Visual Field Loss Glaucoma may be advanced before a patient notices it Glaucoma usually develops slowly. Early defects often occur outside the central line of sight, and the brain can partially compensate for missing information. As a result, patients may not notice a problem until the disease is advanced. Population-based research has found that approximately half of people with manifest glaucoma in developed countries may be unaware that they have the disease. In a screening cohort from the Early Manifest Glaucoma Trial, one-third of people with previously undetected glaucoma had advanced visual field loss in at least one eye. Early Manifest Glaucoma Trial population screening study () The risk is not limited to people with poor visual acuity. A patient can have good central vision and still have loss in the upper, lower, nasal, or temporal field. Visual field loss has also been associated with reduced mobility, falls, and lower quality of life in population studies. Rotterdam Study of visual field loss and daily functioning () Why asymptomatic loss matters clinically Detecting field loss before a patient notices it can: Confirm that structural changes are functionally important Establish the stage of glaucoma Identify patients who need pressure-lowering treatment Reveal progression before a major daily-life problem develops Prompt neurological imaging when the pattern is not typical for glaucoma Trigger medication review when toxicity is suspected The goal is not simply to find an abnormal test. The goal is to find a repeatable, clinically meaningful change that alters care. Glaucoma Suspects A glaucoma suspect may have one or more of the following: Elevated intraocular pressure A large or asymmetric optic nerve cup Suspicious thinning of the retinal nerve fiber layer A disc hemorrhage A suspicious or borderline visual field A strong family history of glaucoma Thin central corneas Myopia, pseudoexfoliation, pigment dispersion, or other risk factors A person can be a glaucoma suspect even when the visual field is normal. In this situation, the field provides an important functional baseline against which later tests can be compared. Who among glaucoma suspects benefits most? Visual field testing is particularly valuable when a patient has: A suspicious optic nerve appearance Asymmetry between the two optic nerves Retinal nerve fiber layer or ganglion cell thinning on imaging Repeatedly elevated intraocular pressure A first-degree relative with glaucoma A disc hemorrhage A thin central cornea High myopia A previous borderline or abnormal field A visual complaint that is not explained by glasses, cataract, or retinal disease The American Academy of Ophthalmology recommends that observed primary open-angle glaucoma suspects generally be reassessed at least every 12 to 24 months, with more frequent assessment when several risk factors are present. American Academy of Ophthalmology Primary Open-Angle Glaucoma Suspect Preferred Practice Pattern () How visual field results change care in a glaucoma suspect Normal and stable field: continued observation may be appropriate. One questionable abnormal field: repeat the test, check reliability, and compare it with the optic nerve and imaging. Repeatable glaucomatous pattern: the diagnosis may change from “suspect” to glaucoma. Field loss that does not match the optic nerve: consider a neurological or retinal cause. Paracentral loss: closer monitoring is often needed because central function may be threatened even when the overall field appears mild. A visual field should therefore be interpreted together with intraocular pressure, optic nerve examination, retinal imaging, corneal thickness, and the patient’s history. People With Ocular Hypertension Ocular hypertension means that the pressure inside the eye is consistently elevated, but there is not yet definite optic nerve damage or visual field loss. Many people with ocular hypertension never develop glaucoma. The Ocular Hypertension Treatment Study found that about 9.5% of untreated participants developed glaucoma over five years, compared with about 4.4% of participants who received pressure-lowering treatment. Risk was not equal among all participants. Higher pressure, older age, larger cup-to-disc ratio, and thinner central corneas increased the likelihood of conversion. American Academy of Ophthalmology EyeWiki: Ocular Hypertension () Why visual fields are still needed when the field is initially normal A normal field helps confirm that elevated pressure has not yet caused detectable functional damage. Repeated testing can later identify conversion from ocular hypertension to glaucoma. For a low-risk patient with normal optic nerves and stable pressure, visual field testing does not need to be performed at every visit. In contrast, a patient with very high pressure, a thin central cornea, a strong family history, older age, suspicious imaging, or a disc hemorrhage generally deserves closer surveillance. The National Institute for Health and Care Excellence recommends reassessment approximately every 18 to 24 months for treated ocular hypertension with controlled pressure and no detected conversion, but approximately every 6 to 12 months when conversion is uncertain or pressure control is inadequate. These intervals are guides rather than rigid rules. National Institute for Health and Care Excellence reassessment guidance () Practical approach for ocular hypertension A reasonable approach is: Obtain a reliable baseline visual field, often repeating it to confirm consistency. Document the optic nerve and retinal nerve fiber layer. Measure central corneal thickness. Estimate conversion risk using the full clinical picture. Repeat the field approximately every 12 to 24 months if risk is low and all findings remain stable. Test every 6 to 12 months when risk is moderate or high. Repeat sooner when pressure rises, the optic nerve changes, or a disc hemorrhage appears. Established Glaucoma Patients with established glaucoma benefit most consistSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/real-world-evidence-outcomes-when-testing-frequency-increasesTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Real-World Evidence: Outcomes When Visual Field Testing Frequency Increases Visual field testing, also called perimetry, measures areas of vision that a person can and cannot see. It is especially important in glaucoma, because damage to the optic nerve may progress without noticeable symptoms until substantial vision has been lost. The practical question is not simply whether more tests produce more data. It is whether more frequent testing leads to earlier detection of true progression, better treatment decisions, preserved vision, and acceptable safety and workload. The current evidence suggests that increasing testing frequency usually improves the speed and precision of detecting visual field change. However, there is not yet strong proof that more frequent testing alone prevents blindness or improves quality of life. Evidence for home visual field testing used alongside clinic care is encouraging but still based mainly on small, selected studies rather than large comparative outcome trials. Key Findings at a Glance Clinic-based testing every six months detects progression earlier than approximately yearly testing, particularly when overall visual field trends are analyzed. In a large United States claims cohort, the median testing frequency was only 0.63 visual field tests per year, and more than three-quarters of patients had fewer than one test per year. Home testing can provide weekly or monthly measurements, reduce measurement noise, and sometimes identify a concerning change before the next planned clinic visit. Adherence is the main limitation. Short studies often report good participation, but longer studies show that testing frequency commonly declines over time. More frequent testing also produces more apparent progression signals, some of which later disappear. Confirmation rules are therefore essential. Direct evidence that increased testing changes long-term visual outcomes remains limited. Home testing should generally be treated as an adjunct to clinical examination, not a replacement for eye pressure measurement, optic nerve examination, imaging, and standard clinic-based perimetry. What Guidelines Recommend The European Glaucoma Society notes that there is still no definitive evidence showing which combination of tests or testing frequency produces the best patient outcomes at a sustainable cost. Nevertheless, it recommends obtaining enough early visual field measurements to estimate the individual rate of change. Newly diagnosed patients are often recommended to have standard automated perimetry approximately three times per year during the first two years, after which the schedule can be tailored to disease severity and observed progression. European Glaucoma Society guidelines The World Glaucoma Association similarly recommends an intensive early series in people at risk of visual disability. It suggests that lower-risk patients may later be tested about once a year, while higher-risk patients may need testing twice a year or more often if progression is suspected. World Glaucoma Association consensus These recommendations are based largely on the need to establish a reliable baseline and identify fast progression early. They should not be interpreted as a requirement for every patient to have the same schedule. Testing frequency should reflect: Existing visual field damage Rate of previous change Age and expected lifetime risk Whether the patient has only one useful eye Pressure control Optic nerve or retinal nerve fiber layer changes Presence of optic nerve hemorrhage Test reliability Patient ability to attend or complete testing How Often Are Patients Actually Tested? United States nationwide data A study of 380,029 people with open-angle glaucoma found that: 8.8% had no visual field test during the study period. 68.2% received fewer than 0.9 tests per year. Only 0.8% received at least 2.1 tests per year. The median testing frequency was 0.63 tests per year. The authors concluded that more than 75% of the population had fewer than one visual field test per year, which is below the frequency commonly recommended for many patients under active glaucoma monitoring. This study described healthcare delivery; it did not prove that increasing frequency would prevent vision loss. United States nationwide glaucoma cohort English hospital eye-service data A large electronic medical record audit evaluated 602,439 visual field records from 73,994 people across five glaucoma clinics in England. Among 25,760 patients with repeatable visual field loss: The median interval between visual field tests was 11.2 months. Approximately 4.6% of tests were classified as unreliable using the study’s reliability measure. The median rate of visual field change was approximately −0.21 decibels per year. About 24% of patients had advanced field loss at presentation. Differences in testing intervals and reliability were observed between clinics. This type of registry evidence is valuable because it reflects routine care rather than a highly controlled clinical trial. It also demonstrates how electronic records can monitor service quality, identify patients at risk, and measure whether a clinic is delivering testing consistently. English glaucoma visual field audit Outcomes When Clinic-Based Testing Frequency Increases Earlier detection of progression One of the clearest real-world analyses came from the Advanced Glaucoma Intervention Study. Researchers compared the original series of visual fields with a reduced-frequency series created by removing approximately every other follow-up test. The higher-frequency series had a median of 20 tests, compared with 12 tests in the lower-frequency series. Using a global measure called mean deviation: Progression was detected in 43.6% of eyes with the higher-frequency data. Progression was detected in 34.2% of eyes with the lower-frequency data. The higher-frequency series was about 69% more likely to identify progression using the mean deviation analysis. Using a point-by-point analysis, progression was detected in 39.5% of eyes with higher-frequency data versus 35.7% with lower-frequency data. The higher-frequency series was still more likely to detect progression, although the difference was smaller. Advanced Glaucoma Intervention Study frequency analysis This is important, but it must be interpreted correctly. The study showed that more frequent testing detects statistical progression sooner. It did not show that the additional tests themselves slowed disease or preserved vision. It was also not a randomized trial of two separate monitoring programs; the lower-frequency series was created by deleting tests from an existing dataset. Six-monthly testing may be a practical compromise A longitudinal cohort study used data from 1,072 eyes of 665 patients to model how quickly different rates of glaucoma progression could be detected. For eyes losing approximately 2 decibels per year, a progression signal could be detected with 80% statistical power after approximately: 3.3 years with yearly testing 2.4 years with testing twice per year 2.1 years with testing three times per year For slower loss of approximately 0.5 decibels per year, detection took approximately: 7.3 years with yearly testing 5.7 years with twice-yearly testing 5.0 years with testing three times per year The improvement from yearly to twice-yearly testing was larger than the improvement from twice-yearly to three-times-yearly testing. The authors concluded that two reliable baseline tests followed by testing approximately every six months, with confirmation of suspected progression, may offer a practical balance between speed and burden. Longitudinal cohort study of visual field testing frequency Personalized schedules may be more efficient than fixed schedules A separate analysis using data from the Advanced Glaucoma Intervention Study and the Collaborative Initial Glaucoma Treatment Study evaluated a personalized testing model. The model increased testing when the patient’s previous results suggested a higher likelihood of progression and reduced testing when the disease appeared stable. Compared with a fixed yearly schedule, the model: Detected progression 57% sooner. Improved progression-detection efficiency by 29%. Did not require more visual field tests overall. This was a model based on previous clinical trial data rather than a prospective implementation study. It supports a risk-based approach, rather than testing every patient at the same frequency. Personalized glaucoma monitoring schedule study Frontloading tests may increase information without adding visits An emerging clinic-based strategy is to perform two visual field tests per eye during the same visit and use their average. A 2025 prospective study found that this “frontloaded” approach reduced variability in global and point-by-point measurements compared with using one test per visit. The average rate of progression was similar, but the estimates were more precise. Frontloaded visual field testing study This may be useful for patients who cannot perform home testing or who have difficulty attending additional appointments. Do More Tests Lead to More Treatment Changes? The clinical pathway A confirmed visual field decline may lead an eye specialist tSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/oxidative-stress-pathways-from-high-sugar-exposure-nrf2-mitochondria-and-rgc-survivalTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Oxidative Stress Pathways from High Sugar Exposure: Nrf2, Mitochondria, and Retinal Ganglion Cell Survival Introduction High sugar exposure is often discussed as though it has one simple effect on the eye. The biology is more complicated. In experimental studies, elevated D-glucose can increase reactive oxygen species, disrupt mitochondrial energy production, alter antioxidant defenses, activate retinal glial cells, and promote retinal ganglion cell injury. Most of the evidence comes from two types of research: Cell-culture studies, in which retinal cells are exposed to glucose concentrations commonly ranging from 20 to 40 millimoles per liter, sometimes for several days. Diabetic animal models, in which chronic hyperglycemia occurs together with vascular dysfunction, inflammation, lipid abnormalities, advanced glycation products, and tissue hypoxia. These models do not prove that one high-sugar meal directly kills retinal ganglion cells. They do, however, support a biological pathway in which persistent or repeated hyperglycemia increases oxidative pressure and reduces the ability of ocular cells to recover. The most consistent model is: > High glucose → increased reactive oxygen and nitrogen species → mitochondrial stress and impaired energy production → inadequate nuclear factor erythroid 2-related factor 2 antioxidant activity → inflammation, glial reactivity, and retinal ganglion cell apoptosis. The strength of each link varies by cell type, glucose concentration, exposure time, and whether the experiment involves diabetes, glaucoma-related stress, or isolated high glucose. --- The central redox system: reactive oxygen species and nuclear factor erythroid 2-related factor 2 Reactive oxygen species are chemically reactive oxygen-containing molecules. In small amounts, they participate in normal cell signaling. When their production exceeds antioxidant capacity, they can oxidize proteins, membrane lipids, mitochondrial DNA, and other cellular structures. The main protective pathway discussed in this context is controlled by nuclear factor erythroid 2-related factor 2, commonly called Nrf2. Under resting conditions, Nrf2 is held in the cytoplasm by Kelch-like ECH-associated protein 1, or Keap1, which promotes its degradation. When oxidative stress is sensed, Nrf2 can stabilize, move into the nucleus, and stimulate antioxidant-response genes. These include genes involved in glutathione production, superoxide removal, hydrogen peroxide breakdown, thioredoxin recycling, and detoxification. () Important Nrf2-regulated defenses in retinal cells include: Glutamate-cysteine ligase, which supports glutathione production Superoxide dismutase 2, a mitochondrial antioxidant enzyme Catalase Thioredoxin Heme oxygenase-1 NAD(P)H quinone oxidoreductase 1 A key finding across the literature is that high glucose does not always completely turn off Nrf2. Instead, the response may be delayed, transient, cell-specific, or insufficient for the amount of oxidative stress produced. --- How high glucose increases oxidative stress in ocular cells Increased metabolic pressure Retinal neurons and glial cells are metabolically active. When excess glucose enters the cell, more carbon is directed through glycolysis and mitochondrial energy pathways. This can increase the supply of reducing equivalents to the mitochondrial respiratory chain. If electron transport becomes overloaded or poorly coordinated, electrons can leak and generate superoxide. Experimental retinal studies have also identified non-mitochondrial contributors, including: Activation of nicotinamide adenine dinucleotide phosphate oxidase Increased inflammatory signaling through nuclear factor kappa B Thioredoxin-interacting protein induction Nitric oxide and reactive nitrogen species production Disruption of glutathione and antioxidant enzyme systems In Müller glial cells, high glucose increased reactive oxygen species within hours and increased reactive nitrogen species even earlier. The same study found increased nuclear factor kappa B signaling and increased inducible nitric oxide synthase, linking redox imbalance to inflammation. () Oxidative stress can become self-reinforcing Mitochondria are both a source and a target of reactive oxygen species. Once mitochondrial proteins, membranes, or mitochondrial DNA are damaged, the respiratory chain may become less efficient. This can produce still more oxidant leakage, creating a feedback loop: > High glucose → mitochondrial stress → more reactive oxygen species → further mitochondrial damage. In Müller cells, high glucose increased mitochondrial superoxide, disrupted mitochondrial membrane potential, and increased the mitochondrial localization of thioredoxin-interacting protein. These changes were associated with mitochondrial dysfunction and impaired mitochondrial quality control. () --- Evidence for glucose-induced mitochondrial dysfunction Müller glial cells One of the clearest mitochondrial studies used a rat Müller cell line exposed to 30 millimoles per liter glucose for seven days. High glucose caused: Mitochondrial fragmentation Greater variation in mitochondrial membrane potential Lower basal and maximal oxygen consumption Lower extracellular acidification Cytochrome c release Increased apoptosis These findings are important because they connect mitochondrial structural changes with functional failure and cell death rather than merely showing an increase in a laboratory oxidative-stress marker. () A related study found that high glucose increased thioredoxin-interacting protein, mitochondrial superoxide, and mitochondrial membrane-potential abnormalities in rat Müller cells. The changes were accompanied by impaired mitophagy, the process that removes damaged mitochondria. () More recent work suggests that mitochondrial remodeling is not always the same in every stage of disease. Under diabetic conditions, Müller cells may initially use mitochondrial fragmentation as an adaptive response to remove damaged segments. In more advanced neurodegeneration, mitochondrial hyperfusion and defective turnover may develop instead. This means that mitochondrial shape alone cannot be interpreted without considering exposure duration and disease stage. () Retinal ganglion cells Retinal ganglion cells are especially vulnerable to mitochondrial stress because they have long axons and substantial energy requirements. In high-glucose retinal ganglion cell models, investigators have reported: Increased reactive oxygen species Loss or abnormality of mitochondrial membrane potential Cytochrome c release Reduced antioxidant enzyme activity Increased B-cell lymphoma-2-associated X protein and caspase signaling Increased terminal deoxynucleotidyl transferase dUTP nick-end labeling, a marker of DNA fragmentation Reduced cell survival In one study, L-carnitine, a mitochondrial-supporting molecule, reduced glucose-induced reactive oxygen species and lipid peroxidation. It also restored mitochondrial membrane potential, reduced cytochrome c release, lowered caspase-9 and caspase-3 activation, and shifted the B-cell lymphoma-2-associated X protein to B-cell lymphoma-2 balance toward cell survival. () A 2024 study using a retinal precursor cell model and diabetic mice found that high glucose or diabetes was associated with mitochondrial dysfunction, reactive oxygen species production, abnormal antioxidant protein expression, and retinal ganglion cell apoptosis. Increasing DJ-1, a protein involved in mitochondrial protection and redox control, improved mitochondrial function and reduced oxidative injury. () Mitochondrial DNA damage Mitochondrial DNA is located close to the respiratory chain and has less protection than nuclear DNA. A recent retinal ganglion cell study reported that high glucose was associated with mitochondrial structural abnormalities, increased reactive oxygen species, abnormal mitochondrial membrane potential, lower oxygen consumption, lower adenosine triphosphate production, and mitochondrial DNA damage. The authors also observed reduced expression of proteins involved in DNA damage repair. () These results support a model in which mitochondrial damage is not simply a consequence of apoptosis. It may occur early enough to contribute to the decision of a retinal ganglion cell to enter an apoptotic pathway. --- Evidence for impaired or inadequate Nrf2 antioxidant responses A transient Nrf2 failure in Müller cells A detailed time-course study exposed primary rat Müller cells to 25 millimoles per liter glucose for one to 48 hours. The findings show why the phrase “Nrf2 impairment” needs to be used carefully: Reactive oxygen species increased from approximately 12 to 48 hours. Reactive nitrogen species rose earlier. Nrf2 protein and nuclear Nrf2 temporarily decreased after approximately three hours. Glutamate-cysteine ligase, superoxide dismutase 2, and thioredoxin messenger RNA fell during the early exposure period. Glutathione remained low even after some Nrf2 measures recovered. Nrf2 and several antioxidant genes increased later, suggesting a delayed compensatory response. Thus, high glucose produced an early window in which oxidative stress increased while the Nrf2 antioxidant program was tempSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/aspartame-sucralose-saccharin-and-stevia-comparative-mechanistic-plausibility-in-glaucomaTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Aspartame, Sucralose, Saccharin, and Stevia: Comparative Mechanistic Plausibility in Glaucoma Introduction People with glaucoma often ask whether diet drinks, artificial sweeteners, or stevia could damage the optic nerve. The question is biologically reasonable because glaucoma is not only an eye-pressure disorder. Retinal ganglion cell injury can also involve vascular dysregulation, impaired endothelial function, oxidative stress, mitochondrial dysfunction, blood-retinal barrier changes, and chronic neuroinflammation. () However, a biologically plausible pathway is not the same as a demonstrated clinical risk. At present, there is no established human evidence that ordinary consumption of aspartame, sucralose, saccharin, or purified steviol glycosides causes glaucoma or accelerates glaucomatous progression. The available evidence is mainly regulatory toxicology, absorption studies, metabolic research, cell experiments, animal studies, and research on cardiovascular or inflammatory outcomes rather than glaucoma itself. Existing glaucoma nutrition reviews do not identify these sweeteners as proven glaucoma risk factors. () The most defensible conclusion is therefore: > For typical intake within established safety limits, all four sweeteners are more likely to be neutral with respect to glaucoma than directly harmful or beneficial. The main potential benefit is indirect: replacing sugar-sweetened foods or beverages may reduce glucose-related vascular stress. The main uncertainty concerns high, chronic intake and individual metabolic or microbiome responses—not a proven direct toxic effect on the optic nerve. How glaucoma physiology relates to sweeteners Glaucoma involves progressive loss of retinal ganglion cells and their optic nerve axons. Elevated intraocular pressure is the most important modifiable risk factor, but some patients continue to lose retinal tissue even when pressure is adequately controlled. This has led to increased interest in blood flow, endothelial function, mitochondrial injury, and immune signaling. () Endothelial function and ocular blood flow The vascular endothelium regulates vessel tone, blood flow, permeability, inflammation, and nitric oxide signaling. Studies of primary open-angle glaucoma have reported systemic vascular abnormalities, including impaired peripheral endothelial function and possible involvement of nitric oxide-related pathways. These observations are particularly relevant to normal-tension glaucoma and other forms in which optic nerve injury occurs at relatively modest eye pressures. () Still, brachial artery flow-mediated dilation is not the same as blood flow at the optic nerve head. A change in systemic vascular function does not automatically cause a change in ocular perfusion, and a laboratory effect on endothelial cells does not establish glaucoma risk. Neuroinflammation and the retinal immune environment The retina contains resident immune cells called microglia, along with astrocytes and Müller cells. Under chronic stress, these cells can release inflammatory mediators such as tumor necrosis factor alpha, interleukin 1 beta, interleukin 6, complement-related proteins, and other signaling molecules. Persistent glial activation may amplify retinal ganglion cell injury. () The blood-retinal barrier normally limits exposure of retinal tissue to circulating substances and inflammatory cells. Barrier disruption can increase vascular leakage and create a more inflammatory environment, but evidence that dietary sweeteners disrupt this barrier in living human eyes is currently lacking. () Basic pharmacology of the four sweeteners For the full table, please open this article on visualfieldtest.com. The United States Food and Drug Administration lists the thresholds above and distinguishes high-purity steviol glycosides from crude stevia leaf products. The World Health Organization Joint Food and Agriculture Organization/World Health Organization Expert Committee on Food Additives uses a lower aspartame threshold of 40 milligrams per kilogram per day, while its table for saccharin, sucralose, and steviol glycosides lists 15, 5, and 4 milligrams per kilogram per day, respectively. () Aspartame Absorption and metabolism Aspartame is a small methyl ester made from two amino acids. It is rapidly broken down in the digestive tract into: Phenylalanine Aspartic acid Methanol The Joint Food and Agriculture Organization/World Health Organization Expert Committee on Food Additives concluded that intact aspartame does not enter the systemic circulation in meaningful amounts. Its metabolites are the same or chemically similar to substances obtained from ordinary foods. () This is important for glaucoma risk assessment. A cell experiment in which retinal neurons are exposed directly to aspartame does not reproduce ordinary human exposure if intact aspartame is absent from the blood. The biologically relevant question would be whether phenylalanine, aspartic acid, methanol, or their downstream products reach the retina at harmful concentrations. People with phenylketonuria, a rare inherited disorder of phenylalanine metabolism, should avoid or strictly limit aspartame according to medical guidance. This is a specific metabolic condition, not evidence that ordinary aspartame intake causes glaucoma in the general population. () Endothelial effects Direct human studies linking aspartame with impaired vascular endothelial function are limited. In one laboratory model using glomerular microvascular endothelial cells, aspartame did not reduce cell viability and, at selected concentrations, helped reduce vascular leakage caused by vascular endothelial growth factor. This finding should not be interpreted as an eye benefit: the cells were kidney-derived, the experiment was performed outside the body, and the vascular stimulus was artificial. () The more clinically relevant comparison is with sugar. Sugar-sweetened beverages can cause acute glucose elevations that increase oxidative stress and impair systemic endothelial function. Replacing those beverages with a noncaloric option may therefore reduce vascular stress, even if the sweetener itself has no special protective effect. () Neuroinflammatory and retinal signals Animal studies have reported oxidative stress, inflammatory signaling, and changes in brain tissue after relatively high or prolonged aspartame exposure. Findings have included increased tumor necrosis factor alpha, interleukin 1 beta, interleukin 6, nuclear factor kappa B signaling, inducible nitric oxide synthase, and glial fibrillary acidic protein. These findings demonstrate biological activity in experimental models, but they do not show that ordinary human intake damages retinal ganglion cells. () A recent retinal study is mechanistically interesting because aspartame increased intracellular calcium in isolated rat retinal neurons, and saccharin produced a similar effect. Excessive intracellular calcium can contribute to neuronal injury in several neurodegenerative diseases. However, the experiment used isolated retinal cells exposed directly to sweeteners, not living animals with glaucoma, and direct exposure to intact aspartame does not mirror its normal human pharmacokinetics. () Overall assessment of aspartame Potential harm: Biologically plausible only in a limited, indirect sense. High-dose animal studies and isolated retinal-cell findings justify continued research but do not establish a dietary glaucoma hazard. Potential benefit: Possible when used instead of sugar-sweetened beverages, particularly if it lowers total sugar intake. Most likely interpretation at ordinary intake: Neutral with respect to glaucoma, provided the person does not have phenylketonuria and intake remains within established limits. Sucralose Absorption and metabolism Sucralose is a chlorinated derivative of sucrose. It is approximately 600 times sweeter than sugar, allowing very small quantities to provide sweetness. In a human pharmacokinetic study, approximately 78 percent of a radiolabeled dose was recovered in feces and approximately 14.5 percent in urine. The material in feces was essentially unchanged sucralose. Most urinary material was also sucralose, with only a small fraction represented by more polar, probably conjugated metabolites. () This means that sucralose is not simply “inert,” but it is also not extensively metabolized into large quantities of reactive compounds. Its strongest potential biological pathway may be through intestinal taste receptors, gut microbial interactions, and metabolic signaling, rather than direct delivery to retinal tissue. Endothelial effects The available human vascular evidence does not show a consistent direct endothelial injury signal. An acute study found that sucralose did not alter brachial artery flow-mediated dilation, and another study in older adults found no acute effect of intestinal sucralose administration on blood pressure or superior mesenteric artery blood flow. These studies were small and short-term, but they do not support a strong immediate vascular toxicity signal. () In a laboratory model of glomerular endothelial cells, sucralose reduced vascular leakage caused by vascular endotheSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/does-dietary-sugar-intake-increase-glaucoma-risk-a-systematic-review-and-meta-analysis-blueprintTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Does Dietary Sugar Intake Increase Glaucoma Risk? A Systematic Review and Meta-analysis Blueprint Introduction Whether dietary sugar contributes to glaucoma risk remains uncertain. The available research is limited and does not consistently measure added sugar itself. Some studies have examined total carbohydrate intake, low-carbohydrate dietary patterns, processed sweets, or ultra-processed foods instead. For example, a prospective Spanish cohort found that participants with the highest total carbohydrate intake had a higher risk of newly diagnosed glaucoma, although no individual carbohydrate food group was clearly responsible. () In contrast, a large analysis of three United States cohorts found no clear association between overall low-carbohydrate dietary scores and primary open-angle glaucoma, although a vegetable-based low-carbohydrate pattern showed a possible association with a specific visual field-loss subtype. () A small case-control study also reported that patients with primary open-angle glaucoma consumed more sweets containing processed sugar than controls, but its retrospective design leaves substantial potential for recall bias and residual confounding. () A 2024 scoping review concluded that most glaucoma nutrition studies relied on food frequency questionnaires and that only a small number of prospective studies had examined carbohydrate-related exposures. () This protocol is designed to determine whether total sugar, added sugar, free sugar, sugary beverages, total carbohydrate, glycemic load, or glycemic index are associated with: Incident primary open-angle glaucoma Change in intraocular pressure Retinal nerve fiber layer loss or glaucoma progression The review should estimate associations carefully without implying that sugar causes glaucoma. Dietary studies are vulnerable to measurement error, confounding, reverse causation, and differences in glaucoma diagnosis. --- Review Objective and Research Question Primary research question Among adults, is higher habitual intake of dietary sugar or sugar-related exposures associated with a greater risk of developing glaucoma or experiencing glaucoma-related structural or pressure changes? Secondary research questions The review should determine: Whether associations differ between added sugar, total sugar, free sugar, and sugar-sweetened beverages Whether glycemic load or glycemic index shows a stronger relationship than sugar grams alone Whether associations differ according to baseline diabetes status Whether findings differ between primary open-angle glaucoma, normal-tension glaucoma, high-tension glaucoma, exfoliative glaucoma, pigmentary glaucoma, and primary angle-closure glaucoma Whether associations are stronger for glaucoma incidence or for disease progression How much results are affected by adjustment for diabetes, body mass index, blood pressure, and total energy intake Whether food frequency questionnaire measurement error may have weakened or distorted reported associations Prespecified causal estimands Because diabetes, body mass index, blood pressure, and total energy intake may play different roles in the causal pathway, the review should distinguish between two related but different questions: Total dietary association: Does a higher sugar exposure relate to glaucoma risk through all plausible pathways, including pathways involving weight gain, diabetes, blood pressure, and vascular or metabolic changes? Metabolic-independent association: Does sugar remain associated with glaucoma after adjustment for diabetes, body mass index, and blood pressure? The second estimate should not be described as the total effect of sugar. It is better described as a conditional or metabolically adjusted association, because adjustment may remove part of the pathway through which diet could influence eye health. --- Eligibility Criteria Population Include studies of: Human adults aged 18 years or older General population samples Occupational or community-based cohorts Patients with ocular hypertension or established glaucoma Participants with or without diabetes Studies involving children may be included in a separate exploratory analysis if sufficient evidence exists, but they should not be pooled with adult studies. Eligible study designs Include: Prospective cohort studies Longitudinal population-based studies Nested case-control studies within prospective cohorts Case-control studies in which dietary exposure was assessed for a period before glaucoma diagnosis or progression Retrospective analyses only if dietary exposure clearly preceded the outcome and the study provides usable effect estimates Prospective studies should be the main evidence base for incidence and progression. Case-control studies should be synthesized separately because their exposure measurement is more vulnerable to recall and selection bias. Required exposure timing The exposure must be measured: Before glaucoma diagnosis Before the progression period being studied Or repeatedly during follow-up in a way that permits a time-ordered analysis Studies measuring diet and glaucoma at the same visit should be excluded from the primary quantitative synthesis because they cannot establish whether dietary exposure preceded the disease. They may be retained for narrative context. Required outcome information Studies must report at least one of the following: Incident glaucoma Change in intraocular pressure Retinal nerve fiber layer loss Glaucoma progression Visual field progression Optic nerve or neuroretinal rim progression Studies must provide a relative risk, hazard ratio, odds ratio, mean difference, annualized rate of change, or enough data to calculate one. Exclude Exclude: Animal or laboratory studies Ecological studies Case reports and case series Studies of blood glucose or glycated hemoglobin without a dietary exposure Studies focused only on diabetic retinopathy Studies that do not distinguish glaucoma from nonspecific visual impairment Studies in which the dietary exposure is a nutritional supplement rather than food or beverage intake Duplicate reports from the same cohort, unless they provide non-overlapping exposure or outcome data If several publications use the same cohort, select the report with the longest follow-up or the most complete outcome ascertainment. Additional reports may be used for subtype or progression analyses without counting participants twice. --- Exposure Definitions Sugar-related exposures must not be treated as interchangeable. The protocol should extract each exposure separately and avoid pooling them unless the definitions are sufficiently comparable. Exposure classification table For the full table, please open this article on visualfieldtest.com. The United States Food and Drug Administration distinguishes total sugars from added sugars: total sugars include sugars naturally present in foods such as fruit and milk, whereas added sugars are incorporated during processing or preparation. () The World Health Organization defines free sugars more broadly to include added sugars and sugars naturally present in honey, syrups, fruit juice, and fruit juice concentrate, while excluding the sugars naturally present in intact fruit, vegetables, and milk. () Sugar-sweetened beverages Sugar-sweetened beverages should be analyzed separately from solid foods because they: Are often consumed quickly May produce a high glycemic exposure Usually provide few or no grams of fiber May be associated with total energy intake and weight gain Can be measured more reliably in some questionnaires than total added sugar Diet beverages should not be combined with sugar-sweetened beverages. They should be analyzed separately as an exploratory exposure because people who choose artificially sweetened drinks may differ systematically from people who do not. One hundred percent fruit juice should also be analyzed separately. It should not automatically be classified as equivalent to either a sugar-sweetened beverage or intact fruit. Glycemic load For studies providing sufficient information, glycemic load should be calculated or extracted as: > Glycemic load = glycemic index × grams of available carbohydrate per serving ÷ 100 Glycemic load reflects both the quality and quantity of carbohydrate. Glycemic index reflects the relative glucose response to a carbohydrate-containing food, whereas glycemic load also accounts for the amount consumed. () Total carbohydrate, glycemic load, and added sugar should not be pooled into a single exposure category. A diet may contain a large amount of carbohydrate from whole grains or legumes but relatively little added sugar. Exposure timing Extract whether exposure was measured: At baseline only As a cumulative average of repeated questionnaires As the most recent diet measure As a change from baseline Using a lagged exposure, such as diet measured two or more years before diagnosis Repeated and cumulative dietary measures should be preferred for chronic outcomes when available because a single questionnaire may not represent long-term dietary habits. --- Outcome Definitions 4.1 Incident primary open-angle glaucoma The primary incidence outcome should be newly diagnoseSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/global-eye-health-2026-tackling-glaucoma-disparitiesTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Global Eye Health 2026: Tackling Glaucoma Disparities Evidence reviewed through June 30, 2026 Glaucoma is often called a “silent thief of sight” because it can damage the optic nerve for years before a person notices a problem. Once vision is lost, it usually cannot be restored. However, early detection, pressure-lowering treatment, laser therapy, and surgery can often slow or stop further damage. The global glaucoma challenge is therefore not simply a lack of effective treatments. It is a problem of late detection, unequal access, medicine cost, weak referral systems, limited surgical capacity, and difficulty maintaining lifelong care. These problems are most severe in low-resource settings, rural communities, and groups facing financial or gender-related barriers. The global glaucoma burden in 2026 There is no single real-time worldwide glaucoma census. Different studies measure different outcomes: Total glaucoma disease includes people with early disease who may have no symptoms. Glaucoma-related blindness counts people whose glaucoma has caused profound vision loss. Disability-adjusted life years measure the combined effect of disability and premature loss of healthy life. These measures should not be treated as interchangeable. For the full table, please open this article on visualfieldtest.com. The long-standing global projection of 76 million people with glaucoma in 2020 and 111.8 million by 2040 comes from a systematic review of population eye studies. The 2024 global analysis of glaucoma-related vision loss estimated 3.61 million people were blind and 4.14 million had moderate-to-severe vision impairment because of glaucoma in 2020. () A study published online in June 2026 using Global Burden of Disease 2021 data found that the absolute number of modelled glaucoma cases increased by approximately 86% between 1990 and 2021, even though age-standardised prevalence and disability-adjusted life-year rates declined. Population growth and ageing explain much of this apparent contradiction: the risk at a given age may be falling, but more people are reaching the ages when glaucoma becomes common. () Regional disparities are marked Sub-Saharan Africa: high disease burden and late presentation Sub-Saharan Africa continues to experience the highest age-standardised burden of glaucoma-related blindness and moderate-to-severe vision impairment. In the 2020 global analysis, the age-standardised prevalence of glaucoma-related blindness among people aged 50 years and older was approximately 0.66% in Sub-Saharan Africa, compared with 0.20% globally. The region also had the highest age-standardised prevalence of glaucoma-related moderate-to-severe vision impairment. () A 2025 systematic review and Bayesian meta-analysis estimated glaucoma prevalence in Africa at 5.59%, with primary open-angle glaucoma accounting for approximately 5.07%. The pooled prevalence was highest in Southern Africa and lowest in East Africa, although the authors noted substantial variation between countries and studies. () Nigeria illustrates the scale of the problem. A national population survey estimated glaucoma prevalence at approximately 5.02% among people aged 40 years and older. In clinical and outreach settings, many people present after substantial damage has already occurred. These findings should not be interpreted as evidence that every Nigerian patient is diagnosed late, but they demonstrate the consequences of limited case detection and weak access to continuing care. () The problem is intensified by workforce distribution. A review of glaucoma needs among people of African descent reported that most ophthalmologists in Africa work in urban centres while much of the population lives in rural areas. It also cited estimates that approximately 90% of people with glaucoma in Africa may be unaware that they have the disease, although this figure comes from older and heterogeneous sources and should be interpreted cautiously. () Asia: large absolute numbers and angle-closure risk Asia contains a large share of the global population and therefore carries a substantial absolute glaucoma burden even where prevalence rates are lower than those reported in parts of Africa. The pattern of glaucoma also differs. Primary angle-closure glaucoma is more common in many East and Southeast Asian populations than in people of European ancestry. It can cause rapid and severe visual loss, particularly when an acute pressure crisis occurs. Primary open-angle glaucoma remains important throughout Asia, especially as populations age. () In younger regions of South and Southeast Asia, glaucoma may represent a smaller proportion of all blindness because cataract and other conditions remain more common. This does not mean the glaucoma burden is small. As life expectancy rises, the number of people needing long-term glaucoma monitoring is expected to increase. Europe and North America: better access, but underdiagnosis remains common High-income health systems generally have more ophthalmologists, diagnostic equipment, medicines, and insurance coverage. Yet they have not eliminated the detection gap. A 2025 analysis of 55,415 participants from seven European countries estimated glaucoma prevalence at 2.99% among adults aged 40 years and older. More than half of cases, 56.4%, had not previously been diagnosed. In people younger than 50 years, the proportion of undiagnosed disease exceeded 80%. Applying these estimates to the European population produced an estimate of 12.26 million people with glaucoma in 2024, including 6.86 million who were undiagnosed. () High-income countries had the highest proportion of blindness attributed to glaucoma in the 2020 global analysis—approximately 26%. This does not mean that high-income countries had the highest glaucoma blindness rate. Rather, cataract and other treatable causes of blindness are more often managed, leaving glaucoma as a larger share of the remaining blindness burden. () The Caribbean and African-descended populations People of African descent, including African-Caribbean populations, have a higher risk of primary open-angle glaucoma and may develop it at younger ages. The disease may also progress more aggressively in some patients. Barbados and several other Caribbean countries have reported a particularly high contribution of glaucoma to blindness. () These risks interact with social conditions. High medicine prices, missed appointments, limited surgical capacity, and mistrust after poor surgical experiences can produce severe disease even where specialist services technically exist. Why people are missed or untreated Glaucoma is usually asymptomatic early Early glaucoma often causes no pain and does not noticeably reduce central vision. People may continue reading, working, and driving while peripheral vision is gradually lost. This makes glaucoma different from conditions that encourage people to seek care quickly. A person may not feel an immediate benefit from eye drops, while side effects, inconvenience, and cost occur every day. This is one reason why diagnosis alone is not enough: patients must be able to start, continue, and monitor treatment. For this reason, the most practical approach is usually targeted case-finding followed by confirmatory assessment, rather than referring every person with one abnormal screening measurement directly into lifelong treatment. National Institute for Health and Care Excellence guidance describes a two-stage assessment in which an initial abnormal result is confirmed through a more detailed examination. () Affordability affects every stage of care The cost of glaucoma care includes more than the price of an eye drop. Patients may need to pay for: Transport to a clinic Several diagnostic tests Repeated visits Medicines for the rest of their lives Time away from work or caregiving Surgery and postoperative reviews Travel to a distant referral hospital A worldwide comparison of glaucoma treatment prices found that affordability varied greatly by country and household income. Timolol was generally the least expensive medicine, but the overall cost of treatment, laser, and surgery could still be substantial relative to household income in lower-income countries. () A 2024 Ghanaian cost-of-illness study found an average patient cost of approximately 60.78 United States dollars for glaucoma management. Direct costs accounted for about 94% of the total, with medicines responsible for 42% and laboratory or diagnostic services for 26%. Some patients paid out of pocket for timolol even though they expected it to be covered by the national insurance system. () These findings support a shift from isolated fee waivers to broader financial protection: essential medicines, diagnostic testing, transport support, and surgery all need to be considered. Adherence is a health-system issue, not simply a patient issue Common barriers to using glaucoma medicines include: Forgetting doses Difficulty putting drops into the eye Poor vision or arthritis that makes bottle handling difficult Complex schedules involving several medicines Eye irritation and other side effects Lack of understanding about an asymptomatic disease Medicine shortages Long travel distances to pharmacies or clinics Cost and insurance restrictionsSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/glaucoma-and-high-myopia-mid-2026-clinical-insightsTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Glaucoma and High Myopia: Mid-2026 Clinical Insights Evidence reviewed through July 26, 2026. Introduction High myopia and glaucoma often overlap, but they are not the same condition. High myopia changes the shape of the eye, optic nerve, retina, and supporting tissues. These changes can imitate glaucoma on an eye examination, optical coherence tomography, or visual field test. At the same time, high myopia appears to increase the eye’s susceptibility to true glaucomatous damage. High myopia is commonly defined as a spherical equivalent refractive error of −6 diopters or more negative or an axial length of approximately 26 millimeters or longer, although definitions vary between studies. The distinction matters because a highly myopic eye may have an abnormal-looking optic disc and visual field without progressive glaucoma, while another eye may develop glaucoma despite apparently normal eye pressure. Evaluating glaucoma in myopic eyes Interpreting the structure–function relationship in high myopia-associated glaucoma () The most reliable principle through mid-2026 is: > Do not diagnose or exclude glaucoma from one “red” optical coherence tomography result, one tilted disc, one unusual visual field, or one eye-pressure reading. Look for reproducible, anatomically coherent change over time. Why the Glaucoma–Myopia Interface Is Difficult Axial elongation stretches and remodels the back of the eye. The optic disc may become tilted, rotated, enlarged, or obliquely inserted. The surrounding tissue may show a large temporal crescent, peripapillary atrophy, a gamma zone, posterior staphyloma, or other myopic changes. These findings can: Make the optic cup appear larger than it truly is. Shift the normal location of retinal nerve fiber layer bundles. Cause false-positive color warnings on optical coherence tomography. Create visual field defects that resemble nasal steps or arcuate defects. Make the same retinal location appear different on serial scans if the scan is not centered consistently. Hide early central or paracentral glaucoma damage when only a standard 24-2 visual field is used. The 2026 European Glaucoma Society research-priority survey found that the most common questions from glaucoma specialists concerned how to distinguish myopic structural change from glaucomatous damage and progression, followed by the reliability of optical coherence tomography and visual field testing. This indicates that the problem remains clinically unresolved even among specialists. Research priorities for diagnostics, progression monitoring, and treatment of glaucoma in myopic eyes () Optical Coherence Tomography: Recognizing Myopia-Related Artifacts Why a normal optical coherence tomography report may be misleading Most commercial optical coherence tomography devices compare a patient’s measurements with a normative database. These databases may contain relatively few highly myopic eyes. As a result, a healthy myopic eye may be incorrectly labeled as having abnormally thin retinal nerve fiber tissue. Long axial length also creates ocular magnification. A scan circle designed to be a fixed size may actually be placed farther from the optic disc than intended. Retinal nerve fiber tissue is naturally thinner farther from the disc, which can produce an artificially low measurement. In addition, myopic retinal anatomy can cause the scan to cross: Peripapillary atrophy. Posterior staphyloma. Peripapillary intrachoroidal cavitation. Retinoschisis or epiretinal membrane. Areas where the automated software cannot correctly identify the retinal boundaries. How common are artifacts? In one study, optical coherence tomography artifacts were found in approximately 51.9% of scans from highly myopic eyes, compared with 18.6% in eyes without high myopia. Peripapillary atrophy was a leading cause of artifact in highly myopic eyes. The frequency was even higher when high myopia and glaucoma were both present. The prevalence of optical coherence tomography artifacts in high myopia and its influence on glaucoma diagnosis () This does not mean optical coherence tomography is useless. It means the individual scan must be inspected rather than relying only on the summary page. A practical optical coherence tomography quality check Before interpreting a thickness map, the clinician should review: The raw cross-sectional images rather than only the color-coded report. The automated segmentation lines to confirm that they follow the correct retinal layers. The scan centration in relation to the optic disc, Bruch’s membrane opening, and fovea. Signal strength and motion artifacts. Whether the scan passes through peripapillary atrophy or a posterior staphyloma. Whether the same device, scan pattern, and positioning were used at each visit. Whether the apparent change is visible on the actual image or exists only in the software’s color classification. A new “red” sector is much less convincing when it is caused by segmentation failure, scan displacement, or a pre-existing tilted disc. Which optical coherence tomography measurements may help? Several approaches may improve confidence: Macular ganglion cell-inner plexiform layer or ganglion cell complex measurements. These may show better diagnostic performance than standard peripapillary retinal nerve fiber layer measurements in some highly myopic eyes. Bruch’s membrane opening minimum rim width. This measures the minimum rim tissue from the anatomic opening of Bruch’s membrane rather than relying only on the clinically visible disc margin. Anatomically corrected retinal nerve fiber layer scans. These attempt to account for axial length and the shifted position of nerve fiber bundles. Vertical, fovea-centered scans. These may improve structure–function matching when the usual peripapillary scan is distorted. Swept-source or wide-field imaging when posterior staphyloma, peripapillary cavitation, or a very large tilted disc makes conventional imaging difficult. A 2024 study found that macular ganglion cell-inner plexiform layer and peripapillary retinal nerve fiber layer parameters could still have good diagnostic accuracy in high axial myopia, but the results were population-specific and should not replace clinical examination or visual field testing. Diagnostic accuracy of optic nerve head and macula optical coherence tomography parameters Comparison of optical coherence tomography structural parameters for diagnosis of glaucoma in high myopia () Common optical coherence tomography traps For the full table, please open this article on visualfieldtest.com. Disc Tilt, Disc Rotation, and Peripapillary Anatomy What a tilted disc means A tilted disc is often associated with: An oval or vertically elongated disc. Oblique insertion of the optic nerve. Temporal peripapillary atrophy or a crescent. Rotation of the retinal nerve fiber layer pattern. Displacement of the central retinal vessels. A mismatch between the clinically visible disc margin and the true anatomic opening of Bruch’s membrane. A tilted disc does not prove glaucoma. However, it also does not protect the eye from glaucoma. The most concerning findings are not simply “tilt” or “cupping,” but focal, repeatable, progressive loss that corresponds to a visual field defect. Examples include: A focal inferior or superior rim notch. A wedge-shaped retinal nerve fiber layer defect. A disc hemorrhage. Corresponding loss in the macular ganglion cell-inner plexiform layer. A repeatable arcuate, nasal-step, or paracentral field defect. Why disc measurements can disagree In high myopia, the clinical disc margin, Bruch’s membrane opening, and anterior scleral canal opening may not line up. A 2025 prospective study found that highly myopic glaucoma eyes had larger Bruch’s membrane opening and anterior scleral canal opening areas, greater displacement between these structures, and a smaller neural canal minimum cross-sectional area than non-highly myopic glaucoma eyes. These anatomic features were associated with faster temporal visual field and retinal nerve fiber layer change over three years. High myopia-induced optic nerve head deformation and glaucoma progression () This supports a shift away from judging a myopic disc by cup-to-disc ratio alone. The important question is whether the nerve tissue is being lost in a pattern and at a rate consistent with glaucoma. Atypical Visual Field Patterns in High Myopia Visual field defects that may occur without glaucoma Highly myopic eyes can produce several unusual visual field patterns: Enlarged blind spot. Vertical step. Partial peripheral rim loss. Nonspecific or irregular depression. Mixed temporal and nasal loss. “Gourd-shaped” defects. Field loss associated with peripapillary atrophy, posterior staphyloma, or peripapillary intrachoroidal cavitation. A 2025 study found an enlarged blind spot in approximately 37% of eyes with nonpathologic high myopia. The enlarged blind spot was associated with a larger gamma zone, larger peripapillary hyperreflective ovoid mass-like structures, and other myopic anatomic findings. Enlarged blind spot linked to gamma zone and peripapillary hyperreflective ovoid mass-like structures () A standardized classification system separates high-myopia-related defects from glaucoma-like defects. Glaucoma-like patterns inSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/managing-glaucoma-in-pregnancy-2026-evidence-and-consensusTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Managing Glaucoma in Pregnancy 2026: Evidence and Consensus Evidence cutoff: July 24, 2026 Pregnancy does not automatically make glaucoma treatment unsafe, and stopping glaucoma medication without medical supervision can permanently threaten vision. The goal is to protect the pregnant patient’s optic nerve while reducing avoidable exposure of the fetus or breastfed infant to glaucoma medicines. The best available evidence remains limited. There are no large randomized trials of glaucoma treatment during pregnancy. Current recommendations rely on medication labels, animal reproductive studies, pharmacokinetic research, retrospective case series, case reports, and expert consensus. The most current major guidance includes the 2026 American Academy of Ophthalmology Primary Open-Angle Glaucoma Preferred Practice Pattern, the American Glaucoma Society and Canadian Glaucoma Society practical guide, and updated clinical reviews. () > Important: This article is educational and cannot replace individualized care from a glaucoma specialist, obstetric clinician, and—when appropriate—a pediatric or neonatal clinician. Key recommendations at a glance Plan before conception whenever possible. Establish a target pressure, document the optic nerve and visual field, review medications, and consider laser treatment or surgery before pregnancy if glaucoma is advanced or difficult to control. Do not assume that pregnancy will lower pressure enough. Intraocular pressure often falls, but some patients with established glaucoma experience pressure elevation or visual field progression. Use the fewest medicines at the lowest effective exposure. Punctal occlusion and gentle eyelid closure should be used after every drop. Brimonidine is commonly preferred when a glaucoma drop is needed during pregnancy, but it should be stopped before delivery and avoided during breastfeeding because of possible infant central nervous system depression and apnea. Timolol may be used selectively, particularly when the maternal benefit is important, but fetal growth and heart rate should be considered, and newborns may require observation after late-pregnancy exposure. Topical carbonic anhydrase inhibitors such as dorzolamide or brinzolamide are possible alternatives when needed, although human pregnancy and milk data are limited. Oral acetazolamide is generally reserved for serious or refractory pressure elevation. It is often considered acceptable during breastfeeding, but exposure near delivery has occasionally been associated with temporary neonatal metabolic acidosis. Prostaglandin analogues are not first-line during pregnancy because of a theoretical risk of uterine contraction or premature labor and limited human data. Selective laser trabeculoplasty may reduce or eliminate medication exposure. Guidance differs slightly on first-trimester elective treatment, so timing should depend on disease severity and urgency. Incisional surgery is unusual but justified when vision is at meaningful risk. If it cannot be deferred, the second trimester is generally preferred, with local anesthesia and avoidance of antimetabolites whenever possible. How pregnancy changes intraocular pressure Normal physiologic changes Intraocular pressure usually decreases during pregnancy. Proposed explanations include: Increased aqueous humor outflow related to hormonal changes Reduced episcleral venous pressure Effects of progesterone and relaxin Pregnancy-related changes in blood chemistry and vascular physiology One study found that average intraocular pressure in the first trimester was approximately 2 millimeters of mercury higher than in the third trimester. Another study reported an approximately 19.6% reduction in women without ocular hypertension and a 24.4% reduction in women with ocular hypertension, although these studies were relatively small and older. () Pregnancy can also change corneal thickness and biomechanics, which may influence applanation pressure readings. For this reason, clinicians should interpret pressure trends together with the optic nerve, retinal nerve fiber layer imaging, and visual field—not pressure alone. In one review, both intraocular pressure and central corneal thickness had returned toward first-trimester values by approximately three months after delivery. () Why glaucoma can still worsen The average fall in pressure does not protect every patient. In a retrospective series of 28 eyes from 15 women with glaucoma: 57.1% had stable pressure without visual field progression. 17.9% developed visual field progression even though pressure was stable or increased. 17.9% developed pressure elevation without documented visual field progression. Two eyes had inconclusive data. Many patients required glaucoma medication during pregnancy. () The practical lesson is important: a lower pregnancy pressure does not prove that glaucoma is stable, and a normal-looking pressure does not exclude progression. Monitoring during pregnancy and after delivery Minimum monitoring At a minimum, a pregnant patient with established glaucoma should generally be assessed at least once during each trimester. This is a consensus-based recommendation rather than one supported by a large pregnancy trial. () A useful examination may include: Visual acuity Intraocular pressure using the same method when possible Optic nerve examination and photographs Visual field testing when the patient can perform it reliably Optical coherence tomography of the retinal nerve fiber layer and ganglion cell layer Gonioscopy when angle status is uncertain or angle closure is possible Medication review, adherence, and drop technique Heart rate and respiratory history if a beta-blocker is being used Practical monitoring intervals The following schedule is a practical risk-based framework, not a universally validated guideline: For the full table, please open this article on visualfieldtest.com. A visual field and structural baseline should ideally be obtained before conception. Repeating both tests once per trimester may be reasonable for moderate or advanced disease if the patient can tolerate testing, but excessive testing can create fatigue and unreliable results. Postpartum pressure rebound Pressure may rise again after delivery as pregnancy-related physiologic changes resolve. This may be especially important when medication was reduced or stopped during pregnancy. A postpartum plan should therefore be made before delivery rather than waiting for symptoms, because glaucoma progression is often silent. () Medication safety during pregnancy and breastfeeding A note about “pregnancy categories” Many older articles describe glaucoma medicines as Category B or Category C. The United States Food and Drug Administration replaced the former letter categories with descriptive pregnancy and lactation labeling in 2015. The older categories may still appear in reviews, but they should not be interpreted as modern, precise safety rankings. The current labeling emphasizes the quality of human data, animal findings, and the balance between maternal benefit and fetal or infant risk. () Medication comparison For the full table, please open this article on visualfieldtest.com. Brimonidine Brimonidine is frequently described as the preferred first medication during pregnancy because animal studies did not demonstrate fetal malformations at exposures substantially above typical ophthalmic exposure. However, current United States product labeling states that human pregnancy data are inadequate and that the medicine should be used only when the maternal benefit justifies potential fetal risk. () The more important issue is the newborn. Brimonidine crosses the blood-brain barrier and has been associated with central nervous system depression, excessive sleepiness, hypotension, bradycardia, and apnea in infants exposed directly to the medication. Animal studies also demonstrate transfer into milk. For this reason, the American Glaucoma Society handout and product labeling recommend stopping brimonidine before delivery and avoiding it during breastfeeding. () The precise stopping date is not established by high-quality evidence. A practical plan is to discontinue it well before expected delivery, with the exact timing based on disease severity, the alternative treatment, and obstetric and neonatal advice. There are a few reports of breastfeeding without apparent harm, but these involve very small numbers and sometimes multiple medications. LactMed therefore acknowledges the limited reassuring reports while also noting that manufacturers and many clinicians recommend avoiding brimonidine because the potential consequences in a newborn could be serious. () Timolol and other beta-blockers Topical timolol is systemically absorbed and can cross the placenta. Potential fetal or neonatal concerns include a slow heart rate and low blood pressure. Current clinical guidance supports selective use with the lowest effective exposure and consideration of fetal heart-rate and growth monitoring, especially with prolonged or late-pregnancy treatment. () The American Glaucoma Society has suggested that clinicians may consider reducing exposure—for example, using a lower concentration when clinically adequate—but patients should not change concentrSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/wound-healing-modulation-2026-anti-fibrotics-in-filtering-surgeryTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Wound Healing Modulation 2026: Anti-fibrotics in Filtering Surgery Glaucoma filtering surgeries (like trabeculectomy or tube shunts) lower eye pressure by draining fluid out of the eye into a tiny reservoir or bleb under the conjunctiva. After surgery, the eye’s natural wound-healing response (scarring) can close off this drainage, causing the surgery to fail. To prevent excessive scarring, surgeons use anti-fibrotic medications during or after surgery. The most common agents are Mitomycin C (MMC) and 5-fluorouracil (5-FU). These drugs help keep the drainage channel open, improving long-term success. For example, in one study about 95% of eyes reached targets at 6–12 months after trabeculectomy with either MMC or 5-FU (). In other words, both drugs greatly boost the chances of success. Over the past decades and into 2026, new strategies have appeared alongside MMC and 5-FU. Rho-kinase (ROCK) inhibitors and anti-VEGF injections are emerging as wound-healing modulators. Research (in animals and small trials) suggests these may further reduce scarring in filtration surgery () (). In all cases, surgeons balance the benefits of better pressure control against risks of a very thin or leaking bleb (which can lead to infection). Below we summarize the evidence on dosing, outcomes, and safety of these therapies through mid-2026. Anti-Fibrotic Medications: How and How Much Mitomycin C (MMC) Mitomycin C (MMC) is a potent anti-scarring drug originally used in chemotherapy. In glaucoma surgery, it is applied as eye drops or soaked sponges under the conjunctiva at the time of surgery. Standard practice (for many years) is to use MMC at about 0.2 to 0.4 mg/mL concentration for 1–3 minutes on sponges covering the scleral flap area. (For example, the FDA-approved kit “Mitosol” provides 0.2 mg/mL and directs surgeons to apply saturated sponges for 2 minutes ().) In practice, surgeons tailor the dose: a routine case might get 0.2 mg/mL for 2 minutes, while a high-risk case (see risk section below) might get 0.4–0.5 mg/mL. After soaking, the area is rinsed with fluid to stop the drug’s action. Example dosing: In one clinical trial, surgeons applied MMC 0.2 mg/mL for 2 minutes versus 5-FU 50 mg/mL for 5 minutes during trabeculectomy (). Another study on the new PRESERFLO microshunt used 0.2–0.4 mg/mL MMC, lowering mean eye pressure from 21.7 to 14.1 mmHg at 2 years (). Patients given the higher 0.4 mg/mL dose were more likely to be off all medications at 2 years. MMC is very effective at keeping the bleb draining, giving excellent long-term pressure control in many patients (). In the 5-year study above, average pressure with MMC was 9.9 mmHg (from 25.8 pre-op) (), and success was high. However, MMC carries notable risks because it creates a thin, avascular (poorly blood-supplied) bleb. In that same study, about 15% of eyes developed late bleb leaks and 5.7% had blebitis (infection of the bleb) by 5 years (). Very low pressure (hypotony, <6 mmHg) occurred in 42% of eyes. In another study, most MMC-treated blebs became avascular (lack normal blood vessels) within a year, and leak risk increased over time (). Patients must be warned: a thin bleb can leak fluid and even harbor germs. Overall, bleb-related infection after MMC-augmented filtering surgery is uncommon but real – roughly 1–2% per year () () (for example, one survey found 1.1% infection in MMC eyes at follow-up vs 1.3% without MMC ()). Key points for MMC: Standard practice is 0.2–0.4 mg/mL for 1–3 minutes. Higher doses give more pressure lowering but a higher chance of complication. The doctor always rinses thoroughly afterward. 5-Fluorouracil (5-FU) 5-Fluorouracil (5-FU) is another anti-scarring drug used in glaucoma surgery. It is a chemotherapy agent too, but less potent than MMC when used in the eye. In contrast to MMC’s sponge application, 5-FU is often given by injections under the conjunctiva either during or after surgery. A common regimen has been 5 mg (in 0.1 mL) injected once daily for 5–10 days postoperatively. Some older studies also used 5-FU on sponges at surgery. Evidence shows 5-FU significantly reduces scarring. In one randomized trial, trabeculectomy success rates using intraoperative 5-FU were essentially the same as with MMC (), demonstrating that 5-FU can be nearly as effective. A Cochrane review found that 5-FU injections significantly lowered the risk of surgical failure in high-risk eyes. For example, adding perioperative 5-FU to repeat glaucoma surgery cut failure risk by about one-third (relative risk ~0.67) (). In high-failure-risk eyes (like after a prior surgery), they calculated needing to treat only ~4 eyes to prevent one reoperation. 5-FU also produced substantial IOP drops: in the same review, “high-risk” patients getting 5-FU had mean IOP ~16 mmHg lower than controls at 1 year (). Because 5-FU tends to cause less severe thinning of the bleb wall than MMC, it is sometimes preferred for patients at very high risk of complications. Its side effects include corneal irritation (toxicity to the front of the eye), shallow anterior chamber, and bleb leak. The Cochrane summary noted that things like wound leaks and low pressures were more common with 5-FU, though the overall infection risk was low (). In practice today, 5-FU is often used in follow-up clinic if a newly formed bleb shows too much scarring: the surgeon may inject 5-FU in the office or perform needling (bleb revision) with 5-FU to improve flow. Key points for 5-FU: Common regimen is 5 mg daily for ~5 days post-op. It boosts success in tough cases (). It causes less avascular thinning than MMC, but blebs can still leak or stay flat. ROCK (Rho-Kinase) Inhibitors and Other Emerging Drugs ROCK inhibitors are a newer class of glaucoma medications originally developed to lower pressure by relaxing eye outflow channels. Preclinical studies suggest they also have anti-scarring effects. ROCK inhibitors (like ripasudil or netarsudil drops) can slow down fibroblast activity in the conjunctiva. Animal models of glaucoma surgery have shown that adding a ROCK inhibitor to the eye reduces postoperative scarring (). Commercially available ROCK inhibitor eye drops (e.g. netarsudil) are not yet standard in surgery, but researchers are testing whether such drops (or injections) could be given around the time of filtering surgery to improve bleb outcomes. Other agents under investigation include anti-VEGF drugs (like bevacizumab) and experimental molecules that block fibrotic growth factors. For example, a recent randomized clinical trial (2023) found that a single intravitreal bevacizumab injection at the time of trabeculectomy significantly improved results: only 6% of eyes in the bevacizumab group needed glaucoma medications at 1 year (versus 17% of controls), and only 2% needed additional surgery (versus 10% of controls) (). Bleb appearances were also better (larger blebs, less redness) in the bevacizumab group (). These findings suggest anti-VEGF can help modulate wound healing. Ongoing trials are comparing various drugs (topical or injected) in surgery, but as of 2026 these are still emerging and not yet routine in most practices. Sustained-Release and Targeted Delivery Because continuous exposure to anti-fibrotic agents might improve outcomes, researchers are developing sustained-release formulations. For example, a novel gel implant containing MMC was tested in rabbits with a tiny drainage stent. Eyes that got the MMC sustained-release implant maintained a ≥20% IOP drop for a median of 30 weeks, compared to only 6.5 weeks in eyes given a one-time MMC injection and 1 week in untreated eyes (). This shows how a slow-release system can keep the bleb functioning much longer. Other approaches include microparticles or coatings on drainage devices. In lab research, scientists coated a glaucoma tube shunt with microparticles of MMC. The microparticles slowly release the drug locally to the surrounding tissue, aiming to prevent fibrosis around the shunt. Such designs are experimental but promising (). Similarly, there is interest in MMC-loaded biodegradable gels or pads that could be placed during surgery (or injected) to deliver drug over days rather than minutes. As of 2026 these sustained-release products are mostly in animal or early human testing, but they represent a future strategy to make anti-fibrotics safer and more effective. Bleb Morphology and Infection Risks The goal of using anti-fibrotics is to create a well-formed, functioning bleb that continues to drain fluid. Typical bleb appearance with MMC is often a large, thin-walled, leaky bleb. This “cystic” bleb can be ideal for lowering pressure but also precarious. A large multi-lobed bleb covering much of the upper sclera with few surface blood vessels is often seen. With 5-FU, blebs may be a bit thicker and less avascular than with high-dose MMC, but can still be cystic. Few studies have looked at bleb shape by treatment, but one analysis showed that eyes treated with MMC often became avascular (neck), with leaks developing months later (). In that series, 71% of MMC-blebs were avascular by 1 year. Larger avascular blebs were roughly four times more likely to ooze or leak thSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/vision-for-2030-what-july-2026-glaucoma-trends-mean-for-the-next-four-yearsTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Glaucoma by 2030: Innovations and Trends Shaping Future Care Glaucoma – a group of eye diseases that damage the optic nerve and lead to vision loss – already affects tens of millions worldwide and will grow as populations age (). Today, most patients manage glaucoma with daily eye drops, occasional laser treatments, or surgery. But new research, new rules, and new care models are coming that could change how patients are screened, monitored, and treated by 2030. This article reviews cutting-edge trends (as of mid-2026) in glaucoma research & development (R&D), regulation, care delivery, and economics to forecast what glaucoma care might look like by 2030. In particular, we explore three emerging approaches – sustained-release (depot) therapies, artificial intelligence (AI)–enabled screening, and home monitoring – examining optimistic and cautious adoption scenarios for each, along with barriers and enablers. We also outline likely health policy milestones (e.g. screening guidelines, reimbursements) and workforce needs (glaucoma specialists and allied staff) to meet future demand. Finally, we suggest key metrics (like detection rates, treatment adoption, and disease control) that clinics and researchers should track each year to stay on course. Innovation Trends in Glaucoma R&D and Care New Treatment Options Recent years have seen major innovation in how we treat glaucoma. One big area is sustained-release drug delivery. Instead of daily eye drops (which many patients find hard to use exactly every day), doctors are developing implants and devices that slowly release pressure-lowering drugs over months. The first FDA-approved example is Durysta, a tiny biodegradable implant placed inside the eye that slowly releases bimatoprost (a prostaglandin analog) and can control eye pressure for about 4 months (). Another is iDose TR (Glaukos), an anchored titanium implant that releases travoprost; in trials it matched twice-daily eye drops while freeing 81% of patients from drops at 12 months (). Eye doctors expect even more of these devices soon. For example, a review notes that while Durysta is currently the only U.S.-approved sustained-release glaucoma therapy (), several other drug-eluting implants (trabecular meshwork inserts, punctal plugs, drug-coated lenses) are in clinical trials. One promising approach is the BIM-IOL (SpyGlass), an ordinary intraocular lens (like those used in cataract surgery) fitted with a bimatoprost drug pad. In a 2026 study, a single BIM-IOL inserted at cataract surgery allowed 97% of glaucoma patients to stop all other pressure drops for at least a year (). Other new medications are coming too. For example, novel eye drops with new targets (like nitric oxide donors and EP2 receptor agonists) are in late-stage trials or recently approved. These include Roclatan (lanostrasol); Omlonti (omidenepag isopropyl); and others in testing. A 2026 glaucoma pipeline review notes a rich “expanding array” of treatments, from new eye-drop drugs and combinations to implants () (). These advances reflect a shift toward earlier and interventional treatment – using lasers and devices instead of just waiting until vision worsens. Already, trials like the LiGHT study have shown that early laser trabeculoplasty can effectively lower pressure long-term, influencing practice patterns (). Despite all this innovation, some things remain experimental. Doctors remain hopeful but cautious about neuroprotective or regenerative therapies (aimed at healing nerve cells or restoring the drainage tissue) – none are standard yet () (). As one expert panel noted, stem cell or gene approaches are “areas of intense scientific interest” but still largely early-stage (). Guidelines are focusing more on proven tools. Non-medical strategies like patient education (about adherence and lifestyle) are also highlighted, since consistent medication use is crucial for good outcomes (). Artificial Intelligence and Digital Tools Artificial intelligence (AI) is another hot area. Researchers are developing AI software to analyze eye scans or photos and catch glaucoma earlier. For example, deep-learning algorithms have shown high sensitivity and specificity for detecting glaucoma from optic nerve images (). A 2025 review found AI methods that automatically segment the optic disc in photos and match experts’ accuracy () (). In other words, AI can look at a retina picture or OCT scan and flag glaucoma risk, sometimes even before obvious symptoms show. These algorithms can sift through data at lightning speed. One clinician points out that AI could combine imaging, patient records, and visual field tests to predict who is most at risk (). AI isn’t magic, though. Experts note many challenges: existing studies often use limited, non-diverse datasets; models must be “trained” on more early-stage disease cases; and AI tools must fit into clinic workflows. Current AI systems typically automate only parts of the exam (like reading an image) (). Challenges highlighted include data quality and generalizability (ensuring the AI works for different ethnic groups and camera types) (). There are also questions of liability (who’s responsible if AI misses a problem) and reimbursement (will insurers pay for the tests?) () (). So far, no AI device is FDA-approved specifically for glaucoma screening. But regulatory bodies like the U.S. FDA and international agencies are actively working on rules for “AI-based” medical devices. For example, FDA updates now tag devices that use modern AI technology (), and early principles for AI in health have been published by the FDA, Health Canada, and UK regulators. These steps pave the way for AI adoption by clarifying what oversight is needed. AI can already improve aspects of care. Systems used for diabetic retinopathy screening provide a model: clinics without eye doctors can take a retina photo, have AI analyze it, and identify patients needing referral. Early adopters report that such systems save patient time and increase exam capacity () (). We may see similar setups for glaucoma: AI software reading retinal photos in primary care or optometry settings to catch glaucoma “red flags” early. But it will take a few years of evidence and regulatory review to know exactly how to roll this out widely. Remote and Home Monitoring The COVID-19 pandemic accelerated interest in remote care. Glaucoma is a chronic disease, so doctors see patients perhaps 2–4 times a year to check eye pressure and vision. However, those snapshots may not capture the full picture of disease progression. New home-monitoring devices are emerging to fill the gaps. The best-known is home tonometry. These are portable instruments (like the iCare HOME rebound tonometer) that let patients check their own eye pressure at home, several times a day if needed. Clinical studies have found iCare Home readings correlate well with the gold-standard Goldmann tonometer done in a clinic (). Importantly, home checks can reveal pressure spikes that are missed when measurements are only taken during office visits. A recent review noted that peak out-of-office pressures are often higher than those measured in clinic, and devices like iCare HOME can catch these hidden peaks (). Regular home IOP monitoring could help doctors adjust treatment more precisely. Other home tests include virtual reality (VR) perimetry and smartphone vision tests. For example, head-mounted VR devices (like VisuALL) allow patients to do a visual field test at home – mapping their vision without needing a bulky in-clinic machine (). Trials of these tools have shown they can closely match standard visual field results. Similarly, smartphone/tablet apps (like the Melbourne Rapid Fields app) let patients do basic vision checks at home, with data sent to the clinic. A 2025 systematic review of telemonitoring found these home VF and home pressure tools are not only feasible but cost-effective: they reduce patient travel and wait-times and improve satisfaction (). In summary, technical feasibility is there – many studies report that home tests give results very similar to clinic tests (). Barriers remain, however. Many patients (older adults) may struggle to perform tests correctly without help. Devices like iCare HOME can be expensive (thousands of dollars), and insurance coverage for home monitoring is still limited. Some virtual field tests require a smartphone or computer and good understanding of the app. Finally, doctors must handle large amounts of patient-generated data. As one specialist notes, we now have the tools, but key questions are how to integrate them “in the right way” for routine care () (). Implementing these tools will require training staff, setting up data platforms, and getting payers to reimburse remote testing. Enablers include patients’ desire to avoid frequent clinic trips and the healthcare system’s push for telehealth. Many clinics have already started “teleglaucoma” programs where techs gather test data remotely for later review by doctors. The pending shortage of specialists (see below) may also drive wider use of optometrists and telemedicine teams, with home-monitoring devices helpSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/personalizing-a-supplement-plan-after-trabeculectomyTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Personalizing Your Post-Trabeculectomy Diet and Supplements After a trabeculectomy (glaucoma surgery), your eye is healing through several stages. In the first 2–4 weeks, new blood vessels and soft granulation tissue form under the conjunctiva () (). By about 3 weeks, collagen and scar tissue begin to develop. During this subacute phase (2–4 weeks), the bleb (fluid-filtering bubble) is still soft and vascular (). Good nutrition helps healing: a balanced diet rich in fruits, vegetables, vitamins (like C and A), protein, and fluids supports tissue repair () (). However, very high-dose or specialty supplements generally show only modest benefit () (). For example, a clinical trial found that taking 300 mg of vitamin E daily after trabeculectomy did not improve surgical success or complication rates compared to placebo (). Instead of relying on megadoses, follow your doctor’s orders for eye drops and medication. Use supplements only if needed and in safe doses. This means usually not exceeding the Recommended Daily Allowance for vitamins/minerals unless a deficiency is known. Discuss any new supplement with your doctor before starting. Consider Your Medical History and Medications Your overall health can affect healing and interactions with supplements: Blood thinners or anticoagulants (like warfarin, Xarelto, aspirin, Plavix): These make bleeding more likely. Many herbal supplements also have blood-thinning effects. For example, garlic, ginkgo biloba, ginger, ginseng, turmeric (curcumin), and high-dose vitamin E can all increase bleeding risk () (). One review found that garlic and hawthorn supplements were strongly linked to surgical bleeding, and that herbs like ginkgo, turmeric, and others raised bleeding risk in patients on blood thinners (). If you take any of these, tell your doctor. He or she may suggest stopping them or monitoring you closely. On the other hand, normal-dose fish oil (omega-3), ginseng, and saw palmetto did not show increased bleeding in studies (), though we still caution if you are on blood thinners. Practical point: If you are on warfarin, your doctor should check your INR after starting any new supplement. For example, substances like vitamin E or CoQ10 can raise INR and require a dose adjustment (). Vitamin K (in green vegetables) lowers warfarin effect, so keep your vitamin K intake steady. Blood pressure, heart meds, and kidney meds: Some supplements affect blood pressure or potassium levels. For example, potassium-rich supplements or teas (like high-dose potassium or warm medicinal teas) can add to potassium if you’re on ACE-inhibitors or potassium-sparing diuretics. Herbals like licorice can also raise blood pressure. Always check with your doctor: if you have high blood pressure or heart disease, do not take supplements that significantly raise or lower blood pressure without approval. Diabetes: If you have diabetes, avoid supplements that spike blood sugar. Some herbal formulas (like certain Chinese or Ayurvedic mixes) can raise or lower blood sugar, so discuss any new herbals with your endocrinologist. Generally, stick to multivitamins and avoid sweet syrups or products with lots of sugar. Other conditions: Chronic inflammatory conditions or steroid use can slow healing or suppress immune response. In these cases, your doctor may want to avoid immune-boosting herbs (like echinacea) or anti-inflammatory ones (like high-dose turmeric) that could theoretically interfere with your medications. If you have liver or kidney problems, high doses of fat-soluble vitamins (A, D, E, K) or minerals might need lab monitoring. Bottom line: Write down all your health conditions and medications. Review them with your doctor to flag any supplement interactions. For instance, if you use aspirin or warfarin, your doctor will advise stopping “blood-thinning” herbs well before or after surgery (). Surgical Details Matter Details of your surgery guide what to watch for: Anti-scarring agents (MMC/5-FU): Many trabeculectomies use anti-fibrotic drugs (mitomycin-C or 5-fluorouracil) during surgery to prevent aggressive scarring (). If your surgeon used these, the wound is intentionally kept from scarring too fast. In that case, you may tolerate normal healing better and have less natural scarring. You usually do not need extra anti-scarring supplements, since the medication already reduces fibrosis. No anti-scarring agents: If no mitomycin-C or 5-FU was used, your eye relies on its own healing. Certain types of glaucoma, like neovascular or uveitic glaucoma, or repeat surgery cases, are known to scar excessively and often drive surgeons to use anti-fibrotics (). In these high-risk eyes, supplements that might inhibit scarring (like curcumin) could be considered, but evidence is weak. It’s safer to ensure good steroid use (as prescribed eye drops) and a healthy diet rich in anti-oxidants (fruits, vegetables) () () rather than special pills. Needling or leaks: If in follow-up the doctor performed a needling procedure (to break scar tissue) or there’s a bleb leak, it means your eye is having trouble. In such cases, avoid any supplement that could worsen bleeding or fluid leaks. Focus on healing (adequate rest, avoiding strain). For example, if your bleb is leaking, keep eyes lubricated and avoid thickening supplements that dry out fluids; also notify your surgeon before adding anything new. Assess Healing Status At two weeks, your surgeon will examine the bleb. Here’s what to consider for supplements: Bleb appearance & fluids: If the bleb is very vascular (red) or has a tiny leak, skip blood-thinning supplements (fish oil, ginkgo, garlic, etc.) until it’s stable. The aim is to avoid new minor hemorrhages around the surgical site. Intraocular pressure (IOP): Keep track at each visit. A slight upward trend in IOP during the first month could signal scarring (). Avoid supplements that might raise IOP (some people worry about caffeine or certain steroids; check with doctor). Conjunctival and wound health: No serious infection or inflammation should be present. If your eye shows signs of infection (redness, discharge) or excessive inflammation, do not take new supplements that you haven’t used before the surgery. Contact your doctor right away. Weighing Bleeding vs. Fibrosis Risks Weigh your risk of bleeding complications against risk of scar formation: High bleeding risk: This includes patients on blood thinners, with bleeding disorders, or those who had a bloody operative course. Also older patients can have more fragile vessels. In high bleeding-risk cases, be cautious with any supplement that thins blood. For example, a Baylor University review cautions that many supplements can “alter bleeding and coagulation during surgery” (). Garlic and hawthorn were “strongly associated” with surgical bleeding, and others (ginkgo, turmeric, fenugreek, etc.) posed risks in patients on anticoagulants (). If you fall into this category, skip herbals like ginkgo/ginseng/ginger and stop any high-dose multivitamins or fish oil until your doctor gives clearance. Your doctor may even suggest stopping non-essential supplements 2 weeks before and after surgery (). High fibrosis (scarring) risk: Younger patients, Black or African ancestry, and patients with inflammatory glaucoma (like uveitic) or prior failed trabs tend to scar more () (). If you’re in this group, your doctor likely already used an antifibrotic medicine. Still, you can support healthy healing: ensure enough protein (but not extreme “bone broth”), stay hydrated, and possibly use mild anti-inflammatories (see below). There’s no proven supplement that mimics mitomycin, but maintaining a healthy diet of fruits and vegetables (vitamins A, C) and omega-3 fatty acids can modulate inflammation. Safe Supplements to Consider When healing is on track and risk factors are managed, these may be safe: Basic vitamins/minerals: A standard multivitamin (100% of daily values) is fine if your diet is poor or you have a known deficiency. Vitamins C and A are important for collagen and tissue repair; vitamin C deficiency especially delays healing (). However, don’t take mega-doses. For example, excess vitamin A can be toxic – stick to normal amounts. Zinc: An essential mineral for wound repair. Zinc serves in cell growth and immune function. Studies show zinc deficiency is linked to delayed healing (). If you’re deficient (or diet poor), a modest zinc supplement (e.g. 8–11 mg daily) can be helpful. But high-dose zinc can cause nausea or anemia, so don’t overdo it. Omega-3 (fish oil): These fatty acids help resolve inflammation. Some research in wound care notes omega-3s have “profound effects on wound healing” (). Small doses (e.g. 1000 mg fish oil daily) can be safe and may calm inflammation around the bleb. Large doses may thin blood slightly; if you’re on blood thinners, check with your doctor. Large trials have found no significant bleeding risk from normal fish oil use () (), but caution is wise with any anticoagulant use. Arginine: An amino acid involved in collagen production and immune function. Some wound-healing protocols include arginine to support tissue growth. There’s no specific study in trabs, but a review notes arginine (with omega-3s) can improve wound outcomes (). You might get Support the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/vitamin-d-status-and-trabeculectomy-outcomesTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Vitamin D Status and Trabeculectomy OutcomesVitamin D is a crucial nutrient (actually a hormone) known for maintaining bone health, but it also modulates the immune system and inflammation in many tissues, including the eye【6】【25】. Glaucoma – a progressive optic nerve disease – is driven partly by high eye pressure and damaging inflammation. Some studies have found that people with glaucoma tend to have lower blood vitamin D levels than healthy controls【9】. Animal and cell studies suggest the vitamin D hormone (calcitriol) can protect retinal ganglion cells (the nerves damaged in glaucoma) and reduce inflammatory signals in the eye【6】. In fact, in trabecular meshwork (drainage) cells under stress, vitamin D3 blocked many abnormal changes (excessive matrix, collagen, inflammatory cytokines) that contribute to glaucoma pathology【6】. These findings imply vitamin D could help guard the optic nerve and enhance fluid outflow.... Continue reading at https://visualfieldtest.com/en/vitamin-d-status-and-trabeculectomy-outcomesSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/vitamin-d-status-and-trabeculectomy-outcomesTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Vitamin D Status and Trabeculectomy Outcomes Vitamin D is a crucial nutrient (actually a hormone) known for maintaining bone health, but it also modulates the immune system and inflammation in many tissues, including the eye【6】【25】. Glaucoma – a progressive optic nerve disease – is driven partly by high eye pressure and damaging inflammation. Some studies have found that people with glaucoma tend to have lower blood vitamin D levels than healthy controls【9】. Animal and cell studies suggest the vitamin D hormone (calcitriol) can protect retinal ganglion cells (the nerves damaged in glaucoma) and reduce inflammatory signals in the eye【6】. In fact, in trabecular meshwork (drainage) cells under stress, vitamin D3 blocked many abnormal changes (excessive matrix, collagen, inflammatory cytokines) that contribute to glaucoma pathology【6】. These findings imply vitamin D could help guard the optic nerve and enhance fluid outflow. However, clinical evidence on glaucoma progression is mixed. For example, one recent study found that glaucomatous progression (changes in visual fields or nerve structure over time) was not significantly different in patients with vitamin D deficiency versus those with normal levels【3】. Likewise, an ocular disease review concluded there’s no clear link between serum vitamin D levels and glaucoma severity or rate of worsening【6】. In summary, observational data are inconsistent: while many case-control studies report lower vitamin D in glaucoma patients【9】, cohort data do not clearly show that deficiency causes the disease to progress faster【6】【3】. Vitamin D, Immune Modulation, and Wound Healing A trabeculectomy creates a flap that drains fluid under the conjunctiva. Proper healing is crucial: too much scarring (fibrosis) can close the new drainage pathway, while too little healing can lead to leaks or infection. Vitamin D’s immunomodulatory role may influence these processes. It is known to suppress excessive inflammation and promote tissue repair in general【32】【25】. For example, ocular surface studies note that vitamin D dampens chronic inflammation but can enhance early healing inflammation and innate defenses【32】. In a mouse model of corneal abrasion, topical vitamin D actually increased neutrophils in the wound and slightly slowed initial closure (~17% delay at 18h), but it also upregulated antimicrobial peptides【32】. In practical terms, this suggests vitamin D is a double-edged sword: it might prolong the acute inflammatory phase (fine if controlled) but also strengthen early immune defense. Importantly, vitamin D has anti-scarring effects in the context of eye surgery. In lab culture of human Tenon’s fibroblasts (cells that cause scarring after trabeculectomy), vitamin D3 significantly inhibited cell proliferation and migration without harming cell viability【17】. These results indicate that higher vitamin D levels could help prevent the subconjunctival fibrosis that blocks filtration blebs. The authors suggested vitamin D3 might serve as a low-toxicity adjunct to standard anti-fibrotic agents after glaucoma surgery【17】. Vitamin D also supports the health of the ocular surface. Adequate vitamin D stabilizes tear film and nerves on the cornea【25】. Vitamin D deficiency has been linked to worse dry eye symptoms: studies show patients with chronic dry eye often have lower vitamin D than normal, and have worse tear production and symptom scores【24】. Supplementing vitamin D improved dry eye in both clinical and experimental models【25】. For example, in one small study of cataract surgery patients, those given vitamin D supplements maintained better tear volume and comfort than controls【34】. By analogy, after trabeculectomy (when topical glaucoma meds and surgery can cause dryness), ensuring sufficient vitamin D may help the ocular surface recover more quickly【24】【25】. Postoperative Repletion: Timing, Doses, and Safety When to start repletion? There is no formal guideline for glaucoma surgery specifically, but general practice is to correct clear deficiencies. Waiting about two weeks after trabeculectomy is reasonable: the acute inflammation and epithelial healing have usually settled by then, and starting vitamin D does not appear to disrupt normal wound repair【32】. In fact, delaying beyond initial healing may forgo the protective anti-inflammatory effects. The approach might be: measure vitamin D (25-OH vitamin D) soon after surgery, and if it is low, begin repletion a week or two later during routine follow-up. How much to give? Common repletion strategies follow endocrinology guidance. If blood 25-OH vitamin D is below ~20 ng/mL (50 nmol/L), a “loading dose” is often used – for example, 50,000 IU of vitamin D3 once weekly for 6–8 weeks – to rapidly raise levels【59】. Alternatively, some regimens use ~5,000–8,000 IU daily for a similar period. After this loading phase, a maintenance dose of ~1,000–2,000 IU daily is typically continued【59】. These amounts are within safe limits for most adults. Another option is a modest daily dose (e.g. 2,000 IU) started immediately; this will gradually raise levels without a sharp initial spike. The best strategy depends on how deficient the patient is and any risk factors they have (absorption issues, obesity, etc.). Safety – hypercalcemia risk: Vitamin D by itself very rarely causes problems at usual doses. The Institute of Medicine’s upper limit is about 4,000 IU/day for adults【99】. Taking vitamin D in recommended ranges is generally safe. Problems can occur if extremely high doses are taken or if other factors raise calcium. For example, older patients on thiazide diuretics (a blood pressure medication) are at higher risk: thiazides reduce calcium excretion, and if such a patient also takes high-dose vitamin D (especially with extra calcium supplements), their blood calcium can climb too high【45】. Indeed, case reports describe elderly patients on thiazides who developed hypercalcemia when taking vitamin D plus calcium【45】. To stay safe, patients should avoid exceeding ~4,000 IU/day for long periods unless under physician supervision. It’s wise to avoid unnecessary calcium supplements at the same time. The safe approach is to pick a reasonable dose (often 1,000–2,000 IU daily) and check levels after several months rather than using extremely large one-time doses in someone on a thiazide. Where needed, monitoring blood calcium can catch any issue early【45】. Interactions: Other glaucoma medications generally do not interact with vitamin D. However, if the patient takes any calcium-based antacids or high-dose multivitamins, that adds to the calcium‐vitamin D load. In summary: caution is mainly for thiazide diuretics or kidney insufficiency – both increase hypercalcemia risk with vitamin D【45】. Otherwise, vitamin D repletion is quite safe when dosed appropriately. The risk of actual vitamin D toxicity (very high levels causing hypercalcemia, kidney problems, etc.) requires far more vitamin D than typical supplements provide【48】. In ordinary cases, levels up to ~150 ng/mL (375 nmol/L) have been needed before true toxicity appears【48】. Thus modest repletion aimed at normalizing levels (20–40 ng/mL) poses minimal danger. Take-Home and Testing Recommendations Put simply, vitamin D deficiency is treatable and may help after glaucoma surgery. To be practical: Test when indicated: Patients with risk factors (older age, limited sun exposure, malabsorption, osteoporosis history) should have their 25-OH vitamin D measured. The Endocrine Society defines deficiency as <20 ng/mL and insufficiency 20–30 ng/mL. If levels are low, plan repletion【59】. (Routine screening of every patient is not mandated by guidelines, but reasonable clinical judgment can apply.) Treat if low: For someone just after trabeculectomy who is deficient, one can use a supervised loading regimen (as above) in the weeks after surgery, then downshift to a maintenance dose. For example, a common course is 50,000 IU once weekly for 2 months, then 1,000–2,000 IU daily thereafter【59】. Alternatively, modest daily dosing (e.g. 5,000 IU/day for 1 month, then 2,000 IU/day) works. The goal is to raise blood 25-OH D into at least the 30–50 ng/mL range (some specialists aim >30 ng/mL) and keep it there. Monitor: Re-check vitamin D after a few months to confirm the level is up. Also monitor calcium if there are risk factors (kidney disease, thiazide use, hyperparathyroidism). Individualize: Elderly or those on interacting meds (thiazides, digoxin, etc.) may need smaller doses and closer follow-up. Weight and body fat can affect dosing (obese patients sometimes need higher doses). Work with your doctor or nutritionist to tailor the dose. Conclusion While no definitive clinical trials yet show that fixing vitamin D levels will speed trabeculectomy healing or prevent glaucoma worsening, the potential benefits and low risks support at least considering it. Vitamin D deficiency is common in older adults, especially those with less sun exposure. Given its role in immune regulation, tissue repair, and ocular surface health【25】【32】【17】, optimizing vitamin D status makes sense as part of comprehensive glaucoma care. In practice, we suggest: test or estimate vitamin D status, and if low, start a sensible repletion plan about two weeks after surgery. Keep doses in aSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/alpha-lipoic-acid-oxidative-stress-neuropathy-and-glycemic-controlTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Introduction Alpha-lipoic acid (ALA) is a powerful antioxidant vitamin-like compound found naturally in foods like spinach and broccoli, and sold as a dietary supplement. It can neutralize damaging free radicals and help regenerate other antioxidants (like vitamins C and E), acting as a “cleanup crew” against oxidative stress () (). These properties have made ALA of great interest for protecting nerves in chronic diseases such as glaucoma and diabetes. Glaucoma involves slow loss of the optic nerve cells (retinal ganglion cells) often aided by oxidative damage, while diabetes causes high blood sugar and nerve damage. In this article we review the evidence on ALA’s effects in the eye and in blood sugar control, and discuss safety considerations. ALA for Glaucoma: Reducing Oxidative Stress and Protecting Nerves In glaucoma, damage to the optic nerve is linked not only to high eye pressure but also to reduced blood flow and oxidative stress in the retina. In fact, experts note “vascular factors may have important roles in the pathophysiology of glaucoma,” underlining the need to measure and improve ocular blood flow (). ALA, as an antioxidant, can help counter these processes. Laboratory studies show promising neuroprotective effects of ALA in glaucoma models. In one well-known study, mice prone to glaucoma were fed ALA in their diet. The treated mice showed higher expression of antioxidant genes and proteins in the retina, with lower levels of oxidative damage markers (damaged lipids, proteins, and DNA) compared to controls (). These mice also had better survival of retinal ganglion cells: after months of treatment the ALA-fed mice had healthier optic nerves and about 13% more optic nerve axons than untreated mice (). In other words, ALA slowed the loss of nerve fibers in glaucoma. The researchers concluded that ALA “reduces oxidative stress and improves RGC [retinal ganglion cell] survival in glaucoma” (). Clinical data in human glaucoma patients is still sparse, but some results are encouraging. For example, a small six-month study gave glaucoma patients a supplement containing R-alpha-lipoic acid (the active form of ALA) plus other antioxidants (vitamins C, E, lutein, omega-3, etc.). After 6 months the patients had significantly higher blood antioxidant capacity and much lower levels of malondialdehyde (a blood marker of oxidative damage) (). They also reported improved tear production (important for ocular surface health) and fewer dry-eye symptoms. Importantly, the supplement was well tolerated with no reported side effects or intolerances (). The authors noted that the antioxidant formula “counteracted oxidative stress […] and stabilized the functional parameters of the ocular surface and the glaucoma, without adverse effects” (). While this study included other nutrients beside ALA, it supports the idea that using ALA in a glaucoma-safe formula can boost antioxidant defenses in the eye. Animal and human studies together suggest ALA can help protect ocular nerves by reducing oxidative stress () (). Future clinical trials should look for objective eye measures of benefit. For example, optical coherence tomography (OCT) can measure the thickness of the retinal nerve fiber layer (RNFL) – a thinner RNFL indicates nerve loss in glaucoma. Inman et al. showed ALA helped preserve optic nerve fibers in mice (), so in patients one could test whether ALA slows RNFL thinning on OCT. Likewise, improved optic nerve blood flow could be an endpoint: newer techniques like OCT angiography measure tiny retinal blood vessels. Indeed, glaucoma patients have significantly reduced peripapillary blood flow indexes on OCT-A (), so an increase in these blood-flow measurements would be a useful sign of improved ocular perfusion. In short, changes in ocular perfusion (by imaging or Doppler) and in RNFL thickness would be key endpoints to watch in eye studies of ALA. ALA in Diabetes: Blood Sugar Control and Neuropathy Aside from eye disease, ALA is widely studied in diabetes, especially for diabetic neuropathy (nerve pain). It also affects blood sugar levels. ALA improves insulin sensitivity and helps cells take up glucose, so it can modestly help lower blood sugar. Several human trials and reviews have tested ALA in type 2 diabetes: A 2022 meta-analysis of 16 randomized trials (total ~1000 patients) found that each additional 500 mg per day of ALA produced statistically significant drops in hemoglobin A1c (average blood sugar) and fasting glucose (). In other words, increasing the daily ALA dose by 500 mg lowered A1c by about 0.3 percentage points and also reduced weight, inflammation (CRP), and triglycerides (). These findings are notable, but the actual changes in blood sugar were relatively small. Another comprehensive review noted that, in routine clinical trials, ALA’s effect on A1c tends to be limited or inconsistent (). Many studies (often with low doses or short duration) found no significant changes in A1c () (). For example, some trials saw mild A1c improvement only at high doses, while others saw no change. Overall, these authors concluded that ALA’s benefits for long-term sugar control in diabetics are promising but mixed () (). The bottom line for patients: ALA can support blood sugar control, but it is not a substitute for diabetes medications. If you have type 2 diabetes, adding ALA (typically 600–1200 mg daily) may slightly improve blood sugar and help with weight/markers (), but results vary. Its more established use is for diabetic neuropathy. Multiple trials have shown that ALA (usually 600–1200 mg IV or oral) significantly improves nerve conduction and reduces neuropathy symptoms (). Many diabetic patients take ALA for nerve pain relief in practice. Safety and Drug Interactions After eye surgery (trabeculectomy): There is little direct data on ALA for patients after glaucoma surgery. However, an animal study is reassuring. In rabbits undergoing trabeculectomy (a common glaucoma surgery), adding ALA eye drops was well tolerated. Over 4 weeks, no rabbits developed infection, cataract, or inflammation from the ALA drops (). The treated group even had better surgical bleb survival than untreated controls (fewer blebs failed). In other words, topical ALA appeared safe and possibly beneficial for wound healing after trabeculectomy in this model (). While human studies are needed, this suggests that using ALA (especially topically) after surgery is unlikely to hurt and may reduce scar tissue. Of course, any supplement after surgery should be discussed with the surgeon. Hypoglycemia risk: Because ALA enhances insulin action, diabetic patients (or those on diabetes drugs) should watch for low blood sugar. Health agencies have noted rare cases of ALA triggering an insulin autoimmune syndrome (IAS) in susceptible people (). In IAS, the body makes antibodies to insulin, causing unexpected low blood sugars. These cases were often genetic and mostly reported in East Asian patients. Importantly, all of the reported hypoglycemia cases resolved after stopping ALA (). In practical terms, if you take ALA with insulin or sulfonylureas, monitor your blood sugar especially when starting or increasing the dose. Symptoms of hypoglycemia (sweating, dizziness, confusion) should prompt stopping ALA and contacting a doctor (). This side effect is very rare, but worth knowing about if you have diabetes. Thyroid medication: Some lab studies suggest ALA might interfere with thyroid hormone. Levothyroxine (T4) is converted in the body to its active form T3, and animal data indicate ALA can slow that conversion (). In practice, this is a theoretical concern: people on thyroid medication should tell their doctor if they start ALA. It may be prudent to take the thyroid pill and ALA at different times of day and to have periodic thyroid blood tests, although strong evidence of a problem is lacking (). Chemotherapy and other drugs: ALA’s antioxidant action raises questions for patients on chemotherapy. Some oncologists worry antioxidants might reduce chemotherapy effectiveness, since certain chemo drugs kill cancer cells via oxidative damage. Research is mixed. HelloPharmacist notes that any ALA–chemotherapy interaction is theoretical: “alpha-lipoic acid’s antioxidant activity might in theory change how well these [cancer] treatments work, though experts disagree” (). In fact, some clinical trials have even given ALA to cancer patients to prevent chemo-induced neuropathy (). The safest approach: if you are on chemotherapy, discuss ALA use with your oncologist. They may allow it for side-effect relief (at trusted doses) or advise caution. Beyond chemo, ALA can have mild blood-thinning effects in lab studies, so it might boost bleeding risk if taken with anticoagulant or antiplatelet drugs (). Again, solid evidence in humans is lacking, but if you’re on a blood thinner (like warfarin or aspirin), mention ALA to your doctor to decide if any extra monitoring is needed. Forms, Dosing, and Bioavailability ALA supplements come in different forms. The natural form of ALA in the body is the R-enantiomer (R-ALA); a mirror-image S-ALA form exists only in synthetic mixtures. MostSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/bromelain-and-proteolytic-enzymes-postoperative-edema-vs-bleeding-concernsTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Introduction Bromelain, serrapeptase, and similar proteolytic (protein-digesting) enzymes are natural supplements sometimes promoted to reduce surgical swelling and pain. People often take them after operations (for example, dental extractions or soft-tissue surgery) in hopes of speeding healing. These enzymes indeed have anti-inflammatory effects and can ease pain. However, they also can thin the blood or interfere with clotting. That raises a particular concern after glaucoma filtration surgery (trabeculectomy), where a delicate “filtering bleb” must heal without bleeding. In this article, we review the evidence on their benefits and risks for postoperative recovery, with a special focus on bleeding (hyphema) and bleb complications after trabeculectomy. We will cover when (and if) it might be safer to start these supplements after surgery, which patients should avoid them, and how future studies could safely measure outcomes. How Bromelain and Serrapeptase Work Bromelain is a mixture of enzymes from pineapple stems (Ananas comosus). Serrapeptase (serratiopeptidase) is an enzyme from a bacterium found in silkworm intestines. Both are proteolytic enzymes that break down proteins. In the body, this gives them several effects: they can reduce inflammation and edema (swelling), dissolve certain blood clots, and potentially prevent excessive scarring. They are often taken orally as capsules (usually in an enteric coating so they survive the stomach). Studies show these enzymes are absorbed in the gut and remain active in the bloodstream for hours () (). They help control inflammation by breaking down inflammatory mediators like bradykinin and serotonin (in the case of serrapeptase) () (). Both enzymes have been used in some settings to aid wound healing (for example, topical bromelain for burn debridement, and oral use in osteoarthritis and respiratory conditions).... Continue reading at https://visualfieldtest.com/en/bromelain-and-proteolytic-enzymes-postoperative-edema-vs-bleeding-concernsSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/collagen-peptides-friend-to-skin-foe-to-the-blebTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Introduction You may have heard that oral collagen supplements can help your skin or joints. But what about your eyes? In glaucoma filtering surgery (such as trabeculectomy), a tiny drainage “blister” called a bleb is created under the conjunctiva to lower eye pressure. For the bleb to work, it needs just enough healing to seal the surgical wound, but not so much scar tissue that fluid flow is blocked. This article explores whether taking collagen or pro-collagen supplements could fuel extra scar formation (fibrosis) in the bleb area, potentially harming its function. We’ll explain how normal wound healing works, what we know about collagen supplements and scarring, and practical advice on timing and safe doses if you have a bleb. We’ll also suggest ways researchers could measure bleb health in future studies. Wound Healing After Glaucoma Surgery After glaucoma surgery, the body repairs the cut tissues through a well-known sequence of steps. First, a blood clot forms to stop bleeding (haemostasis). Next comes inflammation: immune cells rush in to clean out debris and bacteria. Then the proliferative phase begins – special healing cells called fibroblasts multiply and start to rebuild the tissue by laying down new collagen fibers and other components (forming granulation tissue). Finally, in the remodeling phase, the new tissue matures and strengthens over weeks to months. In a trabeculectomy bleb, this process is similar but must be tightly controlled. The conjunctiva and Tenon’s capsule heal and may form scar tissue. If too much collagen and scar form under the bleb, it blocks the new drainage channel. In fact, scarring is the single most common cause of bleb failure () (). For example, one review describes the four key stages of bleb wound healing (clot, inflammation, proliferation, remodeling) and warns that “when dysregulated, [healing] can lead to excessive subconjunctival fibrosis and surgical failure” (). In practice, surgeons work hard to limit fibroblast activity in the early weeks after surgery (often using anti-scarring drugs) so that the bleb remains open. Patients may also see a brief rise in eye pressure in the weeks after surgery – a normal result of the healing process peaking (often around 4–8 weeks) before settling down (). Collagen Supplements 101 Collagen is the protein that gives structure to skin, bones, tendons and many tissues around the body (including the eye’s sclera and conjunctiva). Collagen peptides are small pieces of collagen that are often sold as powders or pills touted for skin and joint health. When you ingest hydrolyzed collagen (the common supplement form), your gut breaks it down into amino acids and tiny peptide fragments – it is not taken up as intact collagen fibers (). In fact, most trials on collagen supplements use doses around 2.5–10 grams per day () (). These peptides then circulate in your blood at very low levels. Some remain “bioactive” – for example, short collagen-derived peptides (like Pro-Hyp or Hyp-Gly) can sometimes be detected in the blood after a few hours. Studies in healthy adults suggest that collagen supplements are quite safe. One summary notes that daily doses up to about 15 grams may be safe and effective, and that collagen is generally a safe, nontoxic supplement () (). Typical side effects at high doses are mild – things like stomach bloating, fullness, or loose stools (). Serious complications are very rare (). (To put this in perspective, one nutrition source notes that supplemental collagen has no official daily requirement, but common trial doses range from 2.5 up to about 10–15 g/day () ().) As always, if you take collagen supplements, follow the product’s instructions and talk to your doctor, especially if you have any health conditions or take medications (for instance, protein supplements can interfere with thyroid medicine absorption ()). Collagen Peptides and Fibroblast Activation How might collagen supplements affect wound healing? Experiments suggest that collagen-derived peptides can signal fibroblasts to lay down more matrix. In lab studies, exposing human skin fibroblasts to collagen peptides led them to make more collagen and related proteins (). Another review notes that collagen peptides can stimulate cell pathways: they may “stimulate collagen synthesis, and regulate inflammation and extracellular matrix remodeling” (). In simpler terms, these small peptides can act like a mild biochemical “alert” that encourages fibroblasts to build more connective tissue in wounds. Practically speaking, when you take collagen supplements, only a tiny fraction of those peptides ever reach tissues intact (). There is no targeted “delivery” to the eye. However, because bleb success depends on limiting fibroblast-driven scarring, many experts caution that any general booster of collagen production could in theory accelerate unwanted fibrosis in the bleb. (Indeed, eye doctors often try to suppress strong fibroblast signals – for example, they sometimes inject agents like 5-fluorouracil or mitomycin C at surgery to kill off some fibroblasts and prevent scar tissue formation in the bleb.) To be clear, no study has directly tested collagen supplements after bleb surgery. But given that collagen peptides seem to promote healing in wounds elsewhere, it is biologically plausible they could speed scarring in the bleb. () () Collagen and Wound Healing: Human Evidence Collagen supplements have shown benefits in other wounds. For instance, in randomized trials of chronic pressure ulcers, patients given collagen hydrolysates healed faster. One study (120 patients) found a high-dipeptide collagen drink (10 g/day) significantly improved ulcer healing scores and reduced wound area versus placebo (). Similarly, in burn victims, high doses of collagen (up to 40 g/day in one trial) led to faster wound closure and better scar scores (). These human studies support the idea that collagen promotes faster healing and stronger new tissue formation in skin wounds. This evidence cuts both ways. On the one hand, it confirms that collagen supplements can meaningfully boost the body’s repair processes in obvious wounds () (). But on the other hand, a filtering bleb is a special type of wound – one where the goal is to keep some space open for fluid flow. Too rapid or excessive healing equals failure. Because the available human data (pressure ulcers, burns) consistently show more collagen leads to better healing, some clinicians speculate collagen supplements “could theoretically cause excessive scarring” in a bleb () (). No trial has followed glaucoma patients taking oral collagen, so the risk remains theoretical. As one patient support site notes, people are often told after glaucoma surgery to avoid high-collagen foods in the first months (e.g. bone broths, pork trotters, fish concentrates), with the idea that a fast-healing diet might close the bleb’s drainage too quickly (). This advice has not been rigorously studied, but it reflects the same concern. Timing: When to Take Collagen Supplements If you have a new filtering bleb, timing is everything. The first month or two after surgery are when fibroblasts are most active. One glaucoma specialist described how scar tissue in a bleb often peaks around 6–9 weeks after surgery (in many patients) (). During this time, bleb resistance to outflow is high (“the pressure hump”) but usually settles as healing matures (). By about 3 months, the bleb typically has “matured” – the initial burst of scarring has passed and the tissue has begun remodeling. Given this, a cautious approach would be to delay collagen supplements until the bleb is well past the active healing phase. Many eye surgeons advise patients to avoid any pro-healing supplements or confusing diets for at least 3 months post-op. In practice, waiting even longer (4–6 months) may be chosen, especially if bleb function is borderline. The idea is to protect the bleb during its most vulnerable remodeling stage (). After that period of “bleb maturation,” ordinary collagen intake as part of a normal diet is unlikely to cause harm. In short: treat collagen supplements like any other wound-healer – hold off in the crucial early months until the bleb is stable. Safe Dosage and Upper Limits When you do start (or resume) collagen supplements, what dose is safe? Most clinical trials on skin or joint benefits use 2.5–10 grams per day for at least 2–3 months () (). Health sources generally agree that doses in this range are safe for most adults () (). In fact, one article notes that up to 15 g daily has been used effectively (), and a nutrition review even mentions a “safe” upper intake as high as 40 g/day () (though such high amounts are rarely needed or practical). The bottom line: there is no formal RDA for collagen, but studies suggest benefits often appear around 5–10 g/day () (), and side effects are minimal. Possible mild side effects include stomach discomfort or diarrhea (). If you consume large collagen supplements continuously, monitor yourself for any unusual symptoms (e.g. digestion issues, rashes), and stay within recommended doses. In particular, people with fish or other animal allergies should choose hypoallergenic sources if needed. Always check with your doctor about any new supplement. MSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/curcumin-after-trabeculectomy-can-it-modulate-scarring-without-increasing-bleedingTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Curcumin after Trabeculectomy: Can It Modulate Scarring Without Increasing Bleeding? Trabeculectomy is a common glaucoma surgery that creates a new drainage pathway for eye fluid. Its success depends on keeping the surgical wound (the conjunctiva and underlying tissue) from scarring down and closing off. Surgeons often use anti-scarring drugs (like mitomycin or 5-fluorouracil) during surgery, but patients and doctors are interested in safer ways to reduce scarring. Curcumin, the active ingredient in the spice turmeric, is known for strong anti-inflammatory and antifibrotic actions. We review evidence that curcumin can calm inflammation and fibrosis in eye tissues, ways to improve its absorption, and safety issues (bleeding, stomach upset, drug interactions). If curcumin is started two weeks after surgery, how would we measure whether it helps? We could track outcomes like bleb needling, 5-FU injections needed, and pressure control, similar to how glaucoma trials report success (). 【61†L51-L54†embed_image】 Figure: A plant extracting curcumin from turmeric rhizomes (picture by CurcuminExtractionPlant, CC BY 3.0).◆ Curcumin is isolated industrially from turmeric at facilities like this. Taking turmeric or curcumin means that compound is dissolved and purified before it can affect healing. Curcumin is obtained from turmeric root (a yellow spice). The powdered spice itself has poor absorption, so most therapeutic preparations use purified curcumin. In the lab, curcumin has powerful effects: it blocks inflammation by inhibiting molecules like TNF-α, NF-κB, IL-6 and IL-8 () (). These inflammatory signals normally drive wound healing and scarring, so curcumin’s anti-inflammatory action is relevant. For example, in cultured eye cells, curcumin (5–20 µM) sharply reduced the secretion of the pro-inflammatory cytokines IL-6 and IL-8 (). In general, curcumin is well-documented as an anti-inflammatory agent by blocking signaling pathways that promote inflammation (). Equally important are curcumin’s antifibrotic effects (reducing scar formation). In normal wound healing (see diagram below), a growth factor called TGF-β1 drives fibroblasts to become myofibroblasts that lay down tight collagen scars. In trabeculectomy blebs, excess myofibroblast activity causes failure. Laboratory studies show curcumin can interrupt this process. For example, in human corneal stromal (keratocyte) cells grown in a dish, adding curcumin under pro-scarring conditions cut the expression of α–smooth muscle actin (α-SMA) – a marker of myofibroblast transformation – by about half (). Correspondingly, curcumin-treatment kept these cells from turning into the spindle-shaped scar cells (myofibroblasts) () (). Similarly, in orbital fibroblasts (cells behind the eye), curcumin dose-dependently suppressed TGF-β1–induced markers of scarring (CTGF and α-SMA) and reduced pro-angiogenic activity (). These studies suggest curcumin can blunt the fibrotic response during healing in eye tissues. 【66†L50-L52†embed_image】 Figure: Phases of normal wound healing. Curcumin’s actions could influence these stages (diagram: Oliver Beiermann, CC BY-SA 3.0).◆ Wound healing happens in phases: inflammation, tissue formation (proliferation), and remodeling. Curcumin’s anti-inflammatory and antifibrotic effects might speed up safe healing and reduce later scar formation. In summary, preclinical evidence shows curcumin dampens the wound-healing signals that drive conjunctival scarring () (). This supports the idea that curcumin after trabeculectomy might reduce bleb scarring. (Clinical trials in eye surgery are lacking, but in other tissues curcumin has been observed to improve healing and reduce fibrosis.) Improving Curcumin Bioavailability and Dosing Curcumin is poorly absorbed on its own, so special formulations are used to boost its blood levels. One class is phospholipid complexes (often called “phytosomes”). A commercial example is Meriva®, a curcumin–phosphatidylcholine complex. In healthy volunteers, Meriva given at 209–376 mg of curcuminoids produced an 18-fold higher total blood curcumin level compared to taking nearly 1800 mg of unformulated curcumin (). In other words, the lecithin (phospholipid) carrier in Meriva greatly increased curcumin uptake across cell membranes () (). Other lipid-based carriers (like nanoemulsions, micelles, or liposomes) similarly improve absorption by helping curcumin enter cells (). Another simple enhancer is piperine (black pepper extract). Piperine inhibits curcumin’s breakdown in the gut. In one comparison, adding 5 mg of piperine to 2 g of curcumin increased blood curcumin levels threefold over curcumin alone (). (Even higher doses up to 24 mg piperine and 4 g curcumin in trials showed large boosts in curcumin levels ().) Because of these tricks, potent curcumin formulations can achieve therapeutic blood levels at much lower doses than plain powder. In practice, safe dosing of curcumin has been well-studied. The NIH notes that oral turmeric extract (standardized to curcumin) is “likely safe” in recommended amounts for a couple of months (). Clinical trials have given people up to 8–12 g of curcumin per day without serious side effects (). (Side effects were mild and uncommon.) For newer high-absorption products, much smaller doses can yield similar blood levels. For example, 80–500 mg of a nano-curcumin daily can produce blood levels like those achieved with grams of plain curcumin. Overall, if using curcumin after surgery, one could choose a high-bioavailability form (phytosome, nanoparticle or added piperine) and expect therapeutic effect from a reasonable oral dose (for instance, ~500–2000 mg of curcumin-equivalent daily, depending on formulation). Safety: Bleeding Risk, Gastrointestinal Effects, and Drug Interactions Curcumin is generally well-tolerated, but there are some important safety considerations when used after surgery. Bleeding risk: Curcumin has a mild blood-thinning effect. In lab studies it inhibited platelet activation and aggregation (), and animal studies confirm anticoagulant effects. This means curcumin could increase bleeding risk, especially in patients already on blood thinners (warfarin, aspirin, clopidogrel, etc.). Indeed, a case report noted a patient on a vitamin-K antagonist who ate turmeric had a high INR (excess warfarin effect) (). For surgery patients, the risk of intraocular bleeding is highest early on, but by two weeks the surgical wounds are more stable. Still, if a patient is taking a prescription anticoagulant, adding curcumin should be discussed with the doctor. For patients on aspirin or similar, curcumin could potentiates the bleeding risk. Gastrointestinal effects: Curcumin or turmeric can cause mild GI upset in some people. According to the NIH, oral turmeric can lead to nausea, stomach pain, acid reflux, diarrhea, or constipation (). These effects are usually minor. In fact, studies report most people tolerate even high doses of curcumin without problems (). To be safe, curcumin supplements are often taken with food. If GI upset occurs, taking it with meals or using a delayed-release formulation can help. Proton pump inhibitors (PPIs) themselves do not have known negative interactions with curcumin; if anything, a PPI might reduce any stomach irritation. Drug interactions: Curcumin can affect certain drug-metabolizing enzymes (for example, it can inhibit CYP3A4 in gut cells ()). This means it might alter levels of drugs processed by those enzymes. In practice, the main concern is additive blood-thinning (see above) or interference with anticlotting drugs. There is no well-known problematic interaction between curcumin and PPIs. Most clinicians consider curcumin safe with PPIs, but if a patient is on medications like chemotherapy or immunosuppressants, doctor consultation is prudent. In summary, curcumin is regarded as safe for short-term use. Side effects are uncommon and usually mild (). A reasonable precaution is to inform the surgical team if one plans to start curcumin postop, especially if on anticoagulants. Monitoring for any bleeding signs (even bruising or gum bleeding) is wise, though significant bleeding complications from curcumin alone are rare. Measuring Clinical Outcomes If we were to test curcumin after trabeculectomy, we would track standard success metrics used in glaucoma surgery trials. The primary goal is lowering and maintaining the intraocular pressure (IOP). A commonly used definition of surgical success is an IOP maintained between about 6 and 21 mmHg without additional surgery (). (This range can vary by study, but it reflects controlling pressure without over-draining or requiring more surgery.) We would measure IOP by Goldmann applanation tonometry at regular follow-ups. Beyond raw IOP numbers, we would count how many eyes required further interventions. Key outcomes would include: Needling rates: how many eyes needed bleb needling (a minor procedure to break scar tissue) to revive the bleb. 5-FU rescue injections: how often must we inject 5-fluorouracil in the clinic to prevent scarring. Additional medications or surgery: how many eyes needed glaucoma drSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/resveratrol-and-fibrosis-pathways-in-the-filtering-blebTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Resveratrol and Fibrotic Scarring after Glaucoma Surgery Glaucoma filtering surgery (trabeculectomy) lowers eye pressure by draining fluid through a small fistula under the conjunctiva. However, normal wound healing can overdo it – fibroblasts invade and transform into myofibroblasts, producing excess collagen and scar tissue. This scarring can plug the new drainage (filtering bleb), causing surgical failure. Surgeons often use anti-scarring drugs like mitomycin C, but these can have serious side effects. Resveratrol, a natural compound in grapes and berries, is known for antioxidant and anti-inflammatory effects. Emerging evidence suggests resveratrol may also dampen fibrotic signals in tissues. This article reviews how resveratrol might modify pathways (like SIRT1 and TGF-β) that drive fibrosis in ocular tissues, evaluates its human safety and dosing, and considers how to test it after trabeculectomy. We summarize what is known about resveratrol’s effects on key scarring processes and how it might be used to help preserve the filtering bleb. Fibrosis Pathways and Resveratrol’s Actions After trabeculectomy, injury to the conjunctiva triggers a cascade of healing steps: inflammation, tissue proliferation, and remodeling. Very early on, inflammatory cells release TGF-β (transforming growth factor beta), a potent growth factor that drives fibroblasts to proliferate and become myofibroblasts. These myofibroblasts produce a dense extracellular matrix (collagen, fibronectin, etc.) and express contractile proteins. In the eye, this scar plugs the bleb so that fluid no longer drains properly () (). In essence, a tightly balanced scarring response is needed for a safe bleb – too much scar widens bleb wall closure and bleb failure, while too little scar can cause leaks or hypotony. Thus, controlling but not completely blocking these pathways is the goal. Resveratrol can influence several molecular targets involved in fibrosis: SIRT1 activation: Resveratrol is known to activate Sirtuin 1 (SIRT1), an enzyme that regulates gene expression. SIRT1 acts like a brake on fibrosis. In skin and organ fibrosis models, boosting SIRT1 sharply reduced collagen production and myofibroblast markers (). One study of human skin cells showed that activating SIRT1 (similar to resveratrol’s effect) almost completely blocked TGF-β-driven collagen synthesis and myofibroblast formation (). In mice with induced skin fibrosis, a SIRT1 activator halted and even reversed scarring. In short, SIRT1 naturally restrains the TGF-β/Smad fibrotic program, and resveratrol’s SIRT1 activation may impart these anti-fibrotic benefits (). Inhibition of TGF-β/Smad signaling: (Transforming Growth Factor-β) is a key switch for fibrosis. When TGF-β binds receptors on fibroblasts, it activates Smad2/3 and SMAD4 proteins that move to the nucleus and turn on scar-making genes (collagen, fibronectin, alpha-smooth muscle actin). Resveratrol interferes with this cascade. In cultured trabecular meshwork cells, resveratrol reduced TGF-β1 levels and the activity of downstream Smad proteins (). It downregulated TGF-β1 and SMAD4 gene expression while upregulating the inhibitory SMAD7 (). Computer simulations suggest resveratrol binds with SMAD4’s MH2 domain, hindering the Smad complex from turning on fibrosis genes (). The result was dramatically lower production of collagens (type I, III, IV), fibronectin and α-SMA by those cells (). Other studies confirm this anti-TGF-β effect: in human ocular fibroblasts (from pterygium tissue), resveratrol blocked TGF-β1–induced fibrosis. It dose-dependently suppressed TGF-β1-induced collagen I, fibronectin and α-SMA expression (), and weakened Smad3 and other signaling (MAPK, PI3K/AKT) activation (). In summary, resveratrol disrupts the canonical TGF-β/Smad fibrotic signals, tipping the balance away from excessive matrix production () (). Suppression of myofibroblast differentiation: Myofibroblasts are the main scar-making cells (they generate contractile fibers and collagen). TGF-β drives fibroblasts to become myofibroblasts (marked by α-SMA). By blocking TGF-β signaling, resveratrol reduces this transformation. In pterygium fibroblasts, resveratrol not only cut α-SMA and collagen expression () but also inhibited fibroblast proliferation, migration, and the contractile (wound-closing) behavior induced by TGF-β (). In skin-wound studies, topical or injected resveratrol improved healing with thinner scars. A review of skin wound models found resveratrol counteracted excessive scarring (). In animal models of hypertrophic scars, resveratrol treatment reduced collagen levels and α-SMA in scar fibroblasts (). Together, these data suggest resveratrol keeps fibroblasts from fully becoming stubborn myofibroblasts. In sum, resveratrol acts on multiple levels of the fibrotic wound-healing cascade. It activates SIRT1 (which inherently suppresses fibrotic gene programs) and directly interferes with TGF-β/Smad signaling and related pathways. This dual action both slows new scar synthesis (lowering collagen and α-SMA expression) and enhances matrix breakdown by boosting enzymes like tPA (shifting toward tissue remodeling). The net effect in cell studies is less collagenous matrix made and more degraded, which could keep a filtering bleb more open () (). The challenge is ensuring enough healing for bleb stability but avoiding over-suppression that leads to bleb leaks. Resveratrol Effects in Ocular Cells and Tissues Although much of the research on resveratrol’s antifibrotic action comes from general wound-healing models, several studies have directly tested resveratrol in eye-related cells: Trabecular meshwork cells: Human trabecular meshwork (TM) cells are responsible for draining fluid from the eye. In glaucoma, steroid exposure or other factors increase collagen in the TM, blocking outflow. Abu Bakar et al. treated cultured human TM cells with dexamethasone (to mimic glaucomatous stress) and resveratrol. Resveratrol (12.5 μM) significantly reversed the steroid-induced rise in collagen I, III, IV, fibronectin and α-SMA at both gene and protein levels (). It achieved this by lowering TGF-β1 and SMAD4 expression and raising SMAD7 (an inhibitor), as noted above (). These changes were accompanied by increased levels of tissue plasminogen activator (tPA) and reduced plasminogen activator inhibitor-1 – markers of a shift toward matrix degradation (). In functional terms, this was linked to improved outflow in animal studies. The TM cells showed no toxicity at these doses (), supporting feasibility of targeting TM fibrosis with resveratrol (). Conjunctival fibroblasts: After trabeculectomy, the conjunctiva and Tenon’s capsule under the bleb are the main sites of scarring. Human Tenon’s fibroblasts have not been studied with resveratrol specifically, but similar cells have. In human pterygium fibroblasts (surplus conjunctival tissue often removed during eye surgery), Jiang and colleagues found resveratrol dose-dependently suppressed TGF-β1–induced fibrotic activation (). This included lower expression of type I collagen, fibronectin and α-SMA, and blocked fibroblast proliferation and migration (). These ocular fibroblasts came from patients’ eyes, so they behave like conjunctival fibroblasts in surgery. Notably, resveratrol here also encouraged some fibroblast apoptosis when challenged with TGF-β1 (), suggesting it helps remove overactive cells. Animal wound models: In mice with skin wounds or scar models, resveratrol applied topically or intradermally improved healing with less scarring (). While skin differs from the eye surface, the cell biology is analogous: reduced fibrosis in skin means resveratrol is modulating the same basic pathways (e.g. TGF-β, SIRT1) that likely apply to conjunctival wound healing too (). In one mouse burn-wound model, intradermal resveratrol suppressed markers of scarring (reduced collagen and α-SMA) and activated SIRT1 in the wound site (). These findings bolster the idea that resveratrol can “counteract excessive scarring” in injured tissues (). Taken together, these data in ocular and analogous cells support the notion that resveratrol could mitigate bleb fibrosis by dampening the cellular processes that make scar tissue. The remaining question is whether systemic or local treatment in patients could achieve these beneficial molecular effects safely and at the right time in healing. Safety, Dosing, and Drug Interactions Resveratrol supplements are widely available over-the-counter (often 100–500 mg per capsule, typically from grape extract or Japanese knotweed). Human trials have tested much larger doses. In a landmark study of 40 healthy adults, volunteers took 0.5, 1.0, 2.5 or 5.0 g of resveratrol per day for 29 days (). All doses up to 5 g were generally well tolerated. Mild-to-moderate gastrointestinal symptoms (nausea, gas, cramping, diarrhea) were the only common side effects at 2.5–5.0 g (). No serious adverse events were observed and no abnormalities on blood tests were found (). Notably, the higher doses (2.5–5 g/d) often caused GI upset in nearly all volunteers, though symptoms resolved after stopping. Based on this and other reviews, an upper daily limit of about 1 g for Support the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/a-timing-roadmap-supplements-that-may-be-safe-two-weeks-after-trabeculectomyTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Introduction A trabeculectomy is a glaucoma surgery that creates a small drainage “bleb” under the eyelid to lower eye pressure. Like any surgery, the eye needs time to heal. In the subacute phase (about 2–4 weeks after surgery), the new wound is still forming tissue and delicate. Many patients wonder if they can take vitamins or herbal supplements during this time. In general, healing requires good nutrition and care, but some supplements may raise bleeding risk, alter the pressure in the eye, or interfere with medications. We summarize what the eye’s healing process involves and review evidence about common supplements. The goal is safe guidance: what might help gentle healing of the bleb, what could do harm, and when to stop a supplement if problems arise. Wound Healing of the Filtering Bleb After trabeculectomy, the eye’s tissues heal in stages. First (hemostasis and inflammation): immediately after cutting, small clots form and white blood cells arrive to clean up debris. Second (proliferation/granulation): over the next 2–4 weeks the wound builds new tissue. Blood vessels grow in and a soft, red granulation layer forms. This stage usually lasts into the 2nd or 3rd month after surgery (). Third (fibroblast activation and collagen deposition): starting around week 3, specialized cells (fibroblasts in Tenon’s capsule under the conjunctiva) lay down collagen fibers and connective tissue (). Fourth (remodeling and scarring): after a few months, the collagen contracts and the tissue strengthens. Ideally, this scarring seals incision sites but leaves a controlled, thin bleb that permits fluid to drain slowly. Too much scarring will block the bleb and cause the surgery to fail () (). (Indeed, excessive wound fibrosis is the main reason trabeculectomy fails ().) Around 2–4 weeks the eye is in the middle of this process: inflammation is subsiding, and fibroblasts are laying collagen. The bleb still has blood vessels and is fairly soft, not yet a rigid scar. In this subacute period, wound healing is still active but past the highest risks of bleeding and of infection that occur immediately after surgery. Carefully chosen supplements or good nutrition might support healthy healing, but anything that dramatically boosts blood flow, disorganizes collagen, or strongly alters inflammation could alter the outcome. Supplements and Bleb Healing Nutritional Support for Healing The body needs basic nutrients to heal any wound. A balanced diet rich in vitamins, minerals, protein, and calories supports normal recovery. For example, fruits and vegetables rich in vitamins C and E, beta-carotene (vitamin A precursor), and other antioxidants help maintain healthy tissues (). A varied diet (or a standard multivitamin) will cover these needs. In fact, diets high in fruits (sources of vitamin C, E, and carotenoids) are associated with lower risk of glaucoma in population studies (). While this is not direct proof for bleb healing, it suggests antioxidants support eye health. Vitamin C is especially important for collagen formation in wounds (deficiency causes poor healing), and vitamin A is essential for normal skin and mucous membranes. Zinc and protein are also needed for tissue repair. Inadequate nutrition can delay healing, so patients should avoid prolonged fasting or very restrictive diets during recovery. However, more is not always better. There is little evidence that megadoses of vitamins speed up or change bleb healing. For instance, a small clinical trial gave patients 300 mg of vitamin E (alpha-tocopherol) daily for two months after trabeculectomy, and found no difference in surgical success or complications compared to placebo (). In that study the success rate (achieving low pressure without more treatment) was similar whether or not patients took extra vitamin E (). In short, routine high-dose vitamin E did not hurt but also did not help improve outcomes. Some natural compounds have been studied for anti-scarring or anti-inflammatory effects. For example, curcumin (from turmeric) and other plant antioxidants can suppress fibroblast activity in lab tests. One laboratory study showed curcumin can inhibit growth of human ocular fibroblasts (cells like those in the bleb) at certain doses (). In theory, curcumin’s anti-inflammatory properties might reduce too much scarring. Similarly, omega-3 fatty acids (fish oil) have anti-inflammatory effects that might stabilize healing, although their impact on ocular fibrosis is not proven. However, any theoretical benefit is unproven in trabeculectomy patients, and fish oil has other concerns (see below). Overall, strong evidence is lacking for any supplement specifically improving trabeculectomy healing. The best approach is a healthy diet: include fruits, vegetables, lean protein, and fluids. Additional supplements (vitamins/minerals) should match recommended daily allowances unless a deficiency is known. Cancer and other wound-care guides sometimes recommend nutrients like arginine or glutamine for general healing, but these are not specifically studied for filtering bleb wounds. In sum: good nutrition aids healing, but assume supplements give only modest help and discuss them with your doctor. Supplements That May Sharply Alter Healing Just as some supplements may mildly support healing, others could push the wound too hard or in an unwanted direction. In the context of a filtering bleb, overly aggressive healing can be harmful: for example, extremely rapid collagen buildup might close the drainage path. High-dose protein or collagen supplements. Some people take collagen powders or broths to heal incisions. In most surgeries, collagen helps closure. But for trabeculectomy, surgeons often avoid anything that might speed up scarring at the bleb. (In fact, traditional advice warns against very high-protein bone broths or collagen extracts after glaucoma surgery.) If you feel you need more protein, a modest increase (chicken, fish, eggs) is fine, but avoid mega-doses or specialized collagen supplements without doctor’s advice. “Blood-moving” herbs and formulas. In Chinese and folk medicine, some herbs (ginseng, ginkgo, Dong quai/angelica, etc.) are believed to promote circulation. These can actually accelerate healing and scar formation – something you do not want at the filtering site. For example, tonics or placentas (some cosmetic and “health” products) can have growth factors or hormones that stimulate tissue growth. We advise against using any herbal formula intended to “replenish” or strongly activate healing during the first few months after trabeculectomy. High doses of zinc or vitamin A. Zinc and vitamin A are needed, but in very high amounts they can actually dry tissues or affect collagen remodeling. Stick to recommended doses. (For example, topical vitamin A speeds corneal healing, but oral excess can cause other issues.) Omega-3/fish oil. Many take fish oil for heart health. It has mild anti-inflammatory effects which could be helpful, but it also thins the blood. Traditional surgical advice recommended stopping fish oil 1–2 weeks before surgery due to bleeding risk (though some recent reviews suggest the risk is small ()). In the post-op phase, it’s safer to hold off fish oil until healing is more settled (after several weeks) unless your doctor says you need it for another condition. In short: after trabeculectomy, avoid mega-boosts to wound healing. If a supplement is known to “drive repair” strongly, consult your surgeon. A little extra nutrition is fine, but supplements meant to accelerate healing or improve performance should be postponed or cleared with your doctor. Bleeding Risks from Supplements Though the eye surgery uses fine control, bleeding under the conjunctiva (causing a red bruise) or inside the eye (hyphema) can occur if blood doesn’t clot well. Some dietary supplements thin the blood or interfere with clotting factors. In the weeks after surgery — when fragile capillaries are growing — these can increase the risk of a bleed at the surgical site. Key culprits include: Garlic (aged garlic, garlic extract) – this herbal supplement is a strong platelet inhibitor. Studies show garlic significantly increases bleeding in surgery (). It is one of the most consistently dangerous herbs for post-op bleeding. Hawthorn – another cardiovascular herb, also linked to surgical bleeding (). Ginkgo biloba – can increase bleeding tendency, especially if taken with blood thinners. Reviews list it among supplements to stop before surgery (). Ginseng (Panax) – has mixed reports. Some case reports of bleeding exist, but one review found no clear link in trials (). Still, standard advice is to stop Panax ginseng after surgery. Ginger, turmeric, green tea (large quantities) – these have mild antiplatelet effects. The evidence is mixed, but in undiluted supplement form (not normal tea) they might tip the balance. In general, avoid high-dose ginger or curcumin supplements in the first 4–6 weeks, although culinary amounts (like seasoning or a cup of tea) are likely fine. Fish oil (omega-3 capsules) – once thought very risky, recent large studies indicate no strong evidence of excess bleeding in normal doses (). However, many docSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/omega-3-fatty-acids-after-trabeculectomy-anti-inflammatory-ally-or-bleeding-riskTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Omega-3 Fatty Acids after Trabeculectomy: Anti-Inflammatory Ally or Bleeding Risk? Trabeculectomy – a common surgery to lower eye pressure in glaucoma – creates a bleb (a fluid-filled reservoir) under the conjunctiva. After surgery, patients often face ocular surface inflammation and dry eye because of disrupted tear films and inflammation from wound healing. Since omega-3 fatty acids (the anti-inflammatory oils in fish oil) are known to calm inflammation elsewhere in the body, some surgeons and patients wonder: Can fish oil supplements help with eye comfort and bleb health after trabeculectomy, or do they pose a bleeding risk? We review the evidence. Overall, many trials show that the EPA/DHA omega-3 oils can reduce inflammation and improve tear quality after eye surgery, but their direct effects on bleb function are unproven. On the other hand, omega-3s do make platelets less sticky – a theoretical concern for bleeding. Fortunately, large analyses indicate routine omega-3 doses have minimal impact on surgical bleeding. In practice, moderate omega-3 supplements may help with post-op eye comfort, but clinicians should watch for any extra bleeding in high-risk patients. What Are Omega-3 Fatty Acids? Omega-3 fatty acids (especially eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)) are healthy polyunsaturated fats found in fatty fish (salmon, mackerel, etc.) or supplements. They cannot be made by our bodies and must come from diet or pills. Omega-3s are famously anti-inflammatory: in the body they compete with the usual inflammatory fats (arachidonic acid) and lead to the production of anti-inflammatory molecules (resolvins and protectins) (). In practical terms, omega-3s can reduce swelling and improve tissue healing in many parts of the body. In the eye, inflammation and tear-film imbalance underlie dry eye symptoms. Omega-3s are thought to improve the oily layer of tears (from the eyelid glands) and calm surface inflammation. Indeed, trials in dry-eye patients have shown that omega-3 supplements can lengthen the time between eye blinks before tearing occurs (tear break-up time) and reduce tear osmolarity (less irritating, more stable tears) () (). These changes translate to patients feeling less dryness, burning and scratchiness when it works. (Note: for severe chronic dry eye, a very large trial (the DREAM study) found 3,000 mg/day of omega-3 did not beat placebo on symptom scores, a result that some experts debate due to study design ().) In summary: Omega-3s are generally anti-inflammatory fats that can improve tear-film stability and may soothe irritated eyes after surgery () (). This forms the rationale for trying them after trabeculectomy. Omega-3 Supplements and Post-Op Eye Comfort Several randomized trials have tested omega-3 supplements for post-surgical dry eye and inflammation. Although no study has looked specifically at trabeculectomy patients, we can apply findings from cataract and refractive surgery cases: Cataract surgery: In a 2017 trial, patients with new dry eye symptoms after cataract removal were given standard treatment with or without omega-3 capsules (each tablet: 180 mg EPA + 120 mg DHA, taken 3 times daily). After a few weeks, the omega-3 group had significantly greater improvement in symptom scores and tear stability than controls (). For example, the average eye-comfort score fell more in the fish-oil group, and tear break-up time improved more on omega-3 (P<0.05) (). This suggests that adding fish oil to routine therapy reduced postoperative inflammation and improved ocular surface comfort. Photorefractive keratectomy (PRK): Another small trial looked at patients undergoing PRK (another eye surgery that can cause dry eye). Those who took omega-3 supplements before and after surgery healed quicker and had better vision outcomes and tear stability than those without omega-3 (). (This pilot study supports that omega-3 may speed corneal healing after surgery.) Chronic dry eye (non-surgical): A trial comparing krill oil vs. fish oil vs. placebo in people with dry eye (not after surgery) found both omega-3 groups improved objective tear measures. After 3 months, tear osmolarity and tear break-up time were significantly better with krill or fish oil than placebo (). In that study the krill-oil group (higher EPA ratio) also had a significantly greater drop in symptom scores (patient comfort) than placebo (). Meta-analyses of dry-eye trials generally conclude omega-3s give small but real benefits on tear-film health and symptoms – especially when doses are high and used long-term () (). However, not all reviews are uniformly positive. A 2023 Cochrane review concluded that omega-3s probably have little to no effect on patient-reported dry eye symptoms compared to placebo, though they may improve some tear-test signs (). Importantly, the Cochrane authors noted that combining omega-3 with standard treatments (like artificial tears) seemed more helpful than omega-3 alone. In practice, this suggests fish oil is an add-on therapy: it may work best alongside drops, lid hygiene and other post-op care. What does this mean for trabeculectomy? Trab patients often stop many glaucoma drops (which can irritate the surface) but still experience dry eye and inflammation from surgery trauma. The cataract and PRK trials above imply that omega-3 supplements can make a difference in post-op ocular comfort. While we lack a trial in trab patients, it is reasonable to extrapolate: an omega-3 supplement regimen (e.g. several hundred to a few thousand mg of combined EPA/DHA per day) might reduce irritation, dryness and redness after trabeculectomy, improving patient comfort. Potential Effects on Bleb Health A key question is whether reduced inflammation from omega-3 translates into better bleb healing. The ideal bleb is thin, functioning and leak-free; too much early inflammation can cause scarring and bleb failure. In theory, omega-3’s anti-inflammatory action could help keep fibrosis in check. To date, there are no direct trials of omega-3 on bleb outcomes. However, some clues come from studies of tear biochemistry after trabeculectomy. One 3-year cohort study measured inflammatory lipid mediators in tears before and after trab. It found that pro-inflammatory tear lipids (like certain prostaglandins) dropped markedly after surgery in most patients (). Interestingly, patients who later needed needling of their bleb (a sign of failing bleb with scarring) had higher levels of some inflammatory lipids in their tears than those with healthy blebs (). This suggests chronic inflammation may underlie some bleb problems. By extension, if an intervention like omega-3 could suppress that inflammation, bleb health might benefit. However, this is speculative: no data show that fish oil actually prevents bleb scarring or reduces needling rates. It is also possible that reducing inflammation too much could impair the normal wound closure of the conjunctiva. On balance, most experts would say omega-3’s potential benefits on wound healing via inflammation control are theoretical in the bleb context. We note it as a possible plus, but emphasize the lack of direct evidence. Platelet Function and Bleeding Risk Omega-3s and Platelets: One known effect of EPA/DHA is that they make platelets somewhat less likely to clump. In very high-fish diet populations (like Greenland Inuit), scientists observed prolonged bleeding times and altered platelet fatty acids compared to typical Western diets (). This anti-platelet effect has raised caution among surgeons that omega-3 supplements could increase surgical bleeding. In fact, many guidelines currently advise stopping fish oil before surgery and delaying non-urgent ops for a few days if patients are on fish-oil supplements (). The idea is largely precautionary: fish oil does change cell membranes to be less pro-thrombotic (). However, whether this translates into real harm is the question. Clinical evidence on bleeding risk: Recent analyses have been reassuring. A 2024 meta-analysis of 11 randomized trials (over 120,000 patients) compared bleeding rates in those taking omega-3 supplements vs. controls. It found no significant difference in overall bleeding events (including strokes or gastrointestinal bleeds) between the groups (). Only very high-dose purified EPA (like icosapent ethyl used for heart disease) showed a slight relative increase in bleeding (50% higher risk) – but this change was tiny in absolute terms (0.6% more events) (). Likewise, a large perioperative trial (OPERA, n≈1500) tested giving 8–10 g of fish oil before open-heart surgery and 2 g/day after. The fish-oil group did not have more bleeding – in fact, they had slightly fewer blood transfusions than placebo () (). The odds of major bleeding were not higher (OR≈0.8) in the fish-oil group (). These findings suggest that at least in major surgery, fish oil at high dose didn’t worsen bleeding outcomes. Bottom line on bleeding: In practical terms, normal omega-3 use (roughly 1–3 grams/day of fish oil) appears to have negligible effect on surgical bleeding risk () (). The small impairment in platelet function is mostly offsSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/zinc-and-copper-balance-wound-healing-without-tipping-into-fibrosisTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Zinc and Copper Balance: Wound Healing without Tipping into Fibrosis Eye surgery and injuries call for careful healing. One micronutrient under the microscope is zinc – a mineral vital for tissue repair and immunity. Zinc acts as a helper (cofactor) for hundreds of enzymes that rebuild cell membranes, make new cells, and fight infection () (). In fact, the body needs zinc to synthesize DNA and proteins, which lets skin and mucous membranes (like the eye’s surface) renew themselves (). When zinc is too low, wounds heal poorly and skin lesions can appear (). In short, adequate zinc supports epithelial repair (restoring the surface cells of the eye) and boosts immune function to protect against infection () (). However, more zinc is not always better. Because zinc also influences scar tissue processes, patients naturally ask: does extra zinc risk excessive scarring (fibrosis) on the conjunctiva? The good news is that routine zinc supplements do not seem to trigger unwelcome fibrosis. Indeed, zinc is required for enzymes (called MMPs) that help remodel healing tissue. Controlled experiments show zinc actually promotes collagen breakdown and limits excess collagen production in fibroblasts (). For example, one study of hypertrophic (thick) scars found that zinc oxide tape reduced scar redness and thickness by raising collagenase (the enzyme that digests scar collagen) and suppressing new collagen in fibroblasts (). Likewise, laboratory tests on ocular fibroblasts (human Tenon’s capsule cells) showed that zinc oxide inhibited fibroblast growth and lowered key scar factors (like TGF-β and fibronectin). In these eye fibroblast cultures, zinc not only increased cell death of scar-forming cells but also prevented collagen contraction, suggesting an anti-scarring effect (). In summary, the existing science suggests that normal zinc supplementation should help a wound heal normally without “overshooting” into pathological fibrosis. If anything, zinc helps balance the process by activating the enzymes that clear excess matrix and prevent abnormal buildup () (). No strong evidence shows that reasonable zinc doses worsen conjunctival scarring. (Of course, any healing eye can scar from many factors – inflammation, genetics, surgical technique – but zinc itself is unlikely to tip the balance toward too much scar.) Safe Zinc Dosage and Duration For patients, safety is key. The daily need for zinc is quite small (about 8–11 mg for adults) and older guidelines set 40 mg per day as the maximum safe upper limit (). Taking zinc above this long-term is not recommended, because chronic high intake (e.g. 50 mg or more for weeks) can cause problems (). In large amounts, zinc can upset your stomach and even drive down copper and other minerals in the body () (more on that below). Typical supplement range: For wound support, many experts would use a moderate dose, for example 15–30 mg of elemental zinc per day. This is above the RDA but well below the 40 mg upper limit, especially if used short-term. By comparison, specialized wound-care formulas or burn regimens often use doses around 20–25 mg/day to aid repair (), but those are under medical supervision. Duration: We recommend only a short course (e.g. around 2 weeks) of extra zinc after surgery. The body’s demand for zinc is highest early in healing, so a couple of weeks of supplemental zinc can be helpful (). But after that, continuing high doses offers no proven extra benefit and could cause mineral imbalances. Always follow your doctor’s advice on how long to take it. Food vs. supplement: Zinc is found in meats, seafood, dairy, and whole grains, so a healthy diet usually provides the daily amount needed. Supplements are for times (or diets) when zinc might be low. If you take zinc pills, consider taking them with a meal or snack to reduce stomach upset (above). Keep in mind the science: the NIH sets 40 mg/day as the adult safety limit (). Going above that, even with supplements, risks side effects. Short-term (a few weeks) up to ~30 mg/day is generally safe. If your treatment calls for higher doses, do not self-dose – check with your doctor. Copper Co-Supplementation Zinc and copper balance go hand-in-hand. These two minerals compete for absorption. High zinc intakes (especially above ~50 mg daily over time) can block copper absorption, leading to copper deficiency (). Copper is needed for nerves and blood cells, so deficiency can cause anemia and nerve problems if severe (). In practice, taking a low dose of copper along with zinc is a prudent safeguard if you’re taking zinc supplements longer than a couple weeks. Many eye-health formulas (like the AREDS macular degeneration vitamins) contain 2 mg copper along with 80 mg zinc for this reason (). For our shorter 2-week course, the risk is small, but you could include a bit of dietary copper (nuts, seeds, whole grains, shellfish) or a 1–2 mg copper supplement if concerned. This ensures the two minerals stay in balance and supports overall healing. Interactions with Oral Antibiotics If you are on any oral antibiotics, especially tetracyclines or quinolones, timing matters: Tetracyclines (like doxycycline or minocycline): Zinc can bind these antibiotics in the gut and make them less effective. If you must take both, separate the doses. Aim to take the antibiotic at least 2 hours before or 4 hours after taking zinc (). Fluoroquinolones (ciprofloxacin, levofloxacin, etc.): Similarly, take the antibiotic 2–4 hours away from zinc, for the same reason (). Other minerals: Note that calcium, iron, and other minerals (from food or supplements) can also block zinc uptake. To avoid competition, some recommend taking zinc either on an emptier stomach or at least 2 hours apart from high-calcium meals or iron pills (). In short: if you’re using an antibiotic like doxycycline or ciprofloxacin, plan your schedule. For example, if you take doxycycline with breakfast, consider taking zinc in the afternoon or vice versa. Keeping a few hours apart ensures that both the antibiotic and zinc are properly absorbed. Gastrointestinal (GI) Side Effects Zinc supplements can irritate the stomach, especially on an empty stomach. Common symptoms can include nausea, abdominal pain, vomiting or diarrhea (). This is more likely with high doses or lozenge lozenges kept in the mouth for too long. To minimize these effects: Take zinc with a meal or snack (unless your doctor says otherwise). Even though taking it with food slightly reduces absorption, a modest meal is fine to protect your stomach. Drink a full glass of water with the tablet. If it still upsets you, try a smaller dose or a different salt form (e.g. zinc gluconate or acetate are common), again always under doctor advice. Reportedly, doses above 50 mg are most often where nausea/vomiting appear (). By staying modest (~15–30 mg) and short-term, most people tolerate zinc well. If severe GI upset occurs, stop and consult your doctor. Patient-Friendly Guidelines: 2 Weeks Post-Op For practical post-surgery care, here’s a cautious zinc plan at the two-week mark: Check with your doctor first. Zinc is generally safe at recommended doses, but individual conditions vary. Always let your surgeon or doctor know you plan to take supplements. Use a moderate dose. If approved, take around 15–25 mg of elemental zinc per day. (Many over-the-counter supplements specify the mg content of elemental zinc.) This is above a normal diet but below safety limits. Limit duration. Plan to take zinc for about 2 weeks only, starting roughly in the second week after surgery when you have stabilized eating habits. This timing matches when cell division ramps up in healing. Take with food. Especially if you notice stomach upset. A meal will decrease GI side effects and will not significantly impact the benefit at this dose. Separate from antibiotics. If you are taking any tetracycline or fluoroquinolone pills elsewhere in your regimen, schedule them at least 2–4 hours apart from the zinc dose (). For instance, one could be morning, the other late afternoon. Maintain normal diet. Continue a balanced diet rich in protein (for building blocks) and vitamin C (for collagen formation) alongside zinc. Include copper-rich foods like nuts and shellfish if possible. Watch for side effects. If nausea, vomiting, or diarrhea start, reduce the dose or discuss alternatives (maybe switching form or pausing zinc). If you develop any neurological symptoms (very rare) or signs of copper deficiency, contact your doctor. Stop after two weeks. The idea is to use zinc as a short “boost” for early healing. After two weeks, evidence of additional benefit is lacking, so it’s safest to discontinue. At that point, natural diet should be sufficient to support continued healing. Conclusion: Zinc is a key player in healing and immune defense, and giving a short course of moderate zinc can help ensure proper repair of the ocular surface. Used responsibly, it should not cause excessive conjunctival scarring – in fact it may even help normalize the repair process () (). By sticking to recommended doses, limiting duration, pairing with copper if needed, and minding drug interactions, patients can benefit from zinc’s suppoSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/n-acetylcysteine-nac-antioxidant-replenishment-and-antifibrotic-potentialTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Introduction N-acetylcysteine (NAC) is a supplement of the amino acid cysteine that has long been used as a mucolytic (to thin mucus) and as an antidote for acetaminophen overdose. More recently, doctors and researchers have studied NAC for its role in boosting antioxidants and controlling scarring. NAC enters cells and is converted to cysteine, which is the building block for glutathione, a major natural antioxidant in the body () (). By helping the body make more glutathione, NAC can help neutralize harmful free radicals. In the eye, this antioxidant action may protect delicate tissues. NAC has been shown to reduce oxidative damage in animal models of glaucoma () and to improve retinal cell function in patients with inherited retinal disease (). At the same time, NAC appears to interfere with fibrosis (the scarring process driven by TGF-β) in laboratory studies, suggesting it might soften the wound-healing response that can cause bleb failure after glaucoma surgery () (). This article reviews what we know about NAC’s antioxidant and antifibrotic effects, how it may affect the eye and body, its usual dosing and side effects, and whether it is safe to start after glaucoma surgery. We also suggest how future studies could test NAC’s impact on bleb healing and survival. NAC and Glutathione Synthesis Glutathione (GSH) is a small molecule that cells use to quench free radicals and repair oxidative damage. Our bodies must continually make glutathione, and that requires the amino acid cysteine. NAC is a modified form of cysteine that can enter cells easily. Once inside, NAC is converted to cysteine and boosts glutathione production () (). For example, a review article notes that “NAC’s antioxidant effect is due to [its] ability to act as a reduced glutathione (GSH) precursor” (). In other words, NAC provides the raw material for more glutathione, which in turn helps neutralize harmful oxidants. (Indeed, this is the same principle behind giving NAC for acetaminophen poisoning — it spares glutathione so the liver toxin can be cleared.) In practical terms, taking NAC supplements can raise cellular cysteine and glutathione levels. One study in a mouse model of normal-pressure glaucoma found that NAC increased glutathione in retinal cells and suppressed oxidative stress (). Antioxidant Effects of NAC Because glutathione is so central to our cell’s defense against damage, boosting it can have wide-ranging effects. NAC itself can also act as a direct antioxidant. One mechanism is that NAC (or glutathione made from it) can scavenge harmful molecules like hydrogen peroxide or reactive aldehydes. Another is that NAC helps break unwanted chemical bonds (disulfides) in damaged proteins or mucus, which can restore normal function (). A short review explains that together these actions give NAC broad chemoprotective power: it neutralizes toxic electrophiles, restores glutathione, and even breaks down problematic protein cross-links (). In more biological terms, NAC relaxes mucus in the lungs, protects the liver, and reduces oxidative stress in many tissues. In the eye, oxidative stress is a key factor in many diseases including glaucoma and retinal degeneration. Recent laboratory studies found that NAC can dial down eye-specific oxidation. In a rat glaucoma model with high eye pressure, daily NAC injections plus a glaucoma drop (brimonidine) reduced retinal oxidative damage compared to controls (). In genetic models of glaucoma where pressure is normal, NAC preserved retinal ganglion cells by blocking stress signals (via HIF-1α and autophagy pathways) (). In patients, a small clinical trial gave oral NAC to men with retinitis pigmentosa and found improvements in cone cell function (likely due to reduced oxidative stress) (). These findings suggest NAC can act as an eye-protective antioxidant both systemically and locally. NAC and the TGF-β Fibrotic Pathway After any surgery, including glaucoma (filtering) surgery, the body’s natural healing response involves fibroblast cells laying down scar tissue. In filtering surgery, excessive fibrosis can close the new drain (bleb) and cause the surgery to fail. A key driver of fibrosis is transforming growth factor beta (TGF-β), a signaling protein that tells cells to become scar-forming myofibroblasts. Studies in eye cells show that NAC can blunt this pathway. For example, one laboratory study treated human retinal pigment epithelial cells with TGF-β1, which normally causes them to turn into migratory myofibroblasts (involved in scarring). Adding NAC to these cells kept them from changing. In fact, NAC inhibited TGF-β1-driven transdifferentiation: it prevented the rise in smooth muscle actin, fibronectin, and collagen that TGF-β1 normally causes (). The research suggested that NAC’s antioxidant action lowered reactive oxygen species and blocked MAP kinase signaling triggered by TGF-β1, thus stopping the fibrotic switch (). (In plain terms, NAC prevented cells from becoming scar-making myofibroblasts.) Similarly, other studies have found that NAC can suppress TGF-β–induced fibrosis in lung and other tissues. One 2009 study in human lung fibroblasts showed NAC reverses TGF-β1–driven fibrosis markers: it stopped gel contraction, and blocked production of fibronectin and α-smooth muscle actin (). By extension, NAC might also blunt TGF-β–driven scarring in the eye. Though direct clinical data in glaucoma surgery are lacking, the lab evidence supports the idea that NAC can modulate the TGF-β fibrotic pathway, potentially reducing scar formation. Moreover, NAC influences enzymes involved in tissue remodeling. For instance, corneal cell studies indicate that NAC reduces MMP-9 (matrix metalloproteinase-9) secretion and slows cell migration (). MMP-9 breaks down extracellular matrix and is linked to inflammation; dampening MMP-9 may help stabilize healing tissues. In summary, NAC seems to exert an antifibrotic influence by both damping the TGF-β signals and lowering enzymes that drive scar remodeling () (). Ocular and Systemic Evidence on NAC Ocular Data Beyond its antifibrotic and antioxidant effects seen in cell studies, NAC has been tested in several eye-related conditions. In dry eye, NAC eye drops have been used (anecdotally and in small trials) to improve tear quality by breaking up mucus, thanks to its disulfide-reducing action (). For glaucoma, most of the evidence is preclinical: animal and lab models suggest NAC could protect retinal cells and limit scarring. As noted above, glaucoma models showed less retinal stress and ganglion-cell loss with NAC treatment (). A landmark phase I trial in retinitis pigmentosa showed that high-dose oral NAC improved cone photoreceptor function in patients (), demonstrating that NAC can reach and help eye cells in humans. These studies indicate NAC can reach ocular tissues (for example, measurable NAC levels were found in eye fluid) and exert its effects. Systemic Data and Dosing Systemically, NAC is sold as a dietary supplement and used as a prescription drug. Typical oral dosing is 600–1200 mg per day, often divided into two or three doses. In clinical trials, doses up to 1800 mg three times daily have been tested (), but the usual recommended range for antioxidant purposes is 600–1200 mg daily. NAC is well absorbed orally, though its bioavailability is modest. Because it supplies cysteine, high-dose NAC supplementation can raise glutathione levels gradually over days to weeks. NAC is generally well tolerated. Common side effects are gastrointestinal. According to drug references, NAC can cause nausea, vomiting, diarrhea or constipation in some people (). Occasionally it causes headache, dizziness or rash, but serious allergic reactions to oral NAC are rare. In the JCI retinitis pigmentosa trial, adverse effects were mostly mild GI upset; some patients needed dose reduction, but none had severe issues (). In summary, at doses around 600–1200 mg/day, NAC’s side effects are usually mild and transient (). NAC After Glaucoma Surgery (Trabeculectomy) Trabeculectomy is a surgery to lower eye pressure by creating a drainage bleb. The big risk after surgery is scarring that closes the bleb. Ophthalmologists already use anti-scarring agents like mitomycin C at surgery to improve success rates. NAC’s profile suggests it could be useful as a safer anti-scarring agent if given after surgery. Starting NAC two weeks after surgery seems reasonable because initial wound closure is complete by then, but scar remodeling is still active. By two weeks, the conjunctival wound has closed, and systemic NAC might gently restrain the fibroblasts before they lay down thick scar tissue. There are no clinical trials yet on NAC for post-trabeculectomy care, but the available evidence (antioxidant and antifibrotic) suggests a potential benefit with low risk. Safety considerations: NAC does not usually impair normal wound healing or carry serious surgical risks. However, caution is advised with certain cardiovascular drugs. In particular, NAC can interact with nitroglycerin (and related nitrate medications). NAC can potentiate the blood pressure lowering effect of nitrates – inSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/aqueous-humor-and-tear-biomarkers-july-2026-omics-updatesTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Introduction Glaucoma, a leading cause of irreversible vision loss, can be hard to detect early. Researchers are now looking at biomarkers in the eye’s body fluids – the aqueous humor (the fluid inside the front of the eye) and tear fluid (the film covering the eye) – to find signs of disease. New “omics” technologies (advanced protein and metabolite profiling) allow scientists to take a detailed molecular snapshot of these fluids. Recent studies (June–July 2026) have identified candidate markers in tears and aqueous humor that might help in diagnosing glaucoma or predicting its progression () (). In this update, we summarize the latest findings on tears and aqueous humor, describe how these studies were done, and discuss what it will take to turn these discoveries into real clinical tests. Tear Fluid Biomarkers Tear fluid is easy to collect (for example, by capillary tubes or filter paper), making it an attractive source of markers. Modern proteomic methods (mass spectrometry) can detect dozens of proteins in a tiny tear sample. A recent tear proteomics study of normal-tension glaucoma (a form of glaucoma with normal eye pressure) found 15 proteins that differed in patients whose visual fields were worsening (). For example, they identified the antioxidant protein peroxiredoxin-4 (PRDX4) and other proteins linked to oxidative stress. One protein, GNAI1, gave a high diagnostic score (AUC≈0.89) in distinguishing rapid progressors from slow progressors (). This suggests tear proteins may predict disease progression (prognostic use) rather than just presence of disease. Another study (in Eye Discovery, June 2026) looked across several glaucoma types and tear compositions, finding unique patterns for each subtype. These preliminary results hint that tear markers might eventually help subtype glaucoma or monitor changes, but they need confirmation. Sampling methods matter. Tears can be collected by Schirmer strips or capillary tubes, and these methods give slightly different results – for example, capillary collection is less irritating and preserves more tear proteins (). Such technical details can affect reproducibility, so it’s important to standardize collection when comparing studies. Overall, tear studies show promise. They have identified candidate biomarkers (linked to oxidative stress and inflammation) () (). But most findings are so far from small groups of patients. Larger validation studies are needed before any tear test could be used in the clinic (). Aqueous Humor Biomarkers The aqueous humor is the clear fluid bathing the front of the eye. It is obtained during procedures like cataract or glaucoma surgery. Because volumes are small, each sample is precious. Recent studies have profiled its content to find glaucoma clues: Protein and EV profiling: One work used label-free proteomics to map the protein “portraits” of aqueous humor in two common glaucoma types (primary open-angle and pseudoexfoliation glaucoma) (). They found many proteins that differed by disease type. (This study is under peer review but highlights how mass spectrometry can reveal glaucoma-specific protein changes.) Exosomal miRNA: Tiny vesicles called extracellular vesicles (exosomes) carry microRNAs (miRNAs) that regulate genes. A recent pilot study sequenced miRNAs from aqueous humor–derived exosomes in two glaucoma forms. It found, for example, that miR-451a was higher in primary open-angle glaucoma and miR-26a-5p higher in exfoliation glaucoma, while the anti-scarring miR-29a-3p was down in both types (). These miRNAs target extracellular-matrix and fibrotic pathways. As the authors note, this “first profile” of AH exosomal miRNAs highlights potential biomarkers (and even therapeutic targets) for glaucoma (). In lab tests, boosting miR-29a-3p reduced fibrotic changes in eye cells, hinting at a disease link (). Spectral fingerprinting of exosomes: A novel diagnostic approach used surface-enhanced Raman spectroscopy on antibodies that captured AH exosomes. An AI model then classified spectra from glaucoma vs control samples. Impressively, this method achieved ~91% accuracy (AUC=0.96) in distinguishing glaucoma patients (). It shows that even without identifying individual molecules, complex spectral patterns from AH exosomes can serve as diagnostic signatures. Metabolites and lipids: Metabolomic studies (measuring small molecules) have yielded clues too. A recent lipidomic analysis found that glaucoma patients had significantly higher levels of lipoxin A4 (an anti-inflammatory lipid) and its precursor arachidonic acid in their aqueous humor (). This was traced to glaucoma medications: for example, the common drug latanoprost was shown to induce lipoxin production in eye tissues () (). These findings suggest that conventional treatment alters lipid pathways, which now emerge as glaucoma “signatures.” In sum, AH studies are uncovering both molecular markers (specific proteins, miRNAs, lipids) and patterns that differ in glaucoma. Many of the identified changes point to disease pathways (see below). Diagnostic vs. Prognostic Utility and Reproducibility A key question is whether a marker indicates glaucoma is present now (diagnostic) or predicts what happens next (prognostic). In tears, the NTG study was aimed at progression (prognosis) (). In contrast, the AH exosome Raman study was purely diagnostic (glaucoma vs healthy) (). The exosomal miRNA pilot also focused on subtype diagnosis (). Most discovery studies to date are diagnostic in nature. However, none of these putative biomarkers is ready for clinical use. As one review notes, despite identifying many candidates tied to oxidative stress, inflammation or vascular dysfunction, no molecular biomarker has yet been validated for routine glaucoma diagnosis () (). Reproducibility remains a challenge: different labs use different tear collection methods, protein assays, and analytical platforms (). Even aqueous humor studies are small and usually single-center. Validation cohorts (independent patient groups) are rare. For example, the tear proteomics report did not test its biomarkers in a separate population; it only used statistical analysis on the study group (). Thus, while these findings are encouraging, they should be viewed as early leads. Larger-scale studies are required to confirm whether the same markers emerge in other patients and to rule out false positives. In practice, a combination of several markers (a signature panel) might be needed to reach high accuracy. Rigorous standardization of sample handling and analysis will be essential to make results reproducible across clinics. Pathway Enrichment and Biological Insights Beyond individual molecules, researchers look for common pathways that glaucoma targets. Many of the differing molecules fall into a few themes: oxidative stress, inflammation, and extracellular matrix (ECM) remodeling (). For instance, PRDX4 in tears is an antioxidant enzyme, and the AH miRNA results involved ECM-related miRNAs (). Metabolomic analyses reinforce these ideas. A recent meta-analysis pooling data from multiple studies found that pathways involving arginine and proline metabolism were consistently altered in glaucoma – in both aqueous humor and blood (). Arginine/proline metabolism is linked to oxidative stress and neurodegeneration, suggesting these processes play a central role (). The lipoxin study highlighted the arachidonic acid–lipoxin pathway. Lipoxin A4 is a natural anti-inflammatory mediator. Its elevation in glaucoma patients’ AH (likely driven by eye-drop medications) suggests a drug-induced anti-inflammatory response () (). This ties into broader evidence that resolving inflammation may be neuroprotective in glaucoma. In summary, pathway analyses of the new biomarkers point to known glaucoma mechanisms (oxidative damage, immune signaling, wound healing in the eye) () (). These insights help explain why certain markers change and can guide future targets for therapy or monitoring. Steps Toward Clinical Translation Turning these omics findings into a useful clinical test will require many steps. First, candidate markers must be confirmed in larger, independent cohorts. Studies should include diverse populations and controls (e.g. cataract patients) to ensure specificity to glaucoma. Multicenter trials would help establish consistency. Second, a practical assay must be developed. This likely means moving from broad discovery (mass spec, sequencing) to targeted tests. For example, a few key proteins or miRNAs could be measured by antibody-based tests or PCR assays. Any exosome-based test needs a simple way to isolate them (commercial kits) and robust readout (like a Raman sensor or PCR panel). These assays must be optimized for speed, cost, and reproducibility. Regulatory validation will involve defining clear cut-off values, testing sensitivity/specificity in the real world, and comparing with standard glaucoma exams. In the case of tears, methods to collect and store the fluid must be standardized across clinics (). The powerful AI-based exosome classifier () illustrates what is technically possible, but to become a routine test it would need to be replicated (e.g. with blinded new samples) and automated into a user-friSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/laser-therapies-beyond-slt-july-2026-protocol-innovationsTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Laser Therapies Beyond SLT: July 2026 Protocol Innovations Selective Laser Trabeculoplasty (SLT) is a well-known laser treatment that lowers eye pressure by targeting the eye’s drainage tissue (trabecular meshwork). Recent studies (July 2026) have explored new laser approaches and tweaks to SLT for glaucoma and ocular hypertension. These include modified SLT methods (like non-contact SLT and pulsed lasers), micropulse laser techniques, and canal-focused procedures (using either lasers or tiny implants). We summarize the latest dosing (energy), retreatment rates, pressure‐drop results, and safety findings, and explain what they mean for patients. Modified SLT Approaches (Direct SLT and Micropulse SLT) Researchers continue to refine SLT itself. For example, a new “direct SLT” system treats the drainage tissue without touching the eye. In a large series of 218 eyes, Goldberg et al. (2026) found that 67.0% of eyes reached their target pressure at 2 months after direct SLT【Goldberg2026】. The average eye pressure fell about 3.4 mmHg (a 15.6% drop) from a baseline of ~19.7 mmHg【Goldberg2026】. Importantly, eyes that had never used pressure drops before did even better: about 78.4% of these “treatment-naïve” eyes hit the pressure goal, versus 63.5% of eyes already on medication【Goldberg2026】. Side effects were mild: over half of eyes had a small subconjunctival bleed (a tiny bruise on the eye surface), and only 1.8% had a brief pressure spike; no serious complications were seen【Goldberg2026】. Another line of work uses a pulsed laser for the same 360° treatment area of SLT. This “micropulse” SLT applies many tiny bursts of laser energy to gently stimulate the drainage meshwork. In a head-to-head trial, Abramowitz et al. (2018) found that one year after treatment, micropulse SLT and standard SLT gave very similar pressure drops. About 30–37% of eyes in each group had a ≥3 mmHg drop or ≥20% reduction in pressure【Abramowitz2018】. The big difference was comfort: patients reported significantly less pain during and after the micropulse laser (P=0.005)【Abramowitz2018】. In short, modified SLT methods – whether non-contact or pulsed – appear as effective as standard SLT in lowering pressure, with the advantage of easier delivery and less discomfort【Goldberg2026】【Abramowitz2018】. New Micropulse Laser Treatments Beyond SLT-style procedures, micropulse lasers have been applied in other ways. One major application is ciliary-body cyclophotocoagulation, where laser energy is delivered through the sclera (the white of the eye) to reduce fluid production. In a recent retrospective study of 118 eyes with various refractory glaucomas, Toptan et al. (2026) reported dramatic pressure reductions from micropulse transscleral laser. After one treatment session, mean intraocular pressure (IOP) fell by about 46–56% across glaucoma types (for example, 46.5% in primary open-angle glaucoma, 50.4% in neovascular glaucoma, up to 56.2% in juvenile glaucoma)【Toptan2026】. Overall, the group-wide drop was 48.8%. Initially 66.9% of eyes succeeded (reached target IOP) after one session, and after allowing repeat treatments about 75.4% met the goal by 12 months【Toptan2026】. In practice, most patients (67%) needed just one session, while 28% required two and 5% three sessions up to one year【Toptan2026】. Notably, this powerful pressure lowering came with very few serious side effects. No eye developed dangerous chronic low pressure (hypotony) or shrunken eye (phthisis), complications seen with older cyclodestructive lasers【Toptan2026】. A few mild issues were reported (temporary eye inflammation in 3 patients, small bleeding in 1), and one patient had a transient pupil dilation【Toptan2026】. In summary, micropulse transscleral therapy can cut IOP roughly in half with a 1–2 session protocol, at the cost of mostly minor and temporary effects. The dosing used in these studies was high-power but pulsed: typically a 2,000 mW (2 W) laser with a 31% duty cycle (short “on” bursts totaling about 160 seconds of delivery around the eye)【Toptan2026】. This delivered about 70–80 joules of energy per session. The key is that micropulsing lets the tissue cool between bursts, minimizing collateral damage. Canal-Based Procedures (Excimer Trabeculostomy and Canaloplasty) Researchers are also targeting the eye’s fluid canal (Schlemm’s canal) with new techniques. Excimer Laser Trabeculostomy (ELT) is one such method: a tiny ultraviolet laser makes microscopic holes through the trabecular meshwork into Schlemm’s canal. In a small pilot study (Kallab et al., 2026), patients undergoing cataract surgery plus ELT showed measurable improvement in aqueous outflow. Dye angiography before and after the procedure found a significant increase in fluid flow (p=0.03) across the treated drainage area【Kallab2026】. This suggests ELT can enhance the natural channels, although large-scale pressure data are still pending. Separately, non-laser canal procedures (sometimes grouped here) are showing large pressure drops. For instance, an OMNI canaloplasty/trabeculotomy – a micro-catheter device that dilates Schlemm’s canal and cuts through trabecular meshwork – was studied in 18 patients (Olander et al., 2026). Baseline mean IOP was 26.1 mmHg. After 12–24 months, IOP had dropped to about 15.5 mmHg (a 9.7–10.6 mmHg reduction)【Olander2026】, and most patients reduced or stopped their drops. In fact, 67% of patients were off glaucoma medications by 24 months【Olander2026】. Adverse events were mostly mild; no eye lost vision or suffered major complications, and only one case of dry eye was thought related to the procedure【Olander2026】. This demonstrates that opening the canal can yield a ~40% pressure reduction, comparable to traditional glaucoma surgery but with a very favorable safety profile. Patient Factors and Choosing a Protocol Eye Color/Pigmentation: SLT and micropulse lasers target pigmented cells in the drainage tissue. Evidence suggests micropulse methods work well even in darkly pigmented eyes: animal data show these pulses trigger enzymes that remodel the trabecular meshwork without excessive heat【Abramowitz2018】. In practice, no major differences in efficacy by eye color have been reported. All these laser options are intended for open-angle glaucoma; they are ineffective in eyes with closed or very narrow angles. Angle Status: All the laser treatments above require at least a partially open drainage angle. If your angle is closed, the first step is typically a laser peripheral iridotomy or a cataract operation to open the angle. The canal-based surgeries are usually done in open-angle eyes too (often at the time of cataract surgery). Prior Therapy: Timing matters. The direct SLT study found bigger pressure drops in eyes that had never used drops before【Goldberg2026】. For example, medication-naïve eyes had a 20.2% IOP reduction after 2 months of DSLT, versus 14.2% in eyes already on drops【Goldberg2026】. This suggests earlier use of laser (before maximal medications) may give a better percentage drop. In general, laser trabeculoplasty (any type) can be repeated if needed. In the micropulse cyclo series, about one-third of eyes needed a second session to reach target (yielding ~75% success by one year)【Toptan2026】. Expected Results: Based on these studies, patients can expect a moderate IOP drop on average. SLT or micropulse trabeculoplasty (360° treatment) typically reduces pressure by 15–25%, helping ~30–67% of eyes reach their goal with one treatment【Goldberg2026】【Abramowitz2018】. Micropulse cyclodestruction often gives ~40–50% drops and usually requires scheduling 1–2 sessions【Toptan2026】. Canal procedures (like OMNI) can cut IOP by ~40% as well【Olander2026】. However, individual response varies widely. If you have high baseline pressure or aggressive glaucoma, a bigger intervention (multiple sessions, cyclo, or combined surgery) may be needed versus a mild case where single-session SLT suffices. Safety Profile: All these lasers are generally safe when used correctly. In the new studies, serious complications were rare. SLT (even direct SLT) mainly causes brief redness or tiny bleeds, and pressure spikes were under 2%【Goldberg2026】. Micropulse lasers spare tissue and caused minimal inflammation – in one report almost no eyes had permanent loss of vision or severe hypotony【Toptan2026】. Canal surgeries like OMNI had a few mild events (dry eye, transient inflammation) but no vision loss【Olander2026】. Overall, these methods are much less invasive than traditional surgery (trabeculectomy) and typically do not carry high risks of blindness or severe complications. Conclusion July 2026 studies show that innovations in glaucoma lasers are yielding more options beyond standard SLT. Modified SLT techniques (non-contact devices or micropulse pulses) match SLT’s pressure lowering with the promise of quicker treatment and less discomfort【Goldberg2026】【Abramowitz2018】. Micropulse cyclophotocoagulation is proving to be a powerful tool for hard-to-control glaucoma, cutting pressure by nearly half in many eyes with minimal side effects【Toptan2026】. And canal-targeted procedures (both laser and micro-surgical) are delivering large IOP drops (~10 mmHgSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/corneal-biomechanics-as-a-risk-modifier-last-month-evidenceTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Understanding Corneal Biomechanics and Glaucoma Risk Glaucoma is an eye disease where damage to the optic nerve leads to vision loss. The main known risk factor has long been high intraocular pressure (IOP). However, newer research shows the biomechanical properties of the cornea – essentially how “springy” or deformable the cornea is – also influence glaucoma risk. Two key measures are corneal hysteresis (CH) and dynamic corneal response (DCR) parameters. CH measures how well the cornea absorbs and dissipates energy (think of it as corneal “shock absorption”). DCR parameters come from devices like the Corvis ST, which use a quick air puff and high–speed camera to record corneal deformation. These measures are now easier to get in the clinic thanks to instruments such as the Ocular Response Analyzer (ORA) and Corvis ST () (). Recent evidence suggests both CH and DCR can help predict glaucoma development and progression beyond IOP and corneal thickness (CCT). Measuring Corneal Hysteresis and Corneal Response The ORA (introduced in 2005) uses an air puff and infrared light to estimate CH (). It reports two values: CH and a related Corneal Resistance Factor (CRF). The newer Corvis ST system uses a high-speed Scheimpflug camera (over 4,300 frames/sec) to visualize the actual corneal movement during an air puff (). It yields many dynamic response metrics (like deformation amplitude, inverse radius, stiffness) beyond CH () (). Importantly, each device produces different parameters, and they are not interchangeable. For example, one study found that the Corvis ST’s “biomechanically corrected” IOP (bIOP) did not match the ORA’s cornea-compensated IOP (IOPcc) – the two methods showed weak agreement and should not be used interchangeably (). In practical terms, CH (from ORA) and DCR metrics (from Corvis) reflect related but distinct corneal properties () (). Clinicians are beginning to incorporate these tests: one expert review even recommends checking corneal biomechanics at baseline in all glaucoma patients and suspects (). This means measuring CH (and possibly Corvis metrics) as part of the initial exam. In summary, corneal biomechanics can now be measured clinically, and experts suggest doing so in glaucoma care () (). ... Continue reading at https://visualfieldtest.com/en/corneal-biomechanics-as-a-risk-modifier-last-month-evidenceSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/diurnal-and-nocturnal-behavior-of-episcleral-venous-pressureTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Daily Rhythms of Eye Pressure and Venous Pressure Our eyes have a natural 24-hour cycle of pressure changes. Both intraocular pressure (IOP) (the pressure of fluid inside the eye) and episcleral venous pressure (EVP) (the downstream pressure in the veins on the surface of the eye) tend to be highest in the early morning and lower by evening () (). In one recent study of healthy adults, the mean IOP and EVP were both highest at 8 AM and fell by late afternoon (). In other words, like a clock, IOP and EVP peak in the morning and wane later in the day () (). However, night‐time patterns are influenced by sleep posture. When we lie down on our back, blood settles differently, so both IOP and EVP rise. For example, one study found that as soon as a person lies down, EVP jumps by about 3–4 mmHg and stays high while supine (). This contributes to known findings that eye pressure measured at night (when a person is usually lying flat) tends to be higher than daytime sitting measurements () (). In one carefully controlled sleep-lab experiment, volunteers showed higher mean IOP at night partly due to increased EVP and fluid shifting when lying down (). Thus nighttime IOP often exceeds daytime levels because of the supine position and higher venous pressure. In general, IOP and EVP move together across the day. When one study compared them round‐the‐clock, changes in EVP closely paralleled changes in IOP () (). In both healthy people and those on blood-pressure medicines, higher EVP in the morning accompanied higher IOP, and both fell through the afternoon () (). This synchronization means factors that push IOP up (like lying down) also raise EVP, since EVP partly “holds up” IOP from falling below it () (). In short, EVP and IOP share daily rhythms with morning peaks and day/evening troughs () (), but staying flat in bed at night produces higher values for both. How Lifestyle and Body Factors Can Change EVP Several everyday factors affect eye pressures. Staying well hydrated, dietary choices, and nervous system activity all play a role: Hydration (Water Intake): Drinking lots of fluid quickly can raise eye pressure. In one classic study, healthy people who drank a liter of water saw their IOP jump by about 4.4 mmHg for over two hours (). This happens because extra fluid increases the blood and ocular fluid volume. By analogy, EVP likely rises a bit with high fluid intake, although direct EVP data is limited. In clinical practice, patients are sometimes advised to avoid gulping large volumes of water right before IOP checks. Salt Intake: Eating very salty food leads the body to retain water, raising blood volume and pressure. Recent research in a large population found that people with higher dietary salt (measured by urine sodium) had slightly higher IOP and more glaucoma (). The highest-salt group had IOP about 0.45 mmHg above the lowest-salt group. Scientists suggest this may be due to more fluid volume and higher episcleral venous pressure pushing fluid back into the eye (). In other words, excess salt can subtly elevate EVP (and thus IOP) and may increase glaucoma risk () (). Caffeine (Coffee): Caffeine is a mild stimulant that briefly raises IOP. In the same classic study, drinking caffeine led to about a 4.0 mmHg rise in IOP lasting around 95 minutes (). The mechanism likely involves caffeine’s vascular effects. We have less direct data on EVP after caffeine, but by raising overall ocular pressure, it may also raise EVP slightly. For patients sensitive to eye pressure changes, avoiding strong coffee or energy drinks before an eye exam can help avoid an artificial spike. Alcohol: Alcohol has the opposite effect. The 1986 study showed that drinking alcohol caused IOP to drop by up to 3.7 mmHg, with values returning to normal within about an hour (). Alcohol is a vasodilator (it relaxes blood vessels), which may lower both blood and venous pressures, including the episcleral veins. So moderate alcohol can transiently lower EVP and IOP, but this is not considered a therapy (and excessive drinking has many risks). For measurement, it implies having an alcoholic drink just before a pressure check might temporarily make one’s IOP/EVP look lower than usual. Autonomic (Stress and Nerves): The autonomic nervous system (our “fight-or-flight” vs “rest-and-digest” system) can adjust vessel tone throughout the body, including the episcleral vessels. Studies note that changes in autonomic activity can change EVP (). For example, being stressed or anxious (activating the sympathetic system) can constrict some eye vessels, whereas relaxation (parasympathetic) may dilate them. One observation: vigorous exercise caused an immediate drop in IOP of about 4.3 mmHg (). This might be partly due to changes in blood flow and venous tone. In practice, rapid heart rate or adrenaline can slightly alter EVP as well. It is wise to sit quietly before measuring eye pressure, to let things settle. Body Posture: Moving from sitting to lying increases EVP. Multiple studies show that IOP measured lying down is consistently ~2–4 mmHg higher than when sitting (). This is largely due to higher EVP when supine. Thus doctors usually check IOP in a seated position for consistency. But patients should remember: when they lie down (for sleep or rest), their eye pressures rise. Eyelid Closure: As it turns out, simply closing the eyelid (such as when dozing) does not significantly change EVP or IOP (). One study found no effect from keeping one eye closed overnight. So it’s the posture (supine) rather than blinking or shut eyelid that drives pressure changes at night. In summary, factors that boost blood/eye fluid (like too much salt or water, caffeine, lying flat) tend to raise EVP and IOP, while vasodilators or activity (alcohol, exercise) tend to lower them () (). Patients may be advised to minimize heavy salt, caffeine, and alcohol around the time of pressure checks. Implications for Monitoring and Treatment These rhythms and triggers have real-world impacts on glaucoma care. Because IOP (and EVP) peak in the morning, relying on a single afternoon office measurement can miss dangerous spikes () (). A patient whose IOP is “normal” at 2 PM might actually have had a higher pressure earlier that day. Therefore, doctors sometimes repeat IOP checks at different times, or even use extended monitoring. For example, one noninvasive device (the Triggerfish® contact lens sensor) records 24-hour ocular pressure patterns continuously, including while sleeping (). Studies show this lens can safely capture the ups and downs of IOP (and inferred EVP changes) around the clock (). If available, such monitoring can reveal night-time peaks or large swings that single visits miss. Without that technology, home tonometry (self-measuring IOP) or evening clinic visit can help find the highest pressures. Medication timing can also consider these patterns. Many glaucoma eye drops work over 24 hours, but some effects vary. For instance, carbonic anhydrase inhibitors and beta-blockers reduce fluid production, so giving them before the morning rush might blunt the rise. Prostaglandin analogs increase outflow and usually act over a full day, so they are often given at bedtime to cover the early morning period. In any case, discussing timing with one’s doctor is wise. A typical strategy is to try to have the maximum drug effect coincide with the known IOP peak (often morning) () (). (Some doctors note, for example, that beta-blockers like timolol may work best if dosed in the morning when sympathetic tone is higher.) There is no single rule for all patients, but understanding that EVP and IOP ebb and flow suggests chronotherapy (timed dosing) could optimize control. Practically speaking, patients should follow these tips: Record Multiple Readings: If possible, get IOP measurements at different times (morning and afternoon, or during a home period) to catch peaks. Consistent Posture: Always measure IOP sitting upright, both at home or clinic. Note that lying down (even for sleep) raises the pressure. Report Drinks or Meds: Let the doctor know about large water intake, caffeine, salt meals, or new medications (like oral decongestants or stimulants) around measurement time. Tailor Eye Drops: Ask the doctor if any medication timing should adjust for your daily schedule (e.g. take certain drops at night vs morning). By aligning treatment and monitoring with the eye’s daily cycle, one can better manage glaucoma risk. For example, if a patient’s pressure is highest upon waking, an evening dose of medication might be most effective, whereas a midday peak might call for a morning dose. There is ongoing research on “ocular chronotherapy,” but the key idea is clear: when and how often we measure and treat should reflect the clock-like behavior of eye pressure. Recommendations for Future Research Protocols To better understand EVP’s 24-hour behavior, future studies should use standardized, controlled protocols. Here are some suggestions: Controlled Environment: Use a sleep-lab or clinical research setting where lighting, temperature, and noise are kept constant. Keep subjects on a strict sleep-wake schedule (e.g. lights on at 7 AM, off at 11 Support the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/the-optic-nerve-head-perfusion-equation-venous-pressure-iop-and-susceptibility-to-damageTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:The Optic Nerve Head Perfusion “Equation”: Balancing Arterial and Venous Pressures Glaucoma (optic nerve damage) has long been linked to high intraocular pressure (IOP), but doctors now recognize that blood flow through the eye is just as important to optic nerve health. In the eye, blood enters through arteries carrying a high pressure from the heart, and must exit through veins carrying lower pressure. The perfusion pressure that drives blood through the optic nerve head (ONH, where the nerve fibers exit the eye) depends on the difference between these pressures – but with a twist. Unusually, the eyeball’s pressure (IOP) physically squeezes the veins leaving the eye (the vortex and episcleral veins) so that these veins must have pressures just above IOP to stay open (). In other words, ocular veins behave like a “Starling resistor”: their outflow pressure is kept near IOP to prevent collapse. This means eye perfusion pressure is often approximated as arterial pressure minus IOP (). In practice, doctors often estimate ocular perfusion pressure (OPP) by subtracting IOP from mean arterial pressure (roughly ⅔ of blood pressure) () (). However, this is only an approximation. Actual venous pressure can deviate from IOP, especially at low IOPs (), which makes true perfusion pressure lower than the formula predicts. In one eye model, researchers found choroidal venous pressure stayed higher than IOP, so real perfusion might be overestimated by the simple formula (). In addition to IOP acting from inside the eye, the optic nerve head lamina cribrosa (the sieve-like tissue at the back of the eye) is also pressed on by the pressure in the cerebrospinal fluid (CSF) around the optic nerve. Normally CSF pressure (essentially intracranial pressure) is somewhat lower than IOP, so the lamina sees a net gradient pushing it backwards. This translaminar pressure difference (IOP minus CSF pressure) causes posterior bowing of the lamina; when it is large, nerve fibers and blood vessels in the lamina can be strained () (). For example, if IOP is 20 mmHg and CSF pressure is 10 mmHg, the lamina experiences about a 10 mmHg difference. Since the lamina is only a few hundred micrometers thick, that works out to roughly 1 mmHg of gradient per 100 µm of tissue () – one of the steepest pressure gradients in the body. Animal and human studies suggest that this translaminar gradient itself can damage the optic nerve. In fact, modern research shows that a low CSF pressure (leading to a high IOP–CSF difference) can be as damaging to the optic nerve head as a high IOP . In normal-pressure glaucoma patients (IOP < 21 mmHg), low blood pressure or especially low CSF pressure can excessively increase this gradient, starving the lamina of blood flow () (). How Arteries and Veins Drive ONH Perfusion As in any tissue, arterial blood pressure pushes blood into the eye’s circulation, and resistance in the tiny vessels reduces pressure by the time blood reaches the veins. Normally this sets up a downward pressure gradient from arteries to veins. But in the eye the external pressure of IOP compresses the outflow veins, forcing the vein pressure to stay just above IOP (). In practice this means blood must overcome the sum of IOP and any venous pressure to reach the tissues of the ONH. In simple terms, ocular perfusion pressure is often taken as arterial pressure minus IOP (), assuming venous pressure ≈ IOP. This approximation highlights two key factors for flow: arterial pressure (linked to heart blood pressure) and IOP. If blood pressure drops (for example at night) or IOP spikes, perfusion can fall. Indeed, wide swings in IOP or blood pressure are risk factors for glaucoma damage. Recent work confirms that large fluctuations in calculated OPP (blood pressure minus IOP) are linked to progression of normal-tension glaucoma (). For instance, one trial found that although both latanoprost and bimatoprost lowered IOP equally, only latanoprost significantly raised the eye’s calculated perfusion pressure (likely through modest effects on blood flow) (). Importantly, the above formula neglects direct venous pressure terms. In reality, if venous pressure is elevated (for example by raised intracranial pressure, or conditions like heart failure or obstructive breathing that raise thoracic pressures), perfusion pressure is reduced. Research in animal eyes shows that at low IOPs venous pressure can actually exceed IOP, causing actual perfusion pressure (arterial minus venous) to be less than the simple MAP–IOP estimate (). In glaucoma patients, higher episcleral venous pressure (EVP) has been observed with some treatments, blunting pressure reduction (). In one animal model, experimentally raising venous pressure dramatically lowered ONH perfusion. Altogether, narrowing or congestion of the ocular veins lowers the overall pressure gradient that drives blood through the optic nerve, making the nerve tissue more susceptible to damage even if IOP is not very high. Imaging and Blood-Flow Studies in Glaucoma Modern imaging and blood-flow measurements confirm that glaucoma eyes often suffer from poor optic nerve perfusion. Optical coherence tomography angiography (OCTA) shows that glaucoma is associated with loss of capillaries: vessel density in the retina, around the nerve, and in the peripapillary choroid is significantly lower in glaucoma patients (). These microvascular defects correlate closely with nerve fiber loss and visual field defects, suggesting a link between poor blood supply and nerve damage (). In one OCTA study, the overall optic disc “flow index” (a measure of blood flow) was about 25% lower in glaucoma eyes than in normals, even after accounting for scan variability (). Hemodynamic imaging adds to this picture. Color Doppler ultrasound studies show that blood velocities in the eye’s feeding arteries (ophthalmic, central retinal, and short posterior ciliary arteries) are lower in both high-tension and normal-tension glaucoma than in healthy eyes (). Laser-based flowmetry assays similarly record reduced blood flow on the surface of the optic nerve head in glaucoma. For example, laser Doppler velocimetry finds less blood in the small capillaries nourishing the nerve fiber layer of glaucoma eyes (). Scanning laser flowmetry in the nerve head cup and rim also consistently shows lower microvascular perfusion in glaucoma patients than in healthy or ocular-hypertension subjects (). Notably, these reductions in flow correlate with the extent of nerve damage: more severe glaucoma tends to coincide with greater loss of ONH perfusion (). Other techniques have similar findings. Laser speckle flowgraphy (LSFG) studies indicate that even at the earliest stages of glaucoma the optic nerve head blood flow can initially rise (possibly from loss of autoregulation) and then steadily declines as damage progresses (). By the time a large fraction of the nerve fiber layer is lost, ONH blood flow can be 25% below baseline (). Long-term studies also suggest that eyes with poorer baseline perfusion – for example due to higher vascular resistance – are more likely to go on to lose visual field faster. For instance, in a 3-year study of treated glaucoma patients, those who progressed showed higher resistivity (lower flow) in the ophthalmic and ciliary arteries at baseline (). Together, these imaging and blood-flow data show a clear pattern: glaucoma optic nerves often have less blood flow and perfusion than normal. While this is partly a consequence of IOP-related compression (a narrowed pressure gradient), it also implies that any additional factor that reduces flow – such as venous congestion or low arterial pressure – can compound the problem. Therapeutic Approaches: Beyond Just Lowering IOP Because glaucoma damage can happen even at normal IOP, researchers emphasize treatments that also protect or improve optic nerve blood flow. Lowering IOP remains first-line, but supplemental strategies target the vascular side. Some glaucoma drugs have beneficial blood-flow effects. For example, the alpha-2 agonist brimonidine not only lowers IOP, it also improves retinal and ONH circulation. Although brimonidine constricts some vessels on the eye’s surface, it paradoxically dilates retinal arterioles and increases overall ocular blood flow (). Clinically, in one trial of normal-tension glaucoma, patients on brimonidine lost visual field more slowly than those on timolol even though their IOPs were the same (), suggesting the improved perfusion provided some protection. Prostaglandin analogues (first-line IOP drugs) may also affect perfusion. Laboratory studies found that latanoprost enhanced optic nerve blood circulation (in animals and humans) independently of its IOP effect (). In a clinical trial comparing latanoprost with bimatoprost, both drugs lowered IOP equally, but only latanoprost increased calculated ocular perfusion pressure (). It appears that some medications can also change the downstream venous pressure – for example, topical prostaglandins were found to raise episcleral venous pressure in animals (), partially offsetting their benefit. New approaches are looking tSupport the show

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/the-iop-floor-how-episcleral-venous-pressure-limits-trabecular-and-canal-based-glaucoma-proceduresTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Understanding Eye Pressure and the “Floor” Set by Venous Pressure Glaucoma is caused by high pressure inside the eye (intraocular pressure, IOP). Most glaucoma surgeries work by opening new drainage routes for the fluid in the eye. Many modern procedures (known as minimally invasive glaucoma surgeries or MIGS) create openings in the natural drainage system, so fluid can exit through small veins on the surface of the eye (the episcleral veins). A key point is that these episcleral veins already have their own normal pressure – the episcleral venous pressure (EVP) – and you cannot drain eye fluid below that pressure. In other words, EVP sets a physiological floor for IOP. If the eye‐fluid pressure tries to go much below EVP, there is no pressure gradient to drive flow, so it “bottoms out.” Classic equations for eye fluid (Goldmann’s equation) even show that IOP equals the outflow pressure plus EVP (). In practice, this means no matter how much we open the drainage, the pressure cannot drop much below the level of the veins. Eveyscleral venous pressure is normally about 8–10 mmHg in a healthy eye (). So even a perfect trabecular bypass or canaloplasty can only lower IOP toward that range. How MIGS and Canal Surgeries Work Trabecular meshwork–based MIGS (like iStents, Trabectome, Kahook Dual Blade, GATT) and Schlemm’s canal surgeries (like canaloplasty or Hydrus stent) all aim to reduce resistance by removing or bypassing the trabecular meshwork and inner wall of Schlemm’s canal. Once those are opened, aqueous fluid flows through the normal canal and out through collector channels into the episcleral veins. In effect, these surgeries restore the natural pathway. Because the fluid still drains into the veins, the eye can only empty out until the pressure equalizes with the venous pressure. As one review explains, even a full 360° trabeculotomy can only lower IOP “to as low as episcleral venous pressure” (). In other words, if EVP is 9 mm, the IOP usually cannot go below about 9–10 mm from these procedures. Because of this limit, MIGS techniques are best for moderate IOP reduction. A recent evidence review noted that MIGS “typically cannot achieve extremely low IOPs since they do not bypass the episcleral venous pressure (EVP), usually ~8–10 mm Hg” (). In fact, most MIGS studies report IOP only dropping into the mid-teens (mmHg) range. For example, one long-term series found that Trabectome (an ab-interno trabeculotomy) reduced IOP by about 29% (e.g. 23→16.5 mmHg), whereas a trabeculectomy (a traditional bleb surgery) could reduce IOP by ~40–50% (e.g. 24→12 mmHg) in similar patients (). In plain language, MIGS could drop IOP from 23 to around 16–17 on average, whereas a filtering surgery often got pressures into the low teens. Patients and doctors should understand that this “floor” exists. If one needs very low IOP (for example in advanced disease where pressures in the single digits may be desired), simply opening the trabecular outflow may not suffice. By contrast, surgeries that divert fluid to low-pressure reservoirs (like a bleb) can go well below venous pressure, as we will explain below. Evidence from Clinical Studies Clinical studies of microinvasive surgeries support the idea that outflow is limited by downstream resistance. For instance, surgeons often look at the episcleral venous fluid wave (EVFW) during angle surgery: this is a sign of fluid flowing into the veins. If the wave is strong and widespread (meaning many collector channels are open and EVP is not obstructed), patients tend to achieve lower IOP after surgery. In one study of trabeculotomy (Trabectome), eyes with a clear, extensive EVFW (good flow) had a mean IOP of ~13.3 mmHg at 1 year, on only about 1–2 eye drops (). In contrast, eyes with little or no fluid wave (suggesting poor distal outflow) ended up at ~18.4 mmHg on nearly 3 medications (). In other words, when the path to the episcleral veins was effectively narrowed or pressured, the surgery did not lower pressure as much. Similar findings came from gonioscopy-assisted trabeculotomy (GATT): the greater the spread of the episcleral fluid wave during surgery (meaning more open veins), the lower the postoperative eye pressure and the fewer medications were needed (). These reports reinforce that if the eye’s veins or collecting channels are compromised or if EVP is high, simply unblocking the trabecular meshwork won’t achieve very low pressures. Conversely, high EVP can blunt the effect of trabecular surgeries. In practice, eyes with naturally high episcleral vein pressure (for example from vascular congestion or blood abnormalities) are known to respond poorly to MIGS. For example, eyes with conditions like Sturge–Weber syndrome, carotid-cavernous fistulas, or severe thyroid eye disease often have IOP at or above the level of their elevated EVP, and standard outflow surgery usually fails to drop it much further. While large trials on these exact patients are rare, the logic is clear: if EVP is already 15–20 mmHg in such cases, any surgery draining to those veins will likely leave IOP still high. Surgeries That Bypass the EVP Floor When the goal is to lower IOP below the episcleral venous pressure, surgeons turn to procedures that divert fluid away from the conventional venous route. The main options are trabeculectomy, tube shunts, and cyclodestructive treatments. Trabeculectomy (traditional filtration surgery) creates a new channel from inside the eye to a fluid reservoir (bleb) under the conjunctiva (the soft tissue covering the eye). Because the fluid drains into this bleb instead of the episcleral veins, the IOP is no longer tied to venous pressure. In fact, filtered fluid can be absorbed by the tissues or lymphatics at a pressure often well below normal EVP. Clinical studies show trabeculectomy commonly achieves very low pressures: mean postoperative IOP in one long-term study was only around 7–8 mmHg, and most patients easily achieved pressures ≤10 mmHg, on very few medications (). This is about 5–6 mm lower than typical glaucoma drains. In other words, trabeculectomy “bypasses” the EVP floor. Its power to lower IOP comes at the cost of more risks (like bleb leaks or hypotony), but it is the standard choice when very low IOP is needed. Tube shunts (glaucoma drainage devices) place a small tube from the eye to a plate implanted under the conjunctiva. The plate forms its own bleb-like space around it. Like trabeculectomy, the fluid leaves the eye to a tissue space rather than to the venous circulation. Over time, the new bleb capsule develops moderate resistance, but typically tubes achieve IOP around the low teens (often 11–12 mmHg in published comparisons) (). For example, a mixed study found tube patients averaged ~12 mmHg on medications at 5 years, compared to ~7–8 mm in trabeculectomy. Again, tubes are far less constrained by EVP than MIGS, though usually not quite as low as a perfect trabeculectomy. Cyclodestructive procedures (like cyclophotocoagulation) work differently: they reduce the eye’s fluid production by partially destroying the ciliary body (the tissue that makes fluid). These do not depend on outflow at all, so there is no venous pressure floor to consider. Cyclodestruction often achieves moderate drops in IOP (commonly into the mid-teens or lower) and can be repeated. It is generally used when other surgeries have failed or are unsuitable. Some newer MIGS-like options also bypass EVP indirectly. For example, the XEN and PreserFlo gel stents are tiny tubes placed into the eye that drain to a subconjunctival bleb (similar to a trabeculectomy). These work like “mini-trabeculectomies” and thus can achieve lower IOP than trabecular MIGS (). (They still depend on forming a bleb, so they carry some of the same healing issues as trabeculectomy.) Other experimental approaches, like suprachoroidal shunts, also avoid draining to the episcleral veins altogether. Choosing the Right Surgery When EVP is High So how should a patient and surgeon use this information? First, high EVP can often be suspected from clinical clues even if we do not measure it directly. Look for very red, dilated episcleral veins on eye exam, or “blood in Schlemm’s canal” seen on gonioscopy. Certain histories (like thyroid eye disease, Sturge–Weber, or neck vein obstruction) raise suspicion of high EVP. If a patient’s IOP seems out of proportion to their glaucoma severity or to their medications, consider whether elevated EVP could be a factor. If we suspect or know EVP is elevated, we should expect that MIGS or canaloplasty alone may not reach target IOP. These procedures are still valuable if only a modest drop is needed (for example, reducing IOP from 22 to 17 might be worth a MIGS in a mild case). But if the target IOP must be very low (say ≤12) or if the patient already has fairly high IOP despite maximum therapy, then a surgery that does not rely on episcleral outflow is likely a better choice. In practice this means: Severe glaucoma or very high IOP: Prefer trabeculectomy or tube shunt. These can reach lower pressures and can overcome even a high EVP. If a patient absolutely needSupport the show